William John Michael Hrushesky
Curriculum Vitae
[email protected]
803-429-2184
12 North Cobane Terrace
West Orange, NJ 07052
Current Academic/Scientific Positions:
Senior Executive Medical Director and Chief Scientific Officer
Oncology Analytics, Inc
Plantation, Florida
Founder and President
Sine-O-Graph Corporation
West Orange, New Jersey
Most Recent Patient Care, Clinical and Basic Research Leadership Activities:
 Senior Executive Medical Director and Chief Scientific Officer in pharmaceutical utlilization
management research (2010-present)
 Attending physician in general medicine WJB Dorn Veterans Affairs Medical Center (2000-2010)
 Senior attending medical oncologist (outpatient/inpatient/consultation, 2000-2010)
 Medical oncology clinical research providing investigator-initiated investigational cancer care (20002010)
 Co-Director cancer clinical trials program (2000-2010)
 PI for (over 200) commercial cancer clinical trials, over 20 years
 PI (more than 20) investigator initiated peer-review funded single or multi-site international cancer
clinical trials
 Director Medical Chronobiology Basic Cancer Research Laboratory (1976-2010)
Education:
University of Minnesota
Internal Medicine Resident Instructor – Depart. Internal Medicine (Richard V. Ebert), 1976-1978
Medical Oncology Fellowship (B.J. Kennedy), 1978-1979
Post Doctoral Associate (Franz Halberg) 1976-1979
National Institutes of Health
National Cancer Institute, Division of Cancer Treatment,
Cancer Therapy Evaluation Program, 1974-1976
Clinical Associate/Medical Oncology Fellow (Stephen K. Carter)
Johns Hopkins University School of Medicine and Baltimore City Hospitals
Department of Internal Medicine, 1973-1974
Intern in Medicine (Victor McCusick/Philip Zieve/Philip Tumulty)
University of New Castle upon Tyne
Department of Neurology, 1973 (John Walton)
University of Buffalo Medical School, 1970-1973
Buffalo, New York (Years 2, 3 and 4, M.D.)
Cancer Research Scientist RPMI (mentor, Gerald P. Murphy)
State University of New York, 1969-1970
Upstate Medical School
Syracuse, New York (Year 1)
Syracuse University Honors College, 1965-1969
AB Philosophy, Thesis: “Man and Happiness” (Jose Benardete)
Fine Arts (Sidney Alexander)
Zoology (W.D. Russell-Hunter)
Hrushesky • Curriculum Vitae • Page
Table of Contents
Current Positions
1
Most Recent Responsibilities
1
Education
1
Military Service
4
Licensure Status
4
Specialty Board Status
4
Prior Academic Employment
4
Honors and Awards
6
Educational Activities
6
Medical Oncology Competence/Areas of Clinical Investigation
6
Cancer Therapy Development Experience
6
Books Published
8
Monographs Published
8
Poetry, Essays, Columns
8
NCI Drug Development Publications
8
Patents granted
9
Peer Review Funding History
9
Appendix I Heroes, Mentors, Protégés
11
Appendix II Protégé Development History
12
Appendix III Published Peer Reviewed Scientific Papers
18
Appendix IV Published Scientific Abstracts
38
Appendix V Highly Selected Invited Presentations
65
2
Hrushesky • Curriculum Vitae • Page
Military Service:
Active Duty, USPHS, Lieutenant Commander
July 1, 1972-June 30, 1973; July 1, 1974-June 30, 1976
Licensure Status:
New York
Minnesota
Washington, D.C.
Maryland
License to Practice Medicine, 1989 [#179930]
License to Practice Medicine, 1977 [#0237501]
License to Practice Medicine, 1974
License to Practice Medicine, 1974
Active
Inactive (Allowed to lapse)
Inactive (Allowed to lapse)
Inactive (Allowed to lapse)
Specialty Board Status:
 Diplomate ABIM, Medical Oncology, 1979
 Diplomate ABIM, Internal Medicine, 1978
 Diplomate National Board Medical Examiners, 1974 (Candidate Number 065470)
Academic Employment Background (prior positions):
Position
Institution
Professor
University of South Carolina
Oncologist
Dorn VAMC, Columbia, South Carolina
Director of Research Dorn VA Medical Center, Columbia, SC
Visiting Professor
National Cancer Center Hospital,
Tokyo, Japan (6 months)
Professor (tenured)
Albany Medical College of Union Univ.
Department Internal Medicine (Oncology);
Microbiology/Immunobiology
Senior Clinician Investigator
VA Healthcare Network, Upstate New York, Albany
Samuel S. Stratton VA Medical Center
Senior Staff Oncologist
VA Healthcare Network, Upstate New York, Albany
Samuel S. Stratton VA Medical Center
Senior Staff Oncologist
VA Healthcare Network, Upstate New York, Albany
Samuel S. Stratton VA Medical Center
Adjunct Professor
Rensselaer Polytechnic Institute
Department of Chemical Engineering
Adjunct Professor
Albany College of Pharmacy
Adjunct Professor
State University of New York, Albany
School of Public Health, Biomedical Sciences Dept.
Date
2000-2010
2000-2010
2000-2004
1999 - 2000
1989 - 2000
1998 – 2000
1989 – 1998
1989 – 1998
1989 -- 2000
1991 – 2000
1994 - 1997
Associate Professor (tenured)
(Richard Ebert)
(B.J. Kennedy)
(Ellis Benson)
(Perry Blackshear/Otto Schmitt)
University of Minnesota
• Department of Internal Medicine
• Section of Medical Oncology
• Department of Laboratory Medicine and Pathology
• Biomedical Engineering
1986 - 1989
Member
Graduate Faculty in Biomedical
Engineering, University of Minnesota
1987 - 1989
Associate Member
Assistant Professor
Graduate Faculty in Pathobiology,
University of Minnesota
• Department of Internal Medicine
• Section of Medical Oncology and
• Department of Laboratory Medicine
and Pathology – Chronobiology
University of Minnesota
Department of Radiation Therapy
Postgraduate Institute of Medical Research
Chandigarh, India
1986 - 1989
1979 - 1986
UICC Visiting Scientist
(ICRETT Fellow)
1980 (3 mos)
3
Hrushesky • Curriculum Vitae • Page
Medical Research Specialist
Instructor
(B.J. Kennedy)
University of Minnesota
Department of Internal Medicine,
Medical Oncology
Minneapolis, Minnesota
1978 - 1979
Resident in Medicine
(Richard Ebert)
University of Minnesota
Department of Medicine
Minneapolis, Minnesota
1976 - 1978
Lt. Cdr. USPHS
Clinical Associate
(Stephen K. Carter)
National Institutes of Health
National Cancer Institute
Division of Cancer Treatment
Cancer Therapy Evaluation Program
Bethesda, Maryland
Veteran’s Administration Hospital
N.C.I. Oncology Section
Washington, D.C.
Georgetown University Hospital
Department of Internal Medicine
Washington, D. C.
1974 - 1976
Straight Medical Intern
(Phil Zieve)
Baltimore City Hospitals
Johns Hopkins Hospital
Baltimore, Maryland
1973 - 1974
Fellow
(Victor McKusick/P. Tumulty)
Johns Hopkins University
Department of Internal Medicine
Baltimore, Maryland
1973 - 1974
Clin. Student Fellowship
(John Walton)
University Hospital
Department of Neurology
New Castle upon Tyne, England
1973 (3 months)
Commissioned Officer
Surgeon (COSTEP)
USPHS
University of Buffalo
Medical School
Buffalo, New York
1972 - 1973
Cancer Research Scientist
(Gerald P. Murphy)
Roswell Park Memorial Institute
Department of Experimental Surgery
Buffalo, New York
1970 - 1973
Glenn H. Leak Memorial
Special Merit Fellowship
(Gerald P. Murphy)
Roswell Park Memorial Institute
Buffalo, New York
1972
American Cancer Society
Special Merit Fellowship
(Gerald P. Murphy)
Roswell Park Memorial Institute
Buffalo, New York
1971
Fellowship
Basic Immunology
(Noel Rose)
Center for Immunology
State University of New York
Buffalo, New York
1970
Fellowship
Medical Disparities
State University of New York
Buffalo, New York
1970
Teaching Assistant
Histology
Syracuse University
Syracuse, New York
1968 - 1969
Teaching Assistant
Biology
Syracuse University
Syracuse, New York
1967 - 1968
Clinical Instructor
(Marty Cohen)
Associate Staff Member
(Phil Schein)
1975 - 1976
1974 - 1976
4
Hrushesky • Curriculum Vitae • Page
5
Honors and Awards:
• NCI Japan, Visiting Professorship, 1999-2000
• UICC Tech. Transfer. Fellowship Grant, 1980
• ACS Junior Faculty Development Award, 1976-1979
• American Cancer Society, Original Research Grants, 1971, 1972
• Student Research Award, 1973, Association for Academic Surgery
• Best Clinical Essay Award, 1973, American College of Surgeons
• Clara A. March Scholarship, 1972
• Clara A. March Scholarship, 1973
• Health Profession Grants, 1969-1973
• Regents and Trustee Scholarship Grants, 1965-1969
Educational Activities (partial list):
 Advisor to PhD and Masters degree candidates as well as medical students, interns, residents and fellows.
 Mentoring USC junior faculty in USC School of Medicine and School of Public Health, Mentoring junior
faculty in Medical Oncology and other Medical subspecialties
 Mentoring/advising young physicians and scientists on basic & clinical research opportunities
 Building science-based bridges among Veterans Hospital, South Carolina Cancer Center, University of South
Carolina.
 Lectures in Public Health, Medical and Engineering schools
 Funding and organization of International cancer research meetings
Medical Oncology Practice /Area Clinical Investigation
Span
Position
2010-present
Senior Executive Medical Director and
Chief Scientific Officer
1976-2010
Cancer Therapy Development
2000-2010
Professor
University of South Carolina
Senior Clinician Investigator
Dorn VA Medical Center
1990-2000
1979-90
1974-76
Tenured full professor
Albany Medical College, Union Univ.
Senior Clinician Investigator
Stratton VA Medical Center
Resident, Medical Oncology Fellow
through tenured Associate professor
University Minnesota
NCI/DCT Cancer Therapy Evaluation
Program (CTEP) Clinical associate
and medical oncology fellow
Areas of Expertise
*Oncology pharmaceutical
utilization management
*Circadian Cancer Therapy
*Head and neck cancer
*GU cancer
*GI cancer
*Lung cancer
*All other solid tumors
*Lung cancer (all types)
*GU cancers (kidney/prostate/bladder)
*GI cancers
*Breast cancer
*GYN Medical Oncology
(ovarian, endometrial cervical)
*Breast Cancer-all stages
*GU Oncology-kidney
bladder/penis/prostate
*GI Oncology-Colorectal/other
*Medical director loco-regional infusional
therapy program
*Lung, GI, Prostate, Head, and Neck
*Small cell lung cancer/high
dose chemo/Phase I/II studies
Cancer Therapy Development Experience (Discovery/Reduction to Practice)
2000-2010
Professor University South Carolina and Senior Oncologist Investigator, Dorn VAMC
 Created and led the first active cancer clinical trials program at this medical center (PI more than 100 cancer
clinical trials)

Hrushesky • Curriculum Vitae • Page
6
Demonstration of the probable mechanisms by which mammographic breast cancer screening in
premenopausal women results in more frequent and earlier death from breast cancer than unscreened
premenopausal women (VA MERIT Award and DOD IDEA funded).
 Demonstration of the two-fold seasonality of Pap smear detected human cervical epithelial HPV infection,
premalignant and malignant change
 Published evidence that one of the mechanisms responsible for this seasonality may be seasonal population
UVB exposure (VA MERIT Award funded).
 Preclinical and randomized double-blind placebo controlled clinical trial testing the chronobiotic activity of
melatonin in patients with non-small cell lung cancer (VA Merit and CTRF funded).
 Determining how the circadian clock gene, Per-2, functions as a tumor suppressor in both breast and
colorectal cancer models (VA MERIT Award and NIH COBRE Funded).
 Discovery of the tumor suppressor activity of the Per-1 core circadian clock gene
 Genomic discovery of genetic pathways responsible for the menstrual/estrous cycle control of postresection breast cancer spread (VA MERIT Award and DOD funding).
 Discovery that sun spot cysles may coordinate human physiology, infection and malignant potential
1990-2000 Tenured full prof.Albany Med. College/Sr. Clin. Investigator Stratton VAMC, Albany, NY
 Creation, completion, and publication of preclinical and clinical trials demonstrating that the timing of
breast cancer resection within the estrous cycle of mice and menstrual cycle of women determines the
frequency of breast cancer metastasis and death from breast cancer, demonstrating that optimal resection
timing can save 12-15,000 U.S. and 200-260,000 lives worldwide each year (NCI R-01 and VA Merit
Award funded).
 Created staffed and supervised the first active commercial cancer clinical trials program at this VA medical
center (PI for about 100 trials over 11 years).
1976-1990 Assistant and Associate Professor with tenure University of Minnesota Cancer Center
 Design completion and publication of the first General Clinical Research Center-based randomized
controlled trial of circadian cancer therapy
 Participated in Cooperative Group (CALGB) Cancer clinical trials
 Designed and obtained NCI R01 funding for a series of multi center clinical trials of circadian cancer
chemotherapy Results of these studies demonstrate that optimal timing of cytotoxic chemotherapy
diminishes toxicity 3-6 fold while enhancing patient survival four-fold. (NCI R-01 funded and renewed 3
times).
 Largest user of University of Minnesota General Clinical Research Center for detailed human cancer
studies for ten years
 Invention, development, reduction to practice and manufacture of diagnostic medical device to
noninvasively quantify left ventricular compliance and demonstration of its utility for predicting
Doxorubicin-induced heart failure.
Sold to several pharmaceutical firms for research to study
myocardial effects of drugs (SBIRG funded NHLB).
 Demonstration of the utility of FUDR –continuous nighttime infusion - chronotherapy for progressive
metastatic renal cell cancer (NCI R-01 and Medtronic Corp. funded). This remains the only effective
cytotoxic regimen for RCC.
 Creation and completion of the first international multisite controlled randomized clinical trial
demonstrating the value of chronotherapy of cancer. Systemic FUDR found to be safe and effective
therapy for RCC, only when given by chronotherapeutic continuous infusion peaking each night (NCI R01).
 Creation, development and Medical Direction of University of Minnesota intrahepatic cancer therapy
program
 Creation and completion of the first randomized controlled clinical trial demonstrating that
chronotherapeutic FUDR infusion into the hepatic artery for metastatic cancer eliminates FUDR- induced
sclerosing cholangitis, without diminishing cancer control (NCI R-01 funded).
 Designed, performed, published and presented pivotal data to FDA device approval advisory committee,
summarizing clinical experience using the Medtronic Synchromed implantable pump to deliver optimally
timed circadian cancer chronotherapy. These studies resulted in FDA approval of the SynchroMed® device
for delivery of cancer chemotherapy (NCI R-01 and Medtronic-funded).

Hrushesky • Curriculum Vitae • Page
7
Worked with AIZA Corp and Medtronic Corp to develop the first temporally controllable transcutaneous
drug delivery system
1973-1976 Staff physician/clinical associate NCI, DCT (Division of Cancer Treatment), CTEP
 Monitored CTEP-approved and NCI-funded worldwide cancer clinical trials (NCI)
 Worked as NCI staff with FDA drug sponsors cooperative cancer study groups and investigators to develop
and achieve FDA approval for new anti-cancer agents.
 Participated in protocol design and review and decision making to make NCI drugs available to cooperative
groups and investigators around the world
 Participation in NCI intramural clinical trials testing high dose chemotherapy in small cell lung cancer and
prostate clinical trials (NCI, DCT funded). Phase I, Phase II study design
 Prepared NDA summary of worldwide preclinical and clinical data describing the toxicity and efficacy of
the first biological agents, E coli and Erwinia L-Asparaginase, approved for cancer treatment by the US
FDA
 Presentation of these data to the oncology advisory committee of FDA (ODAC).
 This work supported eventual FDA approval of these agents for the treatment of patients with acute
lymphoblastic leukemia (NCI, DCT, CTEP funded).
 Prepared summary of all therapeutic work in Renal Cell Carcinoma in preparation for new RCC therapy
development
1969-1973 Scientist RPCI and Medical Student, Buffalo, NY
 Invention, development, reduction to practice and hospital-wide adoption of a unique diagnostic urine test,
predictive of acute rejection of renal transplant. (1970-1973)
 Development and characterization of the RenCa murine renal cell carcinoma model. (1970-1973)
 The first organized studies of the unique tumor biology associated with orthotopic tumor implantation.
(1969-73) (Renal cell carcinoma)
 First preclinical confirmation of the renal source of erythroprotein (1970)
Books:
 The Pineal Gland and Cancer. Bartsch C, Bartsch H, Blask D, Cardinali D, Hrushesky, WJM, Mecke D
(Editors), Springer-Verlag Press, Berlin, Germany, 2001.
 Circadian Cancer Therapy. Hrushesky WJM (Editor). CRC Press, May 1994.
 Temporal Control of Drug Delivery. Hrushesky WJM, Langer R, Theeuwes F (Editors). Annal NY
Academy of Science, Volume 618, 1991.
Monographs:
 Circadian Disruption and Cancer. Block K, Hrushesky WJM, Blask D. Integrative Cancer Therapies 8 (4),
December 2009.
 Larry Scheving Symposium. Hrushesky WJM (Editor). Journal of Infusional Chemotherapy 5 (1), Winter
1995.
 Scientific Basis for Circadian Cancer Therapy. Hrushesky WJM (Editor). Journal of Infusional
Chemotherapy 3 (3), July 1993.
 Cancer Chronotherapy. Hrushesky WJM (Editor). J of Infusional Chemotherapy 2 (2), April 1992.
Poetry, Essays, Columns:
 “Uneasy Piazzas.” Published in Poetry, December 2001.
 “Home of the Brave” Published in The State, February 24, 2007.
 “Homeless Solution as close as history, and State Hospital” Published in The State, July 7, 2008.
(*Other writings available on the website, www.scmedicalchronobiology.org.)
NCI Drug Development Publications:
Hrushesky WJM, Helman L: Yoshi 864 (NSC 10267), a methanesulphonate derivative. A compilation of what
has been done with clinical emphasis. September 1975 [revised May 1976]. Cancer Therapy Evaluation
Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD.
Hrushesky WJM: L-asparaginase, a summary and guidelines for its use. September 1975. Cancer Therapy
Evaluation Program, National Cancer Institute, Bethesda, MD.
Hrushesky • Curriculum Vitae • Page
8
Handelsman H, Hrushesky WJM, Legha S, Penta J, Strauss G, Vilk P: Proceedings, phase I working group
and new drug liaison. October 1974. National Cancer Institute, Bethesda, MD.
Hrushesky WJM: MER, a new non-specific immunotherapeutic agent. An overview. September 1975. Cancer
Therapy Evaluation Program, National Cancer Institute, Bethesda, MD.
Hrushesky WJM: Analysis of clinical studies of L-asparaginase EC-2 (NSC-109929) 25 November 1975.
Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD.
Patents and Copyrights:
Rodent Inject-Aid: Laboratory Device Allowing Fast and Simple Murine Access Systems.
US Patent #4,709,660 (awarded 12/01/87)
One-Piece Catheter Access Port with Guide Wire:
Letter of Disclosure (12/08/86), U of MN Patent Office
Infuse-a-Fill Manual: Guide to Safe Continuous Chemotherapy Infusion. Copyright (1984)
Needle Support System: Medical Device Stabilizing Access to Subcutaneous Vascular Access
US Patent #4,675,006 (awarded 06/23/87)
Method and Agents for Raising Animal Tolerance to Oxidant Stress-Inducing Antibiotics: Chemical
Method of Modifying Drug Toxicity by Modulating Intracellular Redox Status.
US Patent #4,548,927 (awarded 10/22/85)
Sinus Arrhythmia Monitor:
US Patent #4,930,518 (awarded 06/05/90)
Sine-O-Graph: Diagnostic Medical Device to Measure Myocardial Compliance Noninvasively.
US Patent #4,519,395 (awarded 05/28/85)
Canadian Patent #1,196,012 (awarded 10/19/85)
PEER REVIEW FUNDING HISTORY
PRINCIPAL INVESTIGATOR ONLY
Source
Title
NIH
Center for Colon
Cancer Research, University
of South Carolina
Peer Review
Type
Years
COBRE
2002-2007
(Pathology
(‘08-‘12
CORE Director) renewed)
Initiated
2003-2007
Clinical Trial
Concept
2005-2007
Investigator
Research
2003-2006
Experience
Merit
2002-2006
U.S. Army
Foundation
VA
DOD BCRP
CTRF
MERIT Supplement
VA
Biologic Discrimination of
Key Molecular Targets to
Prevent Metastasis
Pilot Program for AllPACE
Inclusive Care of Elderly
Preliminary Investigation
IDEA
of the Role of Cellular Immunity
in Estrous Cycle Modulation of
Post-resection Breast Cancer Spread
Mechanisms by Which
Merit
The Estrous Cycle
Modulates Cancer Spread
Post-resection Breast
Merit
Cancer Cure Is Modulated by
the Timing of Breast Cancer
Resection within the Estrous Cycle
Circadian Cancer Therapy
RAG
Chronobiology of IL-2/TNF
R01
VA
U.S. Army
VA
VA
VA
NIH/NCI
Direct $ Funding Amount
$300,000
$120,000
$396,000
$86,500
$100,000
$600,000
2002-2005
$4,500,000
1997-2006
$300,000
1997-2000
$288,000
1992-1997
$500,000
1989-91
1984-89
$125,000
$685,000
Hrushesky • Curriculum Vitae • Page
NIH/NHLB
NIH/NCI
ACS
A Device for Quantification
Of RSA
Clinical Application
of Chronobiology to
Cancer Medicine
Junior Faculty Fellowship
SBIRG
Phase I
R01
1983
$100,000
1979-2000
$3.5 million
1976-1979
$200,000
9
Hrushesky • Curriculum Vitae • Page 10
Appendix I- Heroes, Mentors and Protégés
Heroes: Baruch Spinoza, Benjamin Franklin, and Richard P. Feynman
Mentors:
Medicine
The late Philip Tumulty, M.D.
Clinical Professor of Internal Medicine
Johns Hopkins University
Chronobiology
Franz Halberg, M.D.
Professor and Director,
Chronobiology Laboratories
420 Delaware St. SE
Minneapolis, MN 55455
Tel: 612-624-6976, Fax: 612-624-9989
Creative Thinking
The late Otto Schmitt, Ph.D.
Professor Emeritus, Biophysics,
University of Minnesota
Medical Oncology:
The late B.J. Kennedy
Professor University of Minnesota
Role Models:
Philosophy
José Benardete, Ph.D., Professor of Philosophy
Syracuse University, 541 Hall of Languages
Syracuse, NY 13244
Tel: 315-443-2245
Fine Arts
Sidney Alexander, Ph.D.
Professor of Art History
Syracuse University
Piazza Santa Maria Soprarno, #1
50125 Florence Italy
Tel: 39-55-248-095
Zoology
The late W.D. Russell-Hunter, Ph.D.
Emeritus Professor of Zoology
Syracuse University
Biomedical Engineering
Earl Bakken, Ph.D. (hon)
Founder, Medtronic, Inc.
7000 Central Avenue N.E.
Minneapolis, MN 55432
Tel: 612-574-3000
Translational Research
Bernard Fisher, M.D.
University Professor
Pittsburgh University
North Hawaii Community Hospital
67-1125 Mamalahoa Highway
Kamuela, HI 96743
Tel: 808-885-4444
Hrushesky • Curriculum Vitae • Page 11
Appendix II- Protégé Development History
Duration of
Intimate Interaction
Protégé
Type of Interaction
Jane Reusch, MD
Denver VA
(303) 399-8020
Research Supervisor
2 years
Active Investigator,
Professor, University
of Colorado,
Endocrinology and
Staff Physician, Denver
VAMC
John Berestka, MD
Ophthalmologist
Research Supervisor
3 years
Practicing
Marjorie Vukelich, MD
(603) 646-5000
Clinical Research
Supervisor
3 years
Practicing Oncologist
Edward Chute, MD
Research Co-Advisor
2 years
Associate Professor
Academic Surgeon
Scott Nygaard, MD
Research Supervisor
2 years
Associate Professor
Active Investigator,
Academic Pulmonary
Physician, U. of CO
>10 years
Director, Breast
Research Center
Professor, Yale
Donald Lannin, MD, PhD Research Co-Advisor
(203) 785-2328
Current Position
University
School of Medicine
Jan MA Van Tornout, MDResearch Co-Advisor
2 years
Academic Pediatric
Oncologist, UCLA
(Los Angeles, CA)
Rosellen Lanning, RN
(415) 567-1219
Clinical Research
Supervisor
3 years
Co-Director, Pain Clinic
(San Francisco, CA)
Kyle Traynor, MD
Research Supervisor
Advisor, MS Project
1 year
Practicing physician,
Mayo Clinic
Wolfgang Marz, MD
Research Co-Advisor
Post Doctoral Assoc.
3 years
Funded Independent
Investigator, University
of Freiburg, Germany
James Pray, MS
(612) 550-7777
Masters Advisor
2 years
CEO and Founder
Penumbra Inc.
1 year
Practicing surgical
oncologist
Marek Martynovich, MD Advisor and Research
Supervisor, Post
Doctoral Associate
Hrushesky • Curriculum Vitae • Page 12
Miroslaw Markiewicz, MD Advisor and Research
Supervisor, Post
Doctoral Associate
1 year
Professor, Katowice,
Poland, Academic
gastroenterologist
Francis Levi, MD, PhD
33 14 6770000, x 375
fax: 33 14 726 8097
Research Co-Advisor
Mentor/colleague
>20 years
Director, INSER
Chronobiology
Laboratory
(Paris)
Todd Langevin, BS
(612) 572-5548
fax: (612) 574-6459
Research Supervisor
Mentor/colleague
8 years
Vice President
Medtronic Corp.
(Minneapolis, MN)
Robert B. Sothern, PhD
(612) 644-5438
fax: (612) 221-2741
Research Supervisor,
Ph.D. Advisor
Mentor/ Colleague
20 years
Faculty, Botany
University of Minnesota
(Minneapolis, MN)
Darrell Fader, MD
(313) 663-1399
Research Supervisor,
Advisor/Mentor
10 years
Practicing Dermatologist
Randal Olshefski, MD
Research Supervisor,
Advisor/Mentor
>10 years
Pediatric Oncologist
Jeffrey Rabatin, MD
(703) 685-7521
Clinical Research
Supervisor and Advisor
Mentor
3 years
Assistant Professor,
Medicine; Pulmonary
and Critical Care Mayo
School of Medicine
Mayo Clinic
Rochester, MN
Reinhard V Roemeling, MD Research Supervisor,
Clinical Research Adv.
Mentor/Colleague
13 years
Vice President
Clinical Development,
Oncology
Daiichi Sankyo Pharma
Development
Edison, NJ USA
Christine Mormont,MS,BS Research Supervisor,
M.S. Advisor/Mentor
5 years
Asst. Director,
Labratoire
“Rythmes Biologiques et
Chronothérapeutique,”
ICIG Hôpital Paul
Brousse
(Villejuif, France)
Susan Schraufek,MD,MS Research Supervisor,
M.S. Advisor/Mentor
2 years
Practicing Gynecologist
Cheryl Wesen, MD
(313) 876-3161
fax: (313) 876-7354
Clinical Research
Advisor/Mentor
2+ years
Academic Surgical
Oncologist
Henry Ford Hospital, MI
Young Kim, PhD
Research Supervisor
Masters Advisor
1 1/3 years
Research Scientist
Seoul, Korea
Hrushesky • Curriculum Vitae • Page 13
Stelios Tzannis
(415) 494-5000
Ph.D. Advisor
Chem. Eng., RPI
3 years
Group Leader
ALZA Corp., CA
Hemant Gupta
Research Supervisor
6 months
Practicing physician
Georg Bjarnason, MD
(416) 480-4928
fax: (416) 480-6002
Clinical Research
Advisor/Mentor/Colleague
15 years
Investigator
Associate Professor
Medical Oncology,
University of Toronto
Rostislav Vyzula, MD
Basic and Clinical
Research Advisor
Mentor
3 years
Chief of Medical
Oncology, Masaryk
University, Hospital
Czech Republic
5 years
Independent Funded
Investigator
Investigator, Assoc.
Professor of Surgery
Baylor College of
Scott A. Gruber,MD,PhD Research Supervisor,
(518) 262-5618
Ph.D. Co-Advisor
fax: (518) 262-5560
Mentor/Colleague
Medicine
Patricia A. Wood, MD,PhD Research Supervisor,
25 years
(803) 776 – 4000 x5599 Advisor/Mentor
fax: (803) 647- 5656
Basic and Clinical Research Partner
Colleague
Independent funded
Investigator
Associate Prof USC
Chief of Medical
Oncology/Hematology
WJB Dorn VAMC
Columbia, SC
Jason Fishbein, M.S.
Medical and Clinical
Research Mentor
3 months
Working Scientist
Adnan Fateh
Research Advisor
12 weeks
Working Scientist
Andreas Hagen, M.D.
Clinical Research
Free University Berlin
Mentor
0049-30-8445-2591
fax: 0049-30-8445-4477
2 years
Academic Physician
OB/GYN
Hospital Benjamin
Franklin,
Berlin, Germany
Jason Galarneau
Research Mentor
12 weeks
Working Scientist
Kathleen Stapleton
Research Mentor
12 weeks
Working Scientist
David Lincoln, Ph.D.
(518) 462-3311, x 2258
Research Supervisor
20 months
Working Scientist
Tim Sullivan
(518) 674-8246
Advisor/
Research Mentor
3 years
Entrepreneur, Founder,
CEO Multimdeia Corp.
Josip Gazic
Advisor/
Research Mentor
4 months
Physician-scientist
Shameem Shaik
Research Mentor
2 months
Physician
Hrushesky • Curriculum Vitae • Page 14
Angela Wo
Research Mentor
2 months
Physician
Michael Canarie
(518) 462-7545
Research Mentor
6 months
Physician
Monique Lin
(518) 438-8292
Research Mentor
4 months
Physician
Shalini Kansal
Research Mentor
1 month
Physician
Melissa Thrall
Research Mentor
2 years
Physician
Paul Bell
Research Mentor
3 months
Physician
Kathleen Bove
Research Mentor
2 years
Scientist
Imran Iman
Research Mentor
3 years
Physician
Kevin Cranmer
Research Mentor
3 years
Academic
Ophthalmologist
Kerri Kluetzman
Research Mentor
1 year
Working Scientist
Elissa Ball, R.N.
Clinical Research
1 year
Clinical Research Nurse
Kirsten Tallent
Mentor
Research Mentor
2 years
Physician
Elizabeth Rosenmann
Research Mentor
3 years
lost to follow-up
Lawrence Lansing
Research Mentor
1 year
lost to follow-up
Keith Guberman
Research Mentor
1 year
RPI graduate
Joe Blizzard
Research Mentor
1 year
Academic pharmacist
Philip Musk
Research Supervisor
1 year
Research Scientist
Biotech Industry
Daniel Patterson
Research Mentor
Master’s Advisor
3 years
Public health practitioner
Wesley Jones
Research Mentor
6 months
Physician
Minoru Kobayashi
Research Supervisor
2 years
Academic surgeon/
Associate Professor
Jichi Medical University
Japan
Mark You
Post doctoral
Research Supervisor
3 years
Funded Research
Scientist,
Emory University
Hrushesky • Curriculum Vitae • Page 15
Yin Xiong, PhD
PhD advisor
5 years
NIH/NCI scientist,
Bethesda, MD
Peter Miller, MD
Research Mentor
3 years
Current medical resident
Sue Haddock, RN, PhD
Mentor
Masters advisor
2 years
Asst. Professor, Nursing
Current Assoc. COS
Research WJB Dorn
VAMC
Masami Ohmori, MD
Research Supervisor
2 years
Asst. Professor
Medicine,
Academic physician
Jichi Medical University,
Japan
Jovelyn Du-Quiton, MS Research Mentor
5 years
Statistician/Biometrist
Elizabeth Greene
Masters Advisor
2 years
University of South
Carolina
Andrew Taber
Research Mentor
2 years
Gastroenterology Fellow
Alex Friedman
Research Mentor
1 year
Washington University
Undergraduate, Senior
Aziz Chowdry
Research Mentor
2 years
Medical Student,
University of South
Carolina
Jamil Singletary
scientist
Research Mentor
2 years
Working computer
Stacy Ayers
Research Mentor
5 years
Masters Student, SC
State University
Dinah Quiton, MD
Research Mentor
3 years
Clinical Research
Associate
Justin Reynolds
Clinical Research
Mentor
4 years
Clinical Research
Associate, WJBD
VAMC
Stephanie Kidder
PhD Advisor
Research Mentor
1 ½ years
PhD Student, USC
Medical School
(now at Baylor
School of Medicine)
Shalish Jones
Mentor
6 years
Cancer Program
Assistant
Dora Oroian
Research Mentor
1 year
Washington University
Hrushesky • Curriculum Vitae • Page 16
Hamayun Nawaz
Research Mentor
2 years
Medical Fellow
Chris Yang
Research Mentor
2 years
Research Associate
Xiaoming Yang, PhD
Post-Doctorial
Research Advisor
5 years
Senior Post Doctorial
Associate
Christine Ansell
Research Mentor
3 years
Research Associate
University of South
Carolina
Young Oh, PhD, MD
PhD Advisor
Research Mentor
5 years
Pathology Resident
Anmol Baranwal, MD
Research Mentor
ongoing
Research Associate
Avinash Mamgain
Research Mentor
ongoing
Research Associate
Hrushesky • Curriculum Vitae • Page 17
Appendix III- Published Peer Reviewed Scientific Papers:
1.
Hrushesky W, Sampson D, Murphy G. Lymphocyturia in renal allograft rejection. Arch Surg 1972; 105:424426.
2.
Hrushesky W, Sampson D, Murphy G. Carcinogenicity of ethylmethanesulfonate. J Natl Cancer Inst 1972;
49:1077-1083.
3.
Murphy G, Hrushesky W. A murine renal cell carcinoma. J Natl Cancer Inst 1973; 50:1013-1025.
4.
Hrushesky W, Murphy G. Investigation of new renal tumor model. J Surg Res 1973; 15:327-336.
5.
Hrushesky W, Murphy G. Evaluation of chemotherapeutic agents in a new murine renal carcinoma model. J
Natl Cancer Inst 1974; 52:1117-1122.
6.
Williams P, Hrushesky W, Gaeta J, Murphy G. The influence of hormone therapy on rats treated with the
carcinogen ethylmethanesulfonate. Res Comm Chem Path Pharmacol 1974; 7:25-30.
7.
Hrushesky W. L-asparaginase activity in acute non-lymphocytic leukemia. Cancer Treat Rep 1976; 60:966.
8.
Hrushesky W, Slavik M, Penta J, Muggia F. The "other" asparaginase. Med Ped Oncol 1976; 2:441-442.
9.
Hrushesky W. Serpentine supravenous 5-fluorouracil hyperpigmentation. Cancer Treat Rep 1976; 60:639.
10.
Hrushesky W, Murphy G. Current status of the therapy of advanced renal carcinoma. J Surg Oncol 1977;
9:277-288.
11.
Hrushesky W. Thrombocytopenia induced by low-dose subcutaneous heparin. Lancet 1977; 2:1286.
12.
Hrushesky W. Platelets in Thrombocythemia. Ann Int Med 1978; 88:845.
13.
Hrushesky W. Subcutaneous heparin-induced thrombocytopenia. Arch Int Med 1978; 138:1489-1491.
14.
Gordon L, Hrushesky W, Oken M, Kay N, Rydell R. Chronic lymphocytic leukemia in association with a
second lymphoproliferative disorder: response to chemotherapy in two cases. Med Ped Oncol 1979; 7:111117.
15.
Halberg E, Halberg F, Vener K, Scheving L, Cornelissen G, De Prins J, Hrushesky W, Kennedy BJ. Twentyfour hour synchronized chronotolerance of cis-diamminedichloroplatinum (II) by rats on 8h and 12h
photofraction gauged by acrophase and paraphase of rectal temperature. In: Reinberg A, Halberg F, eds.
Chronopharmacology. Oxford/New York: Pergamon Press, 1979:377-387.
16.
Sothern R, Hrushesky W, Halberg F, Haus E, Kennedy B. Circadian temperature rhythm in LOU rats with
and without immunocytoma during polychronochemotherapy with adriamycin and cisdiamminedichloroplatinum II. In: Reinberg A, Halberg F, eds. Chronopharmacology. Oxford/New York:
Pergamon Press, 1979:391.
17.
Levi F, Halberg F, Haus E, Sanchez de la Peña S, Sothern R, Halberg E, Hrushesky W, Brown H, Scheving
L, Kennedy BJ. Synthetic adrenocorticotropin for optimizing murine circadian chronotolerance for
adriamycin. Chronobiologia 1980; 7:227-244.
18.
Levi F, Hrushesky W, Haus E, Halberg F, Scheving L, Kennedy B. Experimental chrono-oncology. In:
Scheving L, Halberg F, eds. Chronobiology: Principles and Applications to Shifts in Schedules, 1980:481511.
19.
Haus E, Halberg F, Sothern R, Lakatua D, Scheving L, Sanchez de la Peña S, Sanchez E, Melby J, Wilson T,
Brown H, Berg H, Lévi F, Culley D, Halberg E, Hrushesky W, Pauly J. Time-varying effects in mice and rats
of several synthetic ACTH preparations. Chronobiologia 1980; 7:211-226.
20.
Hrushesky W. Unusual pigmentary changes associated with 5-fluorouracil therapy. Cutis 1980; 26:181-182.
Hrushesky • Curriculum Vitae • Page 18
21.
Hrushesky W, Levi F, Halberg F, Haus E, Scheving L, Sanchez de la Peña S, Medini E, Brown H,
Kennedy BJ. Clinical chrono-oncology. In: Scheving L, Halberg F, eds. Chronobiology: Principles and
Applications to Shifts in Schedules, 1980:513-533.
22.
Levi F, Hrushesky W, Kennedy B. Perspecitves en chronochimiotherapie anticancereuse. Le Quotidien Du
Medicin Chronobiologia 1981; Suppl 2546:46-51.
23.
Magnus G, CavFallini M, Halberg F, Cornelissen G, Sutherland D, Hrushesky W. Cyclosporine tolerance
improved by circadian timing. S.I.R.M.C.E., Influence of Environment of Man, 1982:13-23.
24.
Levi F, Hrushesky W, Borch R, Pleasants M, Kennedy B, Halberg F. Cisplatin urinary pharmacokinetics and
nephrotoxicity: A common circadian mechanism. Cancer Treat Rep 1982; 66:1933-1938.
25.
Hrushesky W, Levi F, Halberg F, Kennedy B. Circadian stage dependence of cis-diamminedichloroplatinum
lethal toxicity in rats. Cancer Res 1982; 42:945-949.
26.
Hrushesky W. Bone marrow suppression from doxorubicin and cis-diamminedichloroplatinum is
substantially dependent upon both circadian and circannual state of administration [Cell Proliferation, Cancer
and Cancer Therapy. A Conference in Honor of Anna Goldfelder, R Baserga (ed)]. Ann NY Acad Sci 1982;
397:293-295.
27.
Hrushesky W, Borch R, Levi F. Circadian time dependence of cisplatin urinary pharmacokinetics. Clin
Pharm Ther 1982; 32:330-339.
28.
Levi F, Hrushesky W, Halberg F, Haus E, Langevin T, Kennedy B. Lethal nephrotoxicity and hematologic
toxicity of cis-diamminedichloroplatinum ameliorated by optimal circadian timing. Eur J Cancer Clin Oncol
1982; 18:471-477.
29.
Levi F, Hrushesky W, Blomquist C, Lakatua D, Haus E, Halberg F, Kennedy BJ. Reduction of cisdiamminedichloroplatinum nephrotoxicity in rats by optimal circadian timing. Cancer Res 1982; 42:950-955.
30.
Bixby E, Levi F, Haus R, Sackett L, Haus E, Halberg F, Hrushesky W. Circaseptan aspects of murine
nephrotoxicity of cisdiamminedichloroplatinum. In: Takahashi R, Halberg F, Walker C, eds. Toward
Chronopharmacology. New York: Pergamon Press, 1982:339-347.
31.
Hrushesky W. Adjuvant chemotherapy for transitional cell carcinoma of the urinary bladder [Editorial].
World Urology Update 1983; 1:6.
32.
Hrushesky W. The clinical application of chronobiology to oncology. Am J Anat 1983; 168:519-542.
33.
Hrushesky W, Merdink J, Abdel-Monem M. Circadian rhythmicity of polyamine excretion. Cancer Res
1983; 43:3944-3947.
34.
Hrushesky W. Circadian chronopharmacokinetics and chronotoxicology of doxorubicin and cisplatin in
human beings with cancer. In: Reinberg A, Smolensky M, Labrecque G, eds. Annual Review of
Chronopharmacology. Vol. 1. New York: Pergamon Press, 1984:119-122.
35.
Hrushesky W, Vukelich M, Steiner B, Dell I, Mukai K. 24-hour mean pulse: a simple predictor for
doxorubicin-induced cardiac damage. Am J Med 1984; 77:399-406.
36.
Hrushesky W, Vukelich M. Circadian mesor of recumbent pulse—cost effective predictor of doxorubicininduced congestive heart failure. Chronobiol Intl 1984; 1:59-66.
37.
Hrushesky W. The sine-o-graph pulse monitor: a potential quantifier of cardiovascular wellness. In: Reinberg
A, Smolensky M, Labrecque G, eds. Annual Review of Chronopharmacology. Vol. 1. New York: Pergamon
Press, 1984:325-328.
38.
Roelofs R, Hrushesky W, Rogin J, Rosenberg L. Peripheral sensory neuropathy and cisplatin chemotherapy.
Neurol 1984; 34:934-938.
Hrushesky • Curriculum Vitae • Page 19
39.
Hrushesky W. Selected aspects of cisplatin nephrotoxicity in the rat and man. In: Hacker M, Douple E,
Krakoff I, eds. Platinum Coordination Complexes in Cancer Chemotherapy: Martinus Nijhoff Publishers,
1984:165-186.
40.
Hrushesky W. The effect of anticancer drug timing upon therapeutic index. In: Wiernik P, ed. Mediguide to
Oncology. Vol. 4, 1984:1-5.
41.
Hrushesky W. Chemotherapy timing: An important variable in toxicity and response. In: Perry M, Yarbro J,
eds. Toxicity of Chemotherapy. New York: Grune and Stratton, 1984:449-477.
42.
Hrushesky W, Fader D, Gilbertsen V, Schmitt O. The respiratory sinus arrhythmia as an objective measure of
cardiac age. Science 1984; 224:1001-1004.
43.
Hrushesky W, Shimp W, Kennedy B. Lack of age-dependent cisplatin nephrotoxicity. Am J Med 1984;
76:579-584.
44.
Chute E, Rhode T, Rupp W, Goldenberg E, Hrushesky W, Buchwald H. Diurnal variation in glucose levels
can impede single rate continuous intravenous insulin therapy. In: Reinberg A, Smolensky M, Labrecque G,
eds. Annual Review of Chronopharmacology. Vol. 1. New York: Pergamon Press, 1984:185-188.
45.
Touitou Y, Hrushesky W, Levi F, Focan C, Auzeby A, Bogdan A. Plasma carcinoembryonic antigen rhythm
in patients with ovarian cancer: effects of chemotherapy. In: Reinberg A, Smolensky M, Labrecque G, eds.
New York: Pergamon Press, 1984:141-143.
46.
Kennedy B, Covell D, Hrushesky W. Implantable and extracorporeal programmable drug delivery systems:
what to program. In: Reinberg A, Smolensky M, Labrecque G, eds. Annual Review of Chronopharmacology.
Vol. 1. New York: Pergamon Press, 1984:193-196.
47.
Hrushesky W. Biological time structure and some of its implications in cancer medicine. table ronde roussel
uclaf 1985; 54:30-35.
48.
Hrushesky W. Utility of non-invasive instantaneous screening test for drug-induced cardiac damage [Letter
to editor]. J Clin Oncol 1985; 3:1438.
49.
Hrushesky W. Medical relevance of rhythmic biological time structure, 5th Intl Mtg on Clin Lab
Organization and Management, Haifa, Israel, 1985. Karger Publishers: 92-100.
50.
Hrushesky W, Olshefski R, Wood P, Meshnick S, Babson J, Woods W, Eaton J. Methylene blue ameliorates
doxorubicin toxicity. In: Superoxide and Superoxide Dismutase in Chemistry, Biology and Medicine,
Superoxide and Superoxide Dismutase, Rome, Italy, 1985. Elsevier: 642-646.
51.
Hrushesky W, Olshefski R, Wood P, Eaton J, Meshnik S. Modifying intracellular redox balance: an approach
to improving therapeutic index. Lancet 1985; 8428:565-567.
52.
Hrushesky W, Haus E, Lakatua D, Langevin T, Halberg F, Kennedy B. Marker rhythms for cancer chronochemotherapy. In: Haus E, Cabet H, eds. Chronobiology. New York: Karger Publishers, 1985:493-499.
53.
Hrushesky W. Circadian timing of cancer chemotherapy. Science 1985; 228:73-75.
54.
Hrushesky W. Distinguishing between renal allograft and cyclosporine nephrotoxicity. Lancet 1985;
8453:501.
55.
Hrushesky W. The effect of anticancer drug timing upon therapeutic index. In: Reitveld W, ed. Clinical
Aspects of Chronobiology: Meducation Service Hoechst, 1985:141-157.
56.
Hrushesky W. Cyclosporine timing and kidney damage. New Eng J Med 1985:184.
57.
Rosenberg C, Hrushesky W, Langevin T, Kennedy B. Hormonal and chemotherapeutic treatment of prostatic
carcinoma; Dunning adenocarcinoma of the prostate in Copenhagen-Fischer rats. Oncol 1985; 42: 48-54.
58.
Trugman J, Hogencamp H, Roelofs R, Hrushesky W. Cisplatin neurotoxicity: failure to demonstrate vitamin
B12 inactivation. Cancer Treat Rep 1985; 69: 453-455.
Hrushesky • Curriculum Vitae • Page 20
59.
Roemeling R, Christiansen N, Hrushesky W. Lack of antiemetic effect of high-dose metoclopramide. J
Clin Oncol 1985; 3:1273-1276.
60.
Magnus G, Cavallini M, Halberg F, Cornelissen G, Sutherland D, Najarian J, Hrushesky W. Circadian
toxicity of cyclosporine. Toxicol Appl Pharmacol 1985; 77:181.
61.
Focan C, Castronovo V, Collette J, Focan-Henrard D, Frére M, Le Hung S, Touitou Y, Lévi F, Hrushesky W,
Franchimont P. Alteration of circadian variation in serum concentrations of carcinoembryonic antigen (CEA)
in cancer. In: Peeters H, ed. Protides of the Biological Fluids: Proceedings of the Thirty-Second Colloquium.
Oxford/New York/Toronto: Pergamon Press, 1985:703-705.
62.
Hrushesky W, Roemeling R. Reply to: Rausto Roila et al.: Antiemetic effect of high-dose metoclopramide
[Letter to editor]. J Clin Oncol 1986; 4:441.
63.
Bowers L, Rabatin J, Wick M, Canafax D, Hrushesky W, Benson E. Circadian pharmacodynamics of
cyclosporine in rats and man. In: Reinberg A, Smolensky M, Labrecque G, eds. Annual Review of
Chronopharmacology. Vol. 3. New York: Pergamon Press, 1986:219-222.
64.
Roemeling R, Hrushesky W, Kennedy B, Buchwald H. Programmed automatic FUDR chronotherapy
improves therapeutic index, Proc 42nd Ann Sessions of the Forum on Fundamental Surgical Problems, 72nd
Ann Clin Cong, New Orleans, 1986:400-402.
65.
Roemeling R, Langevin T, Rabatin J, Buchwald H, Kennedy B, Hrushesky W. Automatic chronotherapy
using an implanted programmable pump (Medtronic, Inc.). In: Reinberg A, Smolensky M, Labrecque G, eds.
Annual Review of Chronopharmacology. Vol. 3. New York: Pergamon Press, 1986:241-244.
66.
Roemeling R, Wick M, Rabatin J, Berestka J, Langevin T, Lakatua D, Mormont C, Mushiya T, Hrushesky
W. Circadian stage dependence of FUDR toxicity. In: Reinberg A, Smolensky M, Labrecque G, eds. Annual
Review of Chronopharmacology. Vol. 3. New York: Pergamon Press, 1986:191-194.
67.
Hrushesky W, Roemeling R. Chemotherapy-induced vomiting: circadian drug timing as a source of
predictable within-patient variability. Cancer Treat Rep 1986; 70:1347-1348.
68.
Hrushesky W. Circadian drug schedule affects drug toxicity, ovarian cancer response, and patient survival.
In: Reinberg A, Smolensky M, Labrecque G, eds. Annual Review of Chronopharmacology. Vol. 3. New
York: Pergamon Press, 1986:203-206.
69.
Hrushesky W, Langevin T, Fader D, Herzog C. The respiratory sinus arrhythmia: an ultradian rhythm
pregnant with medically relevant information. In: Reinberg A, Smolensky M, Labrecque G, eds. Annual
Review of Chronopharmacology. Vol. 3. New York: Pergamon Press, 1986:353-356.
70.
Roemeling R, Olshefski R, Langevin T, Berestka J, Reusch J, Reusch JE, Lakatua D, Wick M, Hrushesky W.
Cisplatin chronotherapy and disulfiram rescue reduce toxicity without interfering with anticancer activity:
animal findings and preliminary clinical experiences. Chronobiol Int 1986; 3:55-64.
71.
Focan C, Focan-Henrard D, Collette J, Mechkouri M, Lévi F, Hrushesky W, Touitou Y, Franchimont P.
Cancer-associated alteration of circadian rhythms in carcinoembryonic antigen (CEA) and alpha-fetoprotein
(AFP) in humans. Anticancer Research 1986; 6:1137-1144.
72.
Focan C, Collette J, Levi F, Hrushesky W, Touitou Y, Franchimont P. Circadian rhythms in human
carcinoembryonic antigen (CEA), alphafetoprotein (AFP) and prostatic acid phosphatase (PAP): evidence of
chronopathology in cancer. In: Reinberg A, Smolensky M, Labrecque G, eds. Annual Review of
Chronopharmacology. Vol. 3. New York: Pergamon Press, 1986:417-420.
73.
Roemeling R, MacDonald M, Langevin T, Buchwald H, Hrushesky W. Chemotherapy via implanted
infusion pump: new perspectives for delivery of long-term continuous treatment. Oncol Nursing Forum 1986;
13:17-24.
74.
Roemeling R, Hrushesky W. Advanced transitional cell bladder cancer: a treatable disease. Seminars in
Surgical Oncology 1986; 2:76-89.
Hrushesky • Curriculum Vitae • Page 21
75.
Focan C, Focan-Henrard D, Frere M, Hung S, Castronovo V, Collette J, Franchimont P, Touitou Y, Levi F,
Roemeling R, Hrushesky W. Circadian CEA variability: when to sample [Letter to editor]. J Clin Oncol
1986; 4:607.
76.
Mormont C, Berestka J, Mushiya T, Langevin T, von Roemeling R, Rabatin J, Sothern R, Hrushesky W.
Circadian dependency of vinblastin toxicity. In: Reinberg A, Smolensky M, Labrecque G, eds. Annual
Review of Chronopharmacology. New York: Pergamon Press, 1986:187-189.
77.
Skubitz K, Wick M, Skubitz A, Langevin T, Olshefski R, von Roemeling R, Sothern R, Hrushesky W.
Timing of amphotericin B therapy is a critical determinant of toxicity. In: Reinberg A, Smolensky M,
Labrecque G, eds. Annual Review of Chronopharmacology. Vol. 3. New York: Pergamon Press, 1986:183186.
78.
Ratajczak H, Sothern R, Hrushesky W. Single cosinor analysis of vaginal smear cell types quantifies mouse
estrous cycle and its alteration by mammary adenocarcinoma. In: Reinberg A, Smolensky M, Labrecque G,
eds. Annual Review of Chronopharmacology. Vol. 3. New York: Pergamon Press, 1986:223-226.
79.
Hrushesky W, Roemeling R, Rabatin J. Programmable automatic drug delivery: new perspectives for cancer
therapy. In: Ensminger W, ed. Infusion Systems in Medicine. New York: Futura Publishing, 1987:175-188.
80.
Hrushesky W, Roemeling R. The importance of proper circadian timing of cancer chemotherapy. In: Droz J,
Cvitkovic E, Armand J, Khoury S, eds. Clinical Cancer Chemotherapy Handbook. Paris: Fondation
Internationale p'our l'Information Scientifique, 1987:27-30.
81.
Roemeling R, Hrushesky W, Fraley E. Long-term control of locally advanced transitional cell bladder cancer
(TCCB) by high-dose intensity, circadian-based adjuvant chemotherapy. In: Salmon S, ed. Adjuvant Therapy
of Cancer V. Orlando: Grune and Stratton, 1987:571-580.
82.
Roemeling R, Hrushesky W. Circadian pattern of continuous FUDR infusion reduces toxicities. In: Pauly J,
Scheving L, eds. Advances in Chronobiology. New York: Alan Liss, 1987:357-373.
83.
Focan C, Collette J, Franchimont P, Levi F, Touitou Y, Hrushesky W. Rythmes biologiques et marqueurs
tumoraux chez l'homme. Acta Gastroenterologica Belgica 1987; XL:12-21.
84.
Hrushesky W, Roemeling R, Wood P, Langevin, TR, Lange P, Fraley E. High-dose intensity systemic
therapy of metastatic bladder cancer. J Clin Oncol 1987; 5:450-455.
85.
Hrushesky W, Roemeling R, Wood P, Langevin T, Lange P, Fraley E. High dose intensity, circadian timed,
doxorubicin-cisplatin adjuvant therapy for bladder cancer. Cancer Treat Rep 1987; 71:915-919.
86.
Hrushesky W. A case for clinical concentration upon the ultradian frequency domain. In: Scheving L,
Halberg F, Ehret C, eds. Chronobiotechnology and Chronobiological Engineering. The Netherlands: Martinus
Nijhoff, 1987:327-330.
87.
Hrushesky W, Nygaard S, Young J. Timing may be a critical factor in drug therapy. Cancer Treat Rep 1987;
71:1321.
88.
Scheving L, Tsai T, Sothern R, Hrushesky W. Circadian susceptibility-resistance cycles to radiation and their
manipulability by methylene blue (a non-toxic, in vivo oxidation-reduction complex). Pharmacology and
Therapeutics 1988; 39:397-402.
89.
Touitou Y, Sothern R, Levi F, Focan C, Bogdan A, Auzéby A, Franchimont P, von Roemeling R, Hrushesky
W. Sources of predictable tumor marker variation within the so-called normal range: circadian and circannual
aspects of plasma carcinoembryonic antigen (CEA) in health and cancer. Journal of Tumor Marker Oncology
1988; 3:351-359.
90.
Sothern R, Haus R, Langevin T, Popovich J, Wick M, von Roemeling R, Hrushesky W. Profound circadian
stage dependence of mitomycin-c toxicity. In: Reinberg A, Smolensky M, Labrecque G, eds. Annual Review
of Chronopharmacology. Oxford: Pergamon Press, 1988:389-392.
Hrushesky • Curriculum Vitae • Page 22
91.
Tuchman M, Roemeling R, Lanning R, Sothern R, Hrushesky W. Sources of variability of
dihydropyrimidine dehydrogenase activity in human blood mononuclear cells. In: Reinberg A, Smolensky M,
Labrecque G, eds. Annual Review of Chronopharmacology 5. Oxford: Pergamon Press, 1988:399-402.
92.
Canafax D, Cipolle R, Hrushesky W, Rabatin J, Sutherland D, Bowers L. The chronopharmacokinetics of
cyclosporine and its metabolites in recipients of pancreas allografts. Transplant Proc 1988; 20:471-477.
93.
Mormont M, Roemeling R, Sothern R, Berestka J, Langevin T, Hrushesky W. Circadian rhythm and seasonal
dependence in tolerance of mice to 4'-epi-doxorubicin. Investigational New Drugs 1988; 6:273-283.
94.
Canafax R, Cipolle R, Hrushesky W, Rabatin J, Min D, Graves N, Sutherland D, Bowers L. Increased
evening exposure to cyclosporine and metabolites. In: Reinberg A, Smolensky M, Labrecque G, eds. Annual
Review of Chronopharmacology. Oxford: Pergamon Press, 1988:5-8.
95.
Roemeling R, Rabatin J, Tuchman M, Hrushesky W. Circadian timing and mode of fluoropyrimidine
administration markedly impact organ-specific toxicity and maximal dose intensity. In: Reinberg A,
Smolensky M, Labrecque G, eds. Annual Review of Chronopharmacology 5. Oxford: Pergamon Press,
1988:427-430.
96.
Roemeling R, Rabatin J, Fraley E, Hrushesky W. Progressive metastatic renal cell carcinoma controlled by
continuous FUDR infusion. J Urol 1988; 139:259-262.
97.
Ratajczak H, Sothern R, Hrushesky W. Estrous influence on surgical cure of a mouse breast cancer. J Exp
Med 1988; 168:73-83.
98.
Ratajczak H, Thomas P, Vollmuth T, Heck D, Sothern R, Hrushesky W. Seasonal variations of host
resistance and in vitro antibody formation of spleen cells from the B6C3F1 mouse. In: Reinberg A,
Smolensky M, Labrecque G, eds. Annual Review of Chronopharmacology 5. Oxford: Pergamon Press,
1988:49-52.
99.
Kanabrocki E, Sothern R, Scheving L, Halberg F, Pauly J, Greco J, Nemchausky B, DeBartolo M, Kaplan E,
McCormick J, Olwin J, Marks G, Bird T, Redmond D, Graeber R, Ferrara A, Hrushesky W. Ten-year
replicated circadian profiles for 36 physiological, serological and urinary variables in healthy man.
Chronobiology International 1988; 5:237-284.
100. Hrushesky W. The rationale for non-zero-order drug delivery using automatic, computer-based drug delivery
systems (chronotherapy). J Biol Response Modifiers 1988; 6:587-598.
101. Cipolle R, Canafax D, Rabatin J, Bowers L, Sutherland D, Hrushesky W. Time-dependent disposition of
cyclosporine after pancreas transplantation, and application of chronopharmacokinetics to improve
immunosuppression. Pharmacotherapy 1988; 8:47-51.
102. Hrushesky W, Roemeling R, Fraley E, Rabatin J. Circadian-based infusional chrono-chemotherapy controls
progressive metastatic renal cell carcinoma. Seminars in Surgical Oncology 1988; 4:110-115.
103. Gruber S, Hoffman R, Sothern R, Lakatua D, Carlson A, Simmons R, Hrushesky W. Splenocyte natural
killer cell activity and metastatic potential are inversely dependent on estrous stage. Surgery 1988; 104:398403.
104. Cipolle T, Canafax D, Rabatin J, Bowers L, Sutherland D, Hrushesky W. Two-dose chronopharmacokinetic
optimization of cyclosporine in pancreas transplant patients. In: Reinberg A, Smolensky M, Labrecque G, eds.
Annual Review of Chronopharmacology 5. Oxford: Pergamon Press, 1988:13-16.
105. Gruber S, Cipolle R, Canafax D, Erdmann G, Burke B, Rabatin J, Hynes P, Ritz J, Gould F, Ascher N,
Simmons R, Hrushesky W. An implantable pump for intrarenal infusion of immunosuppressants in a canine
autotransplant model. Pharmaceutical Research 1988; 12:781-785.
106. Hrushesky W, Damascelli B, Ravasi G, Spreafico C, Lutman R, Valvassori L, Bellegotti L, Marchianó A,
Del Nero A, Bonalumi M. Cronoterapia infusionale mediante sistemi automatici a totale impianto
sottocutaneo programmabili per telemetria. Medico e Paziente, XIV 1988; 10:56-65.
Hrushesky • Curriculum Vitae • Page 23
107. Hrushesky W. Rationnel de l'administration des medicaments a l'aide d'un systme de perfusion automatise,
pilote par ordinateur (chronotherapie). Cancer Communication 1988; 2:169-179.
108. Hrushesky W, Berestka J, Roemeling R, Olshefski R, Langevin T, Potish R, Delaney J, Ellefson M, Schwartz
S. Methylene blue protects intestinal mucosa from sublethal radiation damage. Free Radical Biology and
Medicine 1988; 5:207-213.
109. Hrushesky W, Gruber S, Sothern R, Hoffman R, Lakatua D, Carlson A, Cerra F, Simmons R. Natural killer
cell activity: age, estrous- and circadian-stage dependence and inverse correlation with metastatic potential. J
Natl Cancer Inst 1988; 80:1232-1237.
110. Hrushesky W. Automatic chronotherapy: an integral part of the future of medicine. In: Hekkens W, Kerkhof
G, Rietveld W, eds. Advances in the Biosciences, Vol. 3, Trends in Chronobiology. Vol. 3. Oxford: Pergamon
Press, 1988:281-293.
111. Van Tornout J, Nesbit M, Bostrom B, Ramsay N, Somani S, Langevin T, Lanning R, von Roemeling R,
Hrushesky W. Feasibility, safety and accuracy of an automated drug delivery system suitable for
chronochemotherapy in pediatric patients. In: Reinberg A, Smolensky M, Labrecque G, eds. Annual Review
of Chronopharmacology. Vol. 5. Oxford: Pergamon Press, 1988:431-432.
112. Gruber S, Cipolle R, Canafax D, Rabatin J, Erdmann G, Hynes P, Ritz J, Gould F, Hrushesky W. Circadianshaped intrarenal cyclosporine delivery. In: Reinberg A, Smolensky M, Labrecque G, eds. Annual Review of
Chronopharmacology. Oxford: Pergamon Press, 1988:29-30.
113. Tuchman M, Roemeling R, Hrushesky W, O'Dea R. Dihydropyrimidine dehydrogenase activity in human
blood mononuclear cells. Enzyme 1989; 42:15-24.
114. Gruber S, Hrushesky W, Canafax D, Cipolle R, Burke B, Matas A, Ascher N, Simmons R. Local
prednisolone infusion of canine renal allografts. Transplantation 1989; 48:1072-1075.
115. Gruber S, Hrushesky W, Cipolle R, Erdmann G, Burke B, Skjei K, Mueller R, Fryd D, Matas A, Sommons
R, Canafax D. Local immunosuppression with reduced systemic toxicity in a canine renal allograft model.
Transplantation 1989; 48: 936-943.
116. Kanabrocki E, Snedeker P, Zieher S, Raymond R, Gordey J, Bird T, Sothern R, Hrushesky W, Marks G,
Olwin J, Kaplan E. Circadian characteristics of dialyzable and non-dialyzable human urinary electrolytes,
trace elements and total solids. Chronobiology Intl 1989:175-184.
117. Gruber S, Burke B, Canafax D, Hrushesky W, Cipolle R, Erdmann G, Matas A, Simmons R, Najarian J.
Feasibility of vascular catheter placement for intrarenal infusion in a canine autotransplant model.
Transplantation Proceedings 1989; 21:1125-1126.
118. Gruber S, Nichol K, Sothern R, Malone M, Potter J, Lakatua D, Hrushesky W. Menstrual history and breast
cancer surgery [Letter to editor]. Breast Cancer Research and Treatment 1989; 13:278.
119. Gruber S, Canafax D, Erdmann G, Cipolle R, Burke B, Rabatin J, Hynes P, Gould F, Heil J, Ascher N,
Simmons R, Najarian J, Hrushesky W. The pharmacokinetic advantage of local 6-mercaptopurine infusion in
a canine renal transplant model. Transplantation 1989; 48: 928-935.
120. Gruber S, Venkataram S, Canafax D, Cipolle R, Bowers L, Elsberry D, McGuiggan M, Hynes P, Ritz J,
Gould F, Matas A, Hrushesky W, Rahman Y-E. Liposomal formulation eliminates acute toxicity and pump
incompatability of parenteral cyclosporine. Pharmaceutical Research 1989; 6: 601-607.
121. Hrushesky W. Delivery systems: the ultimate home care, Proc World Congress on Home Care, Rome, Italy,
1989.
122. Hrushesky W, Gruber S, Sothern R, Hoffman R, Lakatua D, Carlson A, Cerra F, Simmons R. Splenocyte
natural killer cell activity is estrous-stage dependent and correlates inversely with metastatic potential. In:
Ades E, Lopez C, eds. Natural Immunity and Cell Growth Regulators. Switzerland: Karger, Basel, 1989.
Hrushesky • Curriculum Vitae • Page 24
123. Sothern R, Levi F, Haus E, Halberg F, Hrushesky W. Control of a murine plasmacytoma with doxorubicincisplatin depends upon circadian stage of treatment. J Natl Cancer Inst 1989; 81:135-145.
124. Hrushesky W, Roemeling R, Sothern R. Preclinical and clinical cancer chronotherapy. In: Ahrendt J, ed.
Biological Rhythms in Clinical Practice, 1989:225-251.
125. Hrushesky W, Roemeling R, Sothern R. Circadian chronotherapy: from animal experiments to human cancer
chemotherapy. In: Lemmer B, ed. Chronopharmacology: Cellular and Biochemical Interactions. New
York/Basel: Marcel Dekker, 1989:439-473.
126. Hrushesky W, Bluming A, Gruber S, Sothern R. Menstrual influence on surgical cure of breast cancer.
Lancet 1989:949-952.
127. Sothern R, Halberg F, Hrushesky W. Circadian stage not time of day characterizes doxorubicin susceptibility
rhythm of mice in continuous light. Annual Review of Chronopharmacology 1989; 5:385-88.
128. Hrushesky W. Automatic chronotherapy: an integral part of the future of medicine. In: Ensminger W, Selam
J, eds. Update in Drug Delivery Systems. Mount Kisco, NY: Futura Publishing, 1989:13-33.
129. Roemeling R, Hrushesky W. Principles of chemotherapy and immunotherapy for head and neck cancer. In:
Paparella M, Shumrick D, et al., eds. Otolaryngology. Vol. 1. Philadelphia: W.B. Saunders, 1991:617-39.
130. Hrushesky W, Gruber S, Sothern R, Hoffman R, Lakatua D, Carlson A, Cerra F, Simmons R. Estral rhythms
in natural killer cell activity and metastatic behavior. In: Ades E, Lopez C, eds. Natural Killer Cells and Host
Defense. Basel: Karger, 1989:258-61.
131. Roemeling R, Hrushesky W. Circadian patterning of continuous floxuridine infusion reduces toxicity and
allows higher dose intensity in patients with widespread cancer. J Clin Oncol 1989; 7:1710-19.
132. Lanning R, Hrushesky W. Outpatient time-specified infusion of fluoropyrimidines by implanted pump is less
costly than flat delivery by external pump. In: Hayes D, Pauly J, Reiter R, eds. Chronobiology: Its Role in
Clinical Medicine, General Biology and Agriculture, Part B. New York: Wiley-Liss, Inc., 1990:397-409.
133. Lanning R, Roemeling R, Hrushesky W. Circadian-based infusional FUDR therapy. Oncology Nursing
Forum 1990; 17:49-56.
134. Vesely D, Kanabrocki E, Sothern R, Scheving L, Tsai T, Greco J, Bushnell D, Kaplan E, Rumbyrt J,
Sturtevant R, Sturtevant F, Bremner W, Third J, Hrushesky W, Olwin J. Circadian variation of new cardiac
hormones that lower blood pressure and increase sodium excretion. In: Reinberg A, Smolensky M, Labrecque
G, eds. Annual Review of Chronopharmacology. Vol. 7. Oxford: Pergamon Press, 1990:137-40.
135. Vesely D, Kanabrocki E, Sothern R, Scheving L, Tsai T, Greco J, Bushell D, Kaplan E, Rumbyrt J, Sturtevant
R, Sturtevant F, Bremner W, Third J, Hrushesky W, Olwin J. The circadian rhythm of the N-terminus and Cterminus of the atrial natriuretic factor prohormone. Chronobiol Intl 1990; 7:51-57.
136. Kanabrocki E, Sothern R, Scheving L, Vesely D, Tsai T, Shelstad J, Cournoyer C, Greco J, Mermall H,
Nemchausky B, Bushnell D, Kaplan E, Kahn S, Augustine G, Holmes E, Rumbyrt J, Sturtevant R, Sturtevant
F, Bremner F, Third J, McCormick J, Mudd C, Dawson S, Olwin J, Sackett-Lundeen L, Haus E, Halberg F,
Pauly J, Hrushesky W. Circadian reference data for men in fifth decade of life. In: Hayes D, Pauly J, Reiter
R, eds. Chronobiology: Its Role in Clinical Medicine, General Biology and Agriculture, Part A. New York:
Wiley-Liss, Inc., 1990:771-82.
137. Wood P, Sanchez de la Pena S, Hrushesky W. Circadian timing of recombinant human erythropoietin
(rhEPO) in the mouse affects hematopoietic response. In: Reinberg A, Smolensky M, Labrecque G, eds.
Annual Review of Chronopharmacology. Vol. 6. Oxford: Pergamon Press, 1990:173-76.
138. Schraufek S, Sothern R, Voegele M, Ainsworth B, Serfass R, Leon A, Khanuja H, Hrushesky W.
Enhancement of respiratory sinus arrhythmia by moderate exercise. In: Hayes D, Pauly J, Reiter R, eds.
Chronobiology: Its Role in Clinical Medicine, General Biology and Agriculture, Part A. New York: WileyLiss, Inc., 1990:283-96.
Hrushesky • Curriculum Vitae • Page 25
139. Roemeling R, DeMaria L, Salzer M, Connerty M, Wood P, Portuese E, Sanchez de la Peña S, DeConti R,
Chikkappa G, Pasquale D, Ferro T, Hrushesky W. Circadian stage dependent response to interleukin-2 in
mouse spleen and bone marrow. In: Reinberg A, Smolensky M, Labrecque G, eds. Annual Review of
Chronopharmacology. Vol. 6. Oxford: Pergamon Press, 1990:211-14.
140. Roemeling R, Hrushesky W. Fluoropyrimidine pharmacokinetics are circadian stage dependent. In: Lemmer
B, Hüller H, eds. Clinical Pharmacology. Vol. 6. München: W. Zuckschwerdt Verlag, 1990:169-83.
141. Roemeling R, Hrushesky W. Chronobiology of cancer therapy: prototype use of fluoropyrimidine infusions.
In: Lokich J, ed. Cancer Chemotherapy by Infusion. Vol. 2nd edition. Chicago: Precept Press, 1990:619-46.
142. Roemeling R, Hrushesky W. Determination of the therapeutic index of floxuridine by its circadian infusion
pattern. J Natl Cancer Inst 1990; 82:386-93.
143. Teslow T, Zermeno A, Hrushesky W, Ashkenazi I. Chronobionet: global and local area networking in the
chronobiological sciences. In: Hayes D, Pauly J, Reiter R, eds. Chronobiology: Its Role in Clinical Medicine,
General Biology and Agriculture, Part B. New York: Wiley-Liss, Inc., 1990:461-69.
144. Sothern R, Rhame F, Suarez C, Fletcher C, Sackett-Lundeen L, Haus E, Hrushesky W. Oral temperature
rhythmometry and substantial within-day variation in zidovudine levels following steady-rate dosing in
human immunodeficiency virus (HIV) infection. In: Hayes D, Pauly J, Reiter R, eds. Chronobiology: Its Role
in Clinical Medicine, General Biology and Agriculture, Part A. New York: Wiley-Liss, Inc., 1990:67-76.
145. Swoyer J, Rhame F, Hrushesky W, Sackett-Lundeen L, Sothern R, Gale H, Haus E. Circadian rhythm
alterations in HIV infected subjects. In: Hayes D, Pauly J, Reiter R, eds. Chronobiology: Its Role in Clinical
Medicine, General Biology and Agriculture, Part A. New York: Wiley-Liss, Inc., 1990:437-50.
146. Gruber S, Cipolle R, Tzardis P, Skjei K, Jossart G, Abed J, Canafax D, Burke B, Matas A, Hrushesky W.
Pharmacodynamics of local heparin infusion in a canine renal allograft model. Journal of Pharmacology and
Experimental Therapeutics 1990; 252:733-38.
147. Hrushesky W, Bluming A, Gruber S. Menstrual influence on surgical cure of breast cancer [Letter to editor].
Lancet 1990:984.
148. Hrushesky W. Cancer chemotherapy: a drug delivery challenge. In: Hayes D, Pauly J, Reiter R, eds.
Chronobiology: Its Role in Clinical Medicine, General Biology and Agriculture, Part A. New York: WileyLiss, Inc., 1990:1-10.
149. Hrushesky W. More evidence for circadian rhythm effects in cancer chemotherapy: the fluoropyrimidine
story. Cancer Cells 1990; 2:65-68.
150. Hrushesky W, Roemeling R, Lanning R, Rabatin J. Circadian shaped infusions of FUDR for progressive
metastatic renal cell carcinoma. J Clin Oncol 1990; 8:1504-13.
151. Hrushesky W. Health care for US veterans and others [Letter to editor]. Lancet 1990:182.
152. Hrushesky W, Bluming A, Gruber S. Menstrual status and breast cancer surgery-reply [Letter to editor].
Breast Cancer Research and Treatment 1990; 16:121.
153. Gruber S, Canafax D, Cipolle R, Erdmann G, Burke B, Matas A, Simmons R, Hrushesky W. Local
immunosuppression of the vascularized graft. Surgery 1990; 107:209-14.
154. Hrushesky W. Cancer chronotherapy and drug delivery systems, Health is One's Own Responsibility—The
Human Being, Medicine and Society, Hannover, West Germany, 1990:241-63.
155. Grage T, Wesen C, Roemeling R, Lanning R, Olson G, Hrushesky W. Reduction of hepatic toxicity by
circadian modification of intra-arterial hepatic infusion chemotherapy for metastatic colorectal cancer to the
liver. In: Lemmer B, Hüller H, eds. Clinical Pharmacology. Vol. 6. München: W. Zuckschwerdt Verlag,
1990:184-93.
Hrushesky • Curriculum Vitae • Page 26
156. Hrushesky W. Circadian timing and toxicity. In: Perry M, ed. The Chemotherapy Source Book. Baltimore:
Williams & Wilkins, 1990:165-212.
157. Roemeling R, Lanning R, Wagner H, DeConti R, Scheving L, Hrushesky W. 5 Time specified delivery of
chemotherapy by implantable programmable pumps—preliminary data on 5-fluoro-2'-deoxyuridine. In:
Rotman M, Rosenthal C, eds. Concomitant Continuous Infusion Chemotherapy and Radiation. Heidelberg:
Springer Verlag, 1991:57-65.
158. Sánchez de la Peña S, Azar S, Hrushesky W. Murine cardiovascular function during pregnancy: the fetus and
placenta as a closed-loop drug delivery system. In: Hrushesky W, Langer R, Theeuwes F, eds. Temporal
Control of Drug Delivery, Ann NY Acad Sci. Vol. 618, 1991:619-22.
159. Hrushesky W. Cancer chronotherapy. Revue Europeenne de Technologie Biomedicale 1991; 13:168-73.
160. Hrushesky W. Reprogramming SynchroMed pumps: unanticipated inaccuracy. J Clin Oncol 1991; 9:108994.
161. Hrushesky W. What is the impact of the menstrual cycle on outcome and recurrence in premenopausal
women undergoing breast cancer surgery? Oncology Bulletin 1991; 4:4,19.
162. Hrushesky W, Fader D, Berestka J, Sommer M, Hayes J, Cope F. Diminishment of respiratory sinus
arrhythmia foreshadows doxorubicin-induced cardiomyopathy. Circulation 1991; 84: 697-707.
163. Hrushesky W. Temporally optimizable delivery systems: sine qua non for the next therapeutic revolution.
Journal of Controlled Release 1991; 19: 363-68.
164. Wood P, Sánchez de la Peña S, Hrushesky W. Evidence for circadian dependency of recombinant human
erythropoietin (rhEPO) response in the mouse. In: Hrushesky W, Langer R, Theeuwes F, eds. Temporal
Control of Drug Delivery, Ann NY Acad Sci. Vol. 618, 1991:610-12.
165. Hrushesky W. Quantitative respiratory sinus arrhythmia analysis: a simple non-invasive, reimbursable
measure of cardiac wellness and dysfunction. Temporal Control of Drug Delivery, Ann NY Acad Sci 1991;
618:67-101.
166. Hrushesky W. Chemotherapy, circadian timing and nutrition. Report of the Ninth Ross Conference on
Medical Research: Ross Laboratories, Columbus, Ohio, 1991:17-24.
167. Hrushesky W. Timing of surgery in breast cancer [Letter to editor]. Lancet 1991; 337:1603-04.
168. Hrushesky W. Preface: temporally optimizable delivery systems—sine qua non for molecular medicine. In:
Hrushesky W, Langer R, Theeuwes F, eds. Temporal Control of Drug Delivery, Ann NY Acad Sci. Vol. 618,
1991:xi.
169. Hrushesky W. The multifrequency (circadian, fertility cycle and season) balance between host and cancer. In:
Hrushesky W, Langer R, Theeuwes F, eds. Temporal Control of Drug Delivery, Ann NY Acad Sci. Vol. 618,
1991:228-56.
170. Gruber S, Canafax D, Cipolle R, Erdmann G, Burke B, Simmons R, Hrushesky W, Matas A. Intra-arterial
infusion of immunosuppressants, Symposium on Experimental Models in Transplantation Surgery, Minerva
Chiirurrgica, 1991. Vol. 46:75-79.
171. Buchi K, Moore J, Hrushesky W, Sothern R, Rubin N. Circadian rhythm of cellular proliferation in the
human rectal mucosa. Gastroenterology 1991; 101: 410-15.
172. Bluming A, Hrushesky W. The effect of surgical timing within the fertility cycle on breast cancer outcome.
In: Hrushesky W, Langer R, Theeuwes F, eds. Temporal Control of Drug Delivery, Ann NY Acad Sci. Vol.
618, 1991:227-91.
173. Lanning R, Hrushesky W. Estimated costs of continuous infusion chemotherapy. J Infus Chem 1992; 2: 8993.
Hrushesky • Curriculum Vitae • Page 27
174. Traynor K, Newton D, Hrushesky W, Reiter R. A pharmacist's primer on chronotherapeutics. Amer Pharm
1992:1-7.
175. Hrushesky W, Marz W. Chrono-chemotherapy of malignant tumors: temporal aspects of antineoplastic drug
toxicity. In: Haus E, Touitou I, eds. Biologic Rhythms in Clinical and Laboratory Medicine. New York:
Springer-Verlag, 1992:611-34.
176. Hrushesky W, Martynowicz M, Markiewicz M, Roemeling R, Sánchez de la Peña S, Wood P. Chronotherapy
of cancer: a major drug-delivery challenge. Advanced Drug Delivery Reviews: Chronobiology and
chronopharmacology and its Relevance to the Delivery of Drugs 1992; 9:1-83.
177. Bluming A, Hrushesky W. Optimal timing of initial breast cancer surgical [Letter to editor]. Annals of Inter
Med 1992; 116:268.
178. Bjarnason G, Hrushesky W. Circadian cancer chemotherapy: clinical trials. J Infus Chemo 1992; 2: 79-88.
179. Roemeling R, Krames R, Hrushesky W. Leucovorin-FUDR-Cisplatin-Interferon (LFCI) salvage
chronotherapy for refractory adenocarcinomas: a phase I/II study. J Infus Chemo 1992; 2:146-50.
180. Wesen C, Roemeling R, Lanning R, Grage T, Olson G, Hrushesky W. Circadian modification of intra-arterial
FUDR infusion rate reduces its toxicity and permits higher dose intensity. J Infus Chemo 1992; 2: 69-75.
181. Hrushesky W. Chrono-chemotherapy. In: Klein, ed. Renal Cell Carcinoma: Marcel Dekker, Inc., 1992:32542.
182. Hrushesky W, Vyzula R, Slavik M, Wood P, Sánchez de la Peña S, Vorlíek J. Chronoterapie maligních
Onemocnêní. Klinická Onkologie 1992:5-45.
183. Gruber S, Erdmann G, Burke B, Moss A, Bowers L, Hrushesky W, Cipolle R, Canafax D, Matas A.
Mizoribine pharmacokinetics and pharmacodynamics in a canine renal allograft model of local
immunosuppression. Transplantation 1992; 53:12-19.
184. Hrushesky W, Bjarnason G. The application of chronobiology to cancer medicine. In: DeVita V, Hellman S,
Rosenberg S, eds. Cancer: Principles and Practice of Oncology: J.B. Lippincott Co., 1992:2666-86.
185. Hrushesky W. Infusional chrono-chemotherapy for cancer. J Infus Chemo 1992; 2:64.
186. Hrushesky W. Theoretical and practical implications of circadian pharmacodynamics. J Infus Chemo 1992;
2: 66-68.
187. Wood P, Vyzula R, Hrushesky W. Circadian hematopoietic growth factor chronotherapy. J Infus Chemo
1993; 3: 89-101.
188. Hrushesky W. Breast cancer and the menstrual cycle [Editorial]. J Surg Oncol 1993; 53:1-3.
189. Hrushesky W. Diminishing breast cancer chemotherapy toxicity by respecting biological rhythms. Y-ME
Hotline 1993; September/October.
190. Hrushesky W. Chronobiology: a modern science with ancient origins. English Audio Reviews 1993; 4: 9397.
191. Hrushesky W. Circadian cancer pharmacodynamics. Ann First Super Sanita 1993; 29:705-710.
192. Hrushesky W. Cancer: when in the day to treat. J Infus Chemo 1993; 3:82-88.
193. Hrushesky W. Circadian pharmacodynamics of anticancer therapies. Clinical Chemistry 1993; 39:2413-18.
194. Hrushesky W, Bjarnason G, Vyzula R. Circadian Cancer Chronotherapy. In: Cvitkovic E, Droz J, Armand J,
Khoury S, eds. Handbook of Chemotherapy in Clinical Oncology: Scientific Communication International,
Ltd., 1993:109-119.
195. Hrushesky W, Bjarnason G. Circadian cancer therapy. J Clin Oncol 1993; 11:1403-17.
Hrushesky • Curriculum Vitae • Page 28
196. Hrushesky W. Cancer and time. In: Macey S, ed. The Encyclopedia of Time. New York: Garland
Publishing, Inc., 1994:80-83.
197. Tzannis S, Pryzbycien T, Hrushesky W, Wood P. The impact of formulated Interleukin-2/delivery device
surface interactions on bioefficacy, Mat Res Soc Symp Proc, 1994. Vol. 331:227-32.
198. Wood P, Hrushesky W. Chronopharmacodynamics of hematopoietic growth factors and antitumor cytokines.
In: Hrushesky W, ed. Circadian Cancer Therapy: CRC Press, 1994:185-207.
199. Tzannis S, Przybycien T, Hrushesky, W and Wood P. Protein-surface interactions lead to incomplete
delivery of interleukin-2 with an infusion pump/catheter system. Proceedings International Symposia
Controlled Release of Bioactive Materials 21:361-362, 1994
200. Bjarnason G, Hrushesky W. Cancer chronotherapy. In: Hrushesky W, ed. Circadian Cancer Therapy: CRC
Press, 1994:240-63.
201. Bjarnason G, Hrushesky W. Preclinical trials of cancer chronotherapy. In: Hrushesky W, ed. Circadian
Cancer Therapy: CRC Press, 1994:211-39.
202. Hrushesky W. The Department of Veterans Affairs’ unique clinical cancer research effort. Cancer 1994;
74:2701-09.
203. Hrushesky W, Langevin T, Kim Y, Wood P. Circadian dynamics of tumor necrosis factor ∞ (Cachectin)
lethality. J Exp Med 1994; 180:1059-65.
204. Hrushesky W. Epilogue: implications of rhythmic biodynamics for science, cancer drug and cancer therapy
development. In: Hrushesky W, ed. Circadian Cancer Therapy: CRC Press, 1994:279-81.
205. Hrushesky W. Timing is everything. The Sciences 1994; July/August:32-37.
206. Hrushesky W. For autonomy and quality, consider a national health service. Oncology Times 1994; 16:4041.
207. Hrushesky W, Cope F. Fluoropyrimidine cancer chronotherapy. In: Banzet P, Holland J, Khayat D, Weil M,
eds. Cancer Treatment: An Update. Paris, New York and Berlin: Springer-Verlag, 1994:29-39.
208. Hrushesky W. Mammography and the menstrual cycle [Letter to editor]. International J Cancer 1994:151.
209. Hrushesky W. Introduction: cancer and time. In: Hrushesky W, ed. Circadian Cancer Therapy: CRC Press,
1994:3-9.
210. Wood P, Hrushesky W. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest
1995; 95:1650-59.
211. Wood P, Hrushesky W. Biological perspectives on circadian cancer therapy. J of Inf Chemo 1995; 5:182-90.
212. Wood P, Hrushesky W. Erythropoietin usage in patients with cancer. Cancer J 1995; 1,
November/December:243-46.
213. Hrushesky W. Square pegs in round holes [Letter to the editor]. Int J Cancer 1995; 62:651-52.
214. Hrushesky W. Menstrual cycle timing of breast cancer resection: prospective study is overdue. J Natl Cancer
Inst 1995; 87:143-44.
215. Hrushesky W. Circadian Anticancer Treatment (Erna Halberg memorial). In Vivo 1995:315-21.
216. Wong M, Bjarnason G, Hrushesky W, Webster P, Morava-Protzner I, Towers M. Steroid-responsive
interstitial lung disease in patients receiving 2'-deoxy-5-fluorouridine-infusion chemotherapy. Cancer 1995;
75:2558-64.
217. Hrushesky W. Preface: Larry Scheving and cancer chronotherapy. J Infus Chemo 1995; 5:1-3.
218. Hrushesky W. Cancer chronotherapy: is there a right time in the day to treat? J Infus Chemo 1995; 5:38-43.
Hrushesky • Curriculum Vitae • Page 29
219. Wood P, Hrushesky W. Circadian timing of cancer chemotherapy. In: Perry M, ed. The Chemotherapy
Source Book. Vol. 2nd edition: Williams and Wilkins, 1996:177-202.
220. Hrushesky W, Marsh RdW, Wood P. Circadian pharmacodynamics. In: Schilsky R, Milano G, Ratain M,
eds. Principles of Antineoplastic Drug Development and Pharmacology. New York: Marcel Dekker, Inc.,
1996:681-720.
221. Tzannis S, Hrushesky W, Wood P, Przybycien T. Irreversible inactivation of interleukin-2 in a pump-based
delivery environment. Proc Natl Acad Sci USA 1996; 93:5460-65.
222. Hrushesky W. Breast cancer, timing of surgery, and the menstrual cycle: Call for prospective trial. J
Women’s Health 1996; 5:555-65.
223. Hrushesky W. Chao-periodic patterns in the achievement of understanding. In: Razis, DV (ed.). The Human
Predicament: An International Dialogue on the Meaning of Human Behavior. Amherst, New York:
Prometheus Books, 1996:171-81.
224. Hrushesky W. Cosmos, geos, bios, homos. In: Razis, DV (ed.). Multifrequency chao-periodic competitors for
global impact. The Human Predicament: An International Dialogue on the Meaning of Human Behavior.
Amherst, New York: Prometheus Books, 1996:79-85.
225. Wood P, Hrushesky W. Circadian rhythms and cancer chemotherapy. Crit Rev Eukaryotic Gene Expression
1996;6:299-343.
226. Wood P, Hruskesky W. Cisplatin-associated anemia: an erythropoietin deficiency syndrome.
Yearbook of Hematology, Spivak, JL (ed), Ch 1, Red Blood Cells, Mosby, NY, 1997: 3-5.
The
227. Wood P, Hrushesky W. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. Oncology
Digest PMSI Bugamor BV, The Netherlands, 2, pp23-26 1997.
228. Hrushesky W, Wood P. Circadian time structure of septic shock: Timing is everything [letter to editor]. J
Infect Dis 1997; 175 (May):1283-84.
229. Hrushesky W. Breast cancer, surgery, and the menstrual cycle. In: Salmon S, ed. Adjuvant Therapy of
Cancer VIII. Philadelphia: Lippincott-Raven, 1997: 133-44.
230. Tzannis S, Hrushesky W, Wood P, Przybycien T. Adsorption of a formulated protein on a drug delivery
device surface. J Colloid Interface Sci 1997. 189(131): 216-28.
231. Vyzula R, Bjarnason G, Hrushesky W. Chronopharmacology and avoidance of anticancer drug toxicity. In:
Sweetenham, Williams, eds. Supportive Care of the Cancer Patient. London: Arnold 1997: 74-86.
232. Hrushesky W. The Senie/Tenser Article Reviewed. [Editorial] Oncology 1997;11(10):1520-24.
233. Hrushesky W, Wood P. Human circadian rhythms in antifolate and fluoropyrimidine developmental
therapeutics. In: Pfleiderer W, Rokos H, eds. Chemistry and Biology of Pteridines and Folates. Berlin:
Blackwell Wissenschafts-Verlag, 1997:
234. Hrushesky W. Triumph of the Trivial. Perspectives in Biology and Medicine 1998;41(3):341-348.
235. Hrushesky W. Home-Based Circadian Optimized Cancer Chemotherapy, Electronically Controlled Drug
Delivery, Berner B, Dinh S (Eds), Ch 2, pp 9-43, CRC Press, 1998.
236. Hagen A, Hrushesky W. Menstrual timing of breast cancer surgery. Am J Surg 1998;175(3):245-61.
237. Wood P, Hrushesky W, Klevecz R. Distinct circadian time structures characterize myeloid and erythroid
progenitor and multipotential cell clonogenicity as well as marrow precursor proliferation dynamics. Exp
Hematol 1998;26: 523-33.
238. Hagen A, Hrushesky W, Torsten U, Weitzel H. Der operationszeitpunkt beim prän - einfluB auf die
prognose? Gynäkologische Onkologie 1998;58: 282-89.
Hrushesky • Curriculum Vitae • Page 30
239. Hrushesky W, Lannin D, Haus E. Evidence for an ontogenetic basis for circadian coordination of cancer
cell proliferation. J Nat Ca Inst 1998;90(19):1480-84
240. Wood P, Waldo S, Hrushesky W. Lack of major effect of tumor growth and fluoropyrimidine treatment upon
maintenance of fertility cycling. In: Touito Y, ed. Biological Clocks: Mechanisms and Applications.
Amsterdam: Elsevier, 1998:507-10.
241. Hrushesky W, Wood P. The glaspy/cavill article reviewed. Editorial, Oncology 1999;13(4):477-78, 483.
242. Hrushesky W, Bjarnason G, Fukushima M, Hagimoto H. Identification of therapeutic plasma FUDR
concentration during continuous infusion of individually determined maximum tolerated doses. Cancer
Therapeutics 1999;2:50-57.
243. Hrushesky W, Vyzula R, Wood P. Fertility maintenance and 5-fluorouracil timing within the mammalian
fertility cycle. Reprod Toxicol 1999;13:413-20.
244. Hrushesky W, Lester B, Lannin D. Circadian coordination of cancer take and metastatic spread. Int J Can
1999;83:365-73.
245. Wood P, Lincoln D, Imam I, Hrushesky W. Circadian toxicology. Ballantyne B, Marrs T, Syversen T, eds.
General and applied toxicology. Chapter 11, pp 251-270, Macmillan,London: 1999.
246. Wood P, Hrushesky W. Circadian iron and erythropoietin availability and marow responsiveness: Relevance
to treatment of anemia. Anemia in Oncol 1999;2(4):2-4, 8.
247. Thrall M, Wood P, King V, Rivera W, Hrushesky W. Investigation of the comparative toxicity of 5-FU bolus
versus 5-FU continuous infusion circadian chemotherapy with concurrent radiation therapy in locally
advanced rectal cancer. Int J Rad Onc, Biol, Phys 2000;46(4):873-81.
248. Wood P, Hrushesky W. Circadian Timing of Cancer Chemotherapy. The Chemotherapy Source Book, 3rd
Edition, Perry, MD (ed), Chapter 12, Williams and Wilkins, Baltimore Press, pp 114-31, 2000.
249. Hrushesky W. Timing your Medical Treatments. Bottom Line Health 2000: 14 (7): 1-3.
250. Hrushesky W. Rhythmic Menstrual Cycle Modulation of Breast Cancer Biology. J Surg Oncol 2000; 74:
238-41.
251. Hrushesky W. Melatonin Cancer Therapy: The Pineal Gland and Cancer. Bartsch et al (Eds); Pages 476-508,
2000.
252. Lincoln D, Hrushesky W, Wood P. Circadian Organization of Thymidylate Synthase Activity in Normal
Tissues: A Possible Basis for 5-Fluorouracil Chronotherapeutic Advantage. Int J Cancer, 88; 479-85, 2000.
253. Hrushesky W, Matsumura Y, Yamada Y, Saijo N, Sugimura T. The temporal organization of life: the impact
of multi-frequency non-linear biologic time structure upon the host-cancer balance. Japan J Clin Oncol 2000.
254. Retsky M, Demicheli R, Hrushesky, W. Premenopausal Status Accelerates Relapse in node positive breast
cancer:hypothesis links angiogenesis, screening controversy. Breast Cancer Res Treat 2001; 65(3):217-24.
255. Mizumura Yasuo, Matsumura Yasuhiro, Hamaguchi Tetsuya, Nishiyama Nobuhiro, Kataoka Kazunori,
Kawaguchi Takanori, Hrushesky WJM, Moriyasu Fuminori, Kakizoe Tadao. Cisplatin-incorporated
Polymeric Micelles Eliminate Nephrotoxicity, While Maintaining Antitumor Activity. Jpn. J. Cancer Res.,
92, March 2001, pages 328-36.
256. Retsky M, Demichelli R, Hrushesky WJM. Wounding from Biopsy and Breast Cancer Progression. Letter
to The Lancet, Vol 357, No 9261, 31 Mar 01, page 1048.
257. Hrushesky WJM. Timed Delivery, Peer Review – Letters from Readers, The Sciences, Spring 2001, page
48.
Hrushesky • Curriculum Vitae • Page 31
258. Bjarnason G, Jordan R, Wood PA, Li Q, Lincoln D, Sothern R, Hrushesky WJM, Yaacov Ben-David.
Circadian Expression of Clock Genes in Human Oral Mucosa and Skin; Association with Specific Cell-Cycle
Phases. American Journal of Pathology, Vol 158 No 5, May 2001.
259. Hrushesky WJM. Tumor chronobiology. Journal of Controlled Release, Vol 74, 27-30, 2001.
260. Retsky M, Demicheli R, Hrushesky W. Breast Cancer Screening for Women Aged 40-49 Years: Screening
May Not Be the Benign Process Usually Thought. Letter to the Journal of the National Cancer Institute, Vol. 93
No.20: 1572, October 17, 2001.
261. Hrushesky WJM. Review of Rich, Tyvin, et al. Modulation of dose intensity in aerodigestive tract cancers:
strategies to reduce toxicity. Oncology, Vol 15, December 2001, 1614-17.
262. Kobayashi M, Wood P, Hrushesky WJM. Circadian chemotherapy for gynecological and genitourinary
cancers. Chronobiol Int. 2002 Jan;19(1):237-51. Review.
263. Bove K, Lincoln D, Wood P, Hrushesky WJM. Fertility cycle influence on surgical breast cancer cure.
Breast Cancer Res Treat. 2002 Sep;75(1):65-72.
264. Hrushesky WJM. Letter to the Editor-Re:Love et al. J Natl Cancer Inst 2002;94:662-9. Journal of
the National Cancer Institute Vol 94 (22):1719-1721, Nov 20, 2002.
265. Hrushesky WJM. Letter to the Editor. Androgen suppression and irradiation for
locally advanced prostate cancer. The Lancet 360: 1987, 14 December 2002.
266. Retsky M, Demicheli R, Hrushesky W. Breast cancer screening: controversies and future
directions. Curr Opin Obstet and Gynecol. 2003 Feb;15(1):1-8. Review.
267. Lis C, Grutsch J, Wood P, You M, Rich I, Hrushesky W. Circadian Timing in Cancer Treatment: the
Biological Foundation for an Integrative Approach. Integr Cancer Ther. 2003 Jun;2(2):105-11. Review.
268. Waterhouse J, DeCoursey P (Authors) Arendt J, Campbell S, Hrushesky W, Lemmer B, Lewy A, Terman M,
Wehr T, Wirz-Justice A (Contributors) The Relevance of Circadian Rhythms for Human Welfare, Chapter 10
of Chronobiology: Biological Timekeeping, Dunlap et al (Eds); 2003.
269. Patterson D, Wood P, Probst J, Shinogle J, Hrushesky W. Equal access to healthcare in the VA system
works to alleviate racial and rural disparities among prostate cancer patients in South Carolina. Journal of the
South Carolina Medical Association 2003, 99:185-91.
270. Demicheli R, Bonadonna G, Hrushesky W, Retsky M, Valagussa P. Menopausal status dependence of early
mortality reduction due to diagnosis of smaller breast cancer (T1 v T2-T3): Relevance to Screening. J Clin
Oncol. 2004 Jan 1;22(1):102-07.
271. Retsky M, Bonadonna G, Demicheli R, Folkman J, Hrushesky W, Valagussa P. Hypothesis: Induced
angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason
why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Res 2004;6(4):R372-4.
Epub 2004 May 14.
272. Hrushesky W, Blask D. Letter to the Editor- Re: Melatonin and Breast Cancer: A Prospective Study. J Natl
Cancer Inst 2004; 96(11):888-889.
273. Hrushesky W, Wood P, Levi F, von Roemling R, Bjarnason Georg, et al. Letter to the Editor: A Recent
Illustration of Some Essentials of Circadian Chronotherapy Study Design. Re: Randomized Phase III Trial of
Standard Timed Doxorubicin Plus Cisplatin Versus Circadian-Timed Doxorubicin Plus Cisplatin in Stage III
and IV or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2004;
22(14):2971-72.
274. Demicheli R, Bonadonna G, Hrushesky W, Retsky M, Valagussa P. Menopausal Status Dependence of the
timing of breast cancer recurrence after surgical removal of the primary tumour. Breast Cancer Research
2004 (6):R689-96.
Hrushesky • Curriculum Vitae • Page 32
275. Retsky M, Demicheli R, Hrushesky W, Speer J, Swartzendruber D, Wardwell R. Recent Translational
Research: Computational Studies of Breast Cancer. Breast Cancer Res 2004; (7): 37-40.
276. Demicheli R, Bonadonna G, Hrushesky W, Retsky M, Valagussa. Correspondence: Response to Response
by Kopans, Get the Facts Straight. J Clin Oncol 22 (23) 4807-4810, 2004 December 11. RE: #270 above:
Menopausal status dependence of early mortality reduction due to diagnosis of smaller breast cancer (T1 v
T2-T3): Relevance to Screening. J Clin Oncol 2004; 22(1):102-07.
277. You S, Li W, Kobayashi M, Xiong Y, Hrushesky W, Wood P. Creation of a Stable Mammary Tumor Cell
Line That Maintains Fertility Cycle Tumor Biology of the Parent Tumor. In Vitro Cell Dev Biol Anim 2004;
40(7): 187-95.
278. Dominitz J, Boyko E, Koepsell T, Heagerty P, Maynard C, Sporleder J, Hrushesky W. Elevated Prevalence
of Hepatitis C Infection in Users of United State Veterans Medical Centers. Hepatology 2005; 41(1):88-89.
279. Hrushesky W. Timing is Everything: Diverse Strategies for Measuring It. Molecular Biology of Circadian
Rhythms. Book Review: Molecular Biology of Circadian Rhythms, Amita Sehgal, editor. Hoboken, NJ:
Wiley-Liss, 2004. Clinical Chemistry 2005; 51:280-281.
280. Baum M, Demicheli R, Hrushesky W, Retsky M. Does Surgery Unfavorably Perturb the “Natural History”
of Early Breast Cancer by Accelerating the Appearance of Distant Metastases? European J Cancer 2005;
41:508-15.
281. You S, Wood PA Xiong Y, Kobayashi M, Du-Quiton J, Hrushesky WJM. Daily Coordination of Cancer
Growth and Circadian Clock Gene Expression. Breast Can Res Treat 2005; 91(1):47-60.
282. Wood PA, Hrushesky WJM. Sex cycle modulates cancer growth. Breast Can Res Treat 2005; 91(1):95-102.
283. Hrushesky W, Sothern R, Rietveld W, Du Quiton J, Boon M. Season, Sun, Sex and Cervical Cancer. Cancer
Epidemiology, Biomarkers and Prevention 2005; 14(8):1940-47.
284. Hrushesky W, Sothern R, Rietveld W, Du Quiton J, Boon M. Sun Exposure, Sexual Behavior and Uterine
Cervical Human Papilloma Virus. Int J Biometeorol. 2006 Jan; 50(3):167-73.
285. Hrushesky WJM, You S, Du-Quiton J, Li M, Ohmori M, Wood P. Circadian cancer biology: Does the time
of the day we treat matter? Basic and Clinical Medicine 2005; 25(4):289-330.
286. Demicheli R, Miceli R, Moliterni A, Zambetti M, Hrushesky, WJM, et al. Breast Cancer Recurrence
Dynamics Following Adjuvant CMF is Consitent with Tumor Dormancy and Mastectomy-driven
Acceleration of the Metastatic Process. Annals of Oncology 2005; 16(9):1449-57.
287. Wood PA, Bove K, You S, Chambers A, Hrushesky W. Cancer Growth and Spread are Saltatory and PhaseLocked to the Reproductive Cycle Through Mediators of Angiogenesis. Molecular Cancer Therapeutics
2005; 4(7):1065-75.
289. Restsky MW, Demicheli R, Hrushesky WJM. Does surgery induce angiogenesis in breast cancer? Indirect
evidence from bimodal relapse pattern for untreated early breast cancer patients and the mammography
paradox for women age 40-49. International Journal Surgery 2005; 3(3) 179-87.
290. Demicheli R, Bonadonna, P Vagalussa, Retsky M, Hrushesky WJM, et al. Comment to Jatoi et al report:
Hazard Rates of Recurrence Following Diagnosis of Primary Breast Cancer. Breast Cancer Res Treat 2005;
93:1-2.
292. You S, Ohmori M, Pena MM, Nassri B, Du-Quiton J, Al-Assad ZA, Liu L, Wood PA,Berger SH, Liu Z, Wyatt MD,
Price RL, Berger FG, Hrushesky WJ. Developmental Abnormalities in Multiple Proliferative Tissues of Apc Min/+
Mice. Int J Exp Pathol 2006 June;87 (3): 227-36.
294. Retsky M, Hrushesky WJM, Baum M. Correspondence: Sociodemographic determinants of cancer treatment
health literacy Gansler T, Henley SJ, Stein K, et al. Cancer 2006; 106(3):726-7.
Hrushesky • Curriculum Vitae • Page 33
295. Wood PA, Du-Quiton J, You S, Hrushesky WJM. Circadian clock coordinates cancer cell cycle
progression, thymidylate synthase, and 5-fluorouracil therapeutic index. Molecular Cancer Therapeutics
2006;5(8):2023-33.
296. Levin RD, Daehler M, Grutsch JF, Quiton J, Lis CG, Peterson C, Gupta D, Watson K, D Layer, S Adams, B
Desai, P Sharma, M Wallam, M Delioukina, P Ball, M Bryant, M Ashford, D Copeland, M Ohmori, PA Wood
and Hrushesky WJM. Circadian Function in Patients with Advanced Non-small Cell Lung Cancer. British
Journal of Cancer 2005; 93:1202-8.
297. Retsky M, Demicheli R, Hrushesky WJM. Authors Respond to Controversy Surrounding Breast Cancer
Study. International Journal of Surgery 2005; 3(4):235-9.
299. Demicheli R, Hrushesky WJM, Retsky M. Comment on Berry DA, Cronin KA, Plevritis SK, et al. Effect of
screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2006; 354;(7):768-9.
300. Demicheli R, Biganzoli E, Boracchi P, Greco M, Hrushesky WJM, Retsky M. Allometric Scaling Law
Questions The Traditional Mechanical Model For Axillary Lymph Node Involvement In Breast Cancer. J of
Clin Oncology 2006;24 (27):4391-6.
301. Retsky M, Baum M, Demicheli R, Gukas I, Hrushesky WJM. Enhanced Surgery-Induced Angiogenesis for
Premenopausal Women Might Partially Explain Excess Breast Cancer Mortality of Blacks Compared to
Whites. Int Journal of Surgery 2007;5:300-4.
302. Demicheli R, Retsky M, Hrushesky WJM, Baum M. Comment to Babiera GV et al report (Ann Surg Oncol
2006;13;776-782) Ann Surg Oncol. 2007 Apr;14(4):1519-20.
303. Du-Quiton J, Wood PA, Burch J, Grutsch JF, Gupta D, Tyer K, Lis CG, Levin RD, Quiton DF, Reynolds J,
Hrushesky WJM. Actigraphic assessment of daily sleep-activity pattern abnormalities reflect self-assessed
depression and anxiety in outpatients with advanced non-small cell lung cancer. Psycho-Oncology 2010 Feb;
19(2):180-9.
304. Demicheli R, Baum M, Hrushesky WJM, Retsky M. Comment to the paper: Rapiti E, et al:
Complete excision of primary breast tumour improves survival of patients with metastatic breast cancer at
diagnosis J Clin Oncology 2006; 24:2743-9.
306. Berk L, Berkey B, Blask D, Hrushesky WJM, Kudrimoti M, McGarry R, Mehta M, Rich T, Suh
J. A Randomized Phase II Trial of High Dose Melatonin and Radiation Therapy for RPA Class 2 Patients
with Brain Metastases (RTOG 0119). Int J of Radiat Oncol Biol Phys 2007;68(3):852-7.
308. Kanabrocki E, Hermida R, Torossov M, Haseman M, Bettis K, Young J, Potkul R, Hrushesky WJM.
Chronotherapy of Ovarian Cancer: Effect on Blood Variables and Serum Cytokines. A Case Report. Clin Ter
2006 Jul-Aug; 157(4):349-54.
310. Demicheli R, Retsky M, Hrushesky WJM, Baum M. Tumor Dormancy and Surgery-Driven
Dormancy Interuption in Breast Cancer: Learning from Failures. Nature CP Oncology, 2007; 4(12):699-710.
311. Retsky M, Demicheli R, Gukas I, Hrushesky WJM. Letter to the editor – Re: Catherine Elton:
Letters spurred theory about breast cancer deaths in blacks. Boston Globe, 2007.
312. Hrushesky WJM, Retsky M, Baum M, Demicheli R. Letter to the Editor RE: Prognostic Value of
Ki67 Expression after Short-term Presurgical Endocrine Therapy for Primary Breast Cancer. J Nat Ca Inst
2007; 99(13):1053.
313. Retsky M, Demcheli R, Hrushesky WJM, Baum M, Gukas I. Can Surgery Provoke the Outgrowth of Latent
Breast Cancer? A Unifying Hypothesis. Breast Cancer Online, 10 (4): 1-6.
Hrushesky • Curriculum Vitae • Page 34
314. Ramanathan R, Bjarnason G, Desimone P, Bernard S, Evers J, Braich T, Hrushesky WJM, Samson
B. A Phase II, four arm randomized, multicenter trial of oxaliplatin combined with varying schedules
of 5-fluorouracil as first line therapy of previously untreated advanced colorectal cancer. Clinical
Colorectal Cancer 2008;7(2): 134-9.
315. Oh EY, Wood PA, Du-Quiton J, Hrushesky WJM. Seasonal Modulation of Post-Resection
Breast Cancer Metastasis. Breast Ca Res Treat 2008;111(2): 219-28.
316. Demicheli R, Retsky M, Hrushesky WJM, Baum M, Gukas I, Jatoi I. Racial Disparities In Breast
Cancer Outcome: Insights into Host-Tumor Interactions. Cancer 2007; 110(9):1880-8.
317. Halberg F, Cornelissen G, Ulmer W, Blank M, Hrushesky WJM, Wood P, Singh RK, Wang K. Cancer
chronomics III. Chronomics for cancer, aging, melatonin and experimental therapeutics researchers. J Exp
Ther Oncol 2006;6(1):73-84.
318. Retsky M, Demicheli R, Hrushesky WJM, Baum M, Gukas I. Dormancy and surgery-driven escape
from dormancy help explain some of the enigmatic clinical features of breast cancer. APMIS 2008 JulAug;116(7-8):730-41
320. Singletary JK, Wood PA, Du-Quiton J, Wang S, Yang X, Hrushesky WJM. Imaging
Multidimensional Therapeutically Relevant Ciracdian Relationships. Int J Biomedical Imaging. 2009, Article
ID 231539. doi:10.1155/2009/231539.
321. Demicheli R, Retsky M, Hrushesky WJM, Baum M, Gukas I. The effects of surgery on tumour
growth: a century of investigations. Annals of Oncology 2008; 19(11):1821-8.
322. Yang X, Wood PA, Oh EY, Ansell C, Du-Quiton J, Hrushesky WJM. Down regulation of circadian
clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm. Breast
Cancer Res Treat 2009; 117 (2) :423-31.
324. Wood PA, Yang X, Taber A, Oh EY, Ansell C, Ayers S, Al-Assaad Z, Carnevale K, Berger F, Pena
MM, Hrushesky WJM. Period 2 mutation accelerates Apc Min/+ tumorigenesis. Mol Ca Res,
2008;6(10):1786-93.
325. Jatoi I, Baum M, Demicheli R, Retsky M, Hrushesky WJM, Gukas I. Response to: Dobson R. BMJ;337:a586.
Breast Cancer: Black women in US are less likely than white women to survive breast cancer. British Med J.
July 2008.
326. Retsky M, Hrushesky WJM, Gukas I. Hypothesis: Primary antiangiogenic method proposed to treat
early stage breast cancer. BMC Cancer 2009 Jan 8;9:7.
328. Oh EY, Wood PA, Yang X, Hrushesky WJM. Discovery of candidate genes and pathways that may
help explain fertility cycle stage dependent post-resection breast cancer outcome. Breast Cancer Res
Treat. 2009 Nov;118(2):345-59.
329. Nemunaitis J, Clayman G, Agarwala S, Hrushesky WJM, Moore C, Hamm J, Menander K, Licato L,
Chada S, Gibbons R, Roth J, Sobol R, Goodwin WJ. Biomarkers predict p53 therapy efficacy in
recurrent, squamous cell carcinoma of the head and neck. Clin Cancer Res 2009 Dec 15;15(24):771925.
331. Yang X, Wood PA, Ansell CM, Ohmori M, Oh EY, Xiong Y, Berger FG, Pena MM, Hrushesky
WJM. ß-catenin induces b-TrCP mediated PER2 degradation altering circadian clock gene
expression in intestinal mucosa of ApcMin/+ mice. J. Biochem. 2009;145(3):289-97.
Hrushesky • Curriculum Vitae • Page 35
334. Chung H, Lee H, Lamoke F, Hrushesky WJM, Wood PA, Jang WJ. Neuroprotective role of
erythropoietin by anti-apoptosis in the retina. J Neuroscience Research. 2009; 87(10):2365-74.
336. Oh EY, Ansell CM, Nawaz H, Yang CH, Wood PA, Hrushesky WJM. Global Breast Cancer Seasonality.
Breast Cancer Res Treat. 2010 Aug;123(1):233-43. Epub 2010 Feb 4.
338. Burch J, Hrushesky WJM. The Protective Role of Melatonin in Breast Cancer. Breast Diseases. 2009; 20(3):
240-1.
339. Hrushesky WJM. Timing is Everything. BottomLine Health. 2009; 23 (9):1-3.
341. Hrushesky WJM, Grutsch JF, Wood PA, Yang X, Oh EY, Ansell CM, Kidder S, Ferrans C, Quiton
DF, Reynolds JL, Du-Quiton J, Levin R, Lis C, Braun DP. Circadian clock manipulation for cancer
prevention and control and the relief of cancer symptoms. Int Cancer Therapies Dec 2009;8(4):38797.
342. Guess J, Burch J, Ogoussan K, Armstead C, Zhang H, Wagner S, Hebert J, Wood PA, Youngstedt S,
Hofseth L, Singh U, Xie D, Hrushesky WJM. Circadian Disruption, Per3, and Human Cytokine
Secretion. Integr Cancer Ther. 2009 Dec;8(4):329-36. Epub 2009 Nov 18.
343. Yang X, Wood PA, Ansell CM, Quiton DFT, Oh EY, Du-Quiton J, Hrushesky WJM. The
Circadian Clock Gene Per1 Suppresses Cancer Cell Proliferation and Tumor Growth at Specific
Times of Day. Chronobiology International 2009;26(7):1323-39.
344. Yang X, Wood PA, Hrushesky WJM. Mammalian TIM is Required for ATM-dependent Chk2
Activation and G2/M Checkpoint Control. Journal of Biological Chemistry 2010 Jan 29; 285(5):3030-4.
345. Yang F, Yang X, Jiang H, Buckhaults P, Wood PA, Hrushesky WJM, Wang GR. Dielectrophoresis
Separation of Colorectal Cancer Cells. Biomicrofluidics 2010 Jan 4, 013204(2010).
346. Wood PA, Yang X, Hrushesky WJM. Clock Genes and Cancer. Int Cancer Therapies 2009 Dec;
8(4): 303-8.
348. Yang X, Wood PA, Ansell C, Hrushesky WJM. Circadian Time-Dependent Tumor Suppressor
Function of Period Genes. Int Cancer Therapies 2009 Dec; 8(4): 309-16.
349. Zhang R, Hrushesky WJ, Wood PA, Lee SH, Hunt RC, Jahng WJ. Melatonin reprogrammes proteomic profile
in light-exposed retina in vivo. Int J Biol Macromol. 2010 Aug 1;47(2):255-60. Epub 2010 Apr 29.
350. Lee H, Chung H, Arnouk H, Lamoke F, Hunt RC, Hrushesky WJ, Wood PA, Lee SH, Jahng WJ. Cleavage of
the retinal pigment epithelium-specific protein RPE65 under oxidative stress. Int J Biol Macromol. 2010 Aug
1;47(2):104-8. Epub 2010 May 25.
351. Lee H, Arnouk H, Sripathi S, Chen P, Zhang R, Bartoli M, Hunt RC, Hrushesky WJ, Chung H, Lee SH, Jahng
WJ. Prohibitin as an oxidative stress biomarker in the eye. Int J Biol Macromol. 2010 Dec 1;47(5):685-90.
Epub 2010 Sep 9.
352. Demicheli R, Ardoino I, Boracchi P, Coradini D, Agresti R, Ferraris C, Gennaro M, Hrushesky WJ, Biganzoli
E. Recurrence and mortality according to estrogen receptor status for breast cancer patients undergoing
conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within
the residual breast. BMC Cancer. 2010 Nov 30;10:656.
Hrushesky • Curriculum Vitae • Page 36
353. Oh EY, Yang X, Friedman A, Ansell CM, Du-Quiton J, Quiton DF, Wood PA, Hrushesky WJ. Circadian
transcription profile of mouse breast cancer under light-dark and dark-dark conditions. Cancer Genomics
Proteomics. 2010 Nov-Dec;7(6):311-22.
354. Hrushesky WJ, Sothern RB, Du-Quiton J, Quiton DF, Rietveld W, Boon ME. Sunspot dynamics are reflected
in human physiology and pathophysiology. Astrobiology. 2011 Mar;11(2):93-103. Epub 2011 Mar 10.
355. Grutsch JF, Wood PA, Du-Quiton J, Reynolds JL, Lis CG, Levin RD, Ann Daehler M, Gupta D, Quiton DF,
Hrushesky WJ. Validation of actigraphy to assess circadian organization and sleep quality in patients with
advanced lung cancer. J Circadian Rhythms. 2011 May 18;9:4.
356. Grutsch JF, Ferrans C, Wood PA, Du-Quiton J, Quiton DF, Reynolds JL, Ansell CM, Oh EY, Daehler MA,
Levin RD, Braun DP, Gupta D, Lis CG, Hrushesky WJ. The association of quality of life with potentially
remediable disruptions of circadian sleep/activity rhythms in patients with advanced lung cancer. BMC Cancer.
2011 May 23;11:193.
357. Retsky M, Rogers R, Demicheli R, Hrushesky WJ, Gukas I, Vaidya JS, Baum M, Forget P, Dekock M,
Pachmann K. NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse:
particular relevance to triple negative subgroup. Breast Cancer Res Treat. 2012 Jul;134(2):881-8. Epub 2012
May 24.
358. Fishman ML, Kumar A, Davis S, Shimp W, Hrushesky WJ. Guideline-based peer-to-peer consultation
optimizes pegfilgrastim use with no adverse clinical consequences. Am J Manag Care. 2012 May 1;18(5):e16872.
359. Fishman M, Shimp W, Krook J, Kumar A, Hrushesky WJ. Correspondence. J Natl Compr Canc Netw. 2012
Jul 1;10(7)
360. Fishman ML, Kumar A, Davis S, Shimp W, Hrushesky WJ. Guideline-Based Peer-to-Peer Consultation
Optimizes Pegfilgrastim Use With No Adverse Clinical Consequences. J Oncol Pract. 2012 May;8(3
Suppl):e14s-7s.
361. Retsky M, Demicheli R, Hrushesky WJ, Forget P, De Kock M, Gukas I, Rogers RA, Baum M, Pachmann K,
Vaidya JS. Promising development from translational or perhaps anti-translational research in breast cancer.
Clin Transl Med. 2012 Aug 28;1(1):17.
362. Hrushesky WJM, Kumar A, Davis S, and Fishman ML. Countering the Misincentivization of Cancer Medicine
by Real-Time Personal Professional Education. J Oncol Pract. 2012 March; 8(2): 70.
363. Retsky M, Demicheli R, Hrushesky WJ, Forget P, De Kock M, Gukas I, Rogers RA, Baum M, Sukhatme V,
Vaidya JS. Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new
findings and a review. Curr Med Chem. 2013;20(33):4163-76.
364. Shimp WS, Bobolts L, Fishman V, Fishman ML, Kogler J, Huff DF, Hrushesky WJM. The Leucovorin
Shortage: A Tangled Web of Similar Isomers and Huge Cost Differences. Value-Based Cancer Care. 2013 Jul.
(online only) http://www.valuebasedcancer.com/article/leucovorin-shortage-tangled-web-similar-isomers-andhuge-cost-differences
365. Lu ZK, Samuel J Kessler BA, Schulz R, Bian J, Chen B, Wu J, Noxon V, Rao1 GA, Leibnitz R, Restaino J,
Maxwell W, Norris LB, Qureshi ZP, Martin L, Love BL, Bookstaver B, Sutton S, Fayad R, Jacob S,
Georgantopoulos P, Sartor O, Yarnold PR, Huff D, Hrushesky W, Raisch DW, Ablin R, Bennett CLB.
Systematic Approach to Pharmacovigilance beyond the Limits: The Southern Network on Adverse Reactions
(SONAR) Projects. Adv Pharmacoepidemiol Drug Saf. 2014 Apr 30; 3(2): 149.
Hrushesky • Curriculum Vitae • Page 37
Submitted Manuscripts
Demicheli R, Huff DF, Hrushesky WJM. Cancer: When to Treat...When to Watch...When to Think". Nature
Reviews Cancer. Submitted for review Jul 2014
Bennett CL, Chen B, Hermanson T, Wyatt M, Schulz R, Georgantopoulos P, Kessler S, Raisch D, Qureshi Z, Lu K,
Love B, Noxon V, Bobolts LR, Armitage J, Qian C, Leibnitz R, Ray P, Ablin R, Hrushesky W, MacDougall IC,
Sartor O, Armitage JO. Biosimilar oncology drugs: A Southern Network on Adverse Reactions (SONAR)
review. Submitted to NEJM Jul 2014.
Fishman M, Shimp WS, Bennett CL, Armitage MB, Baranwal A, Bobolts LB, Huff DF, Mamgain A, Kogler J,
Hrushesky WJM. Evaluating Efficacy, Toxicity, and Costs of Bone-Modifying Agents in Cancer Care.
Submitted to CA. Jul 2014.
Lis CG, Levin RD, Grutsch JF, Wood PA, Braun RDP, Bridsall TC, Huff DF, Reynolds JL, Daehler MA, Pearl
DK, Shen X, Blask DE, Hrushesky WJM. Evening melatonin (but not morning) prolongs the survival of
patients with advanced non-small cell lung cancer (ANSCLC). Submitted to The Lancet. Jul 2014.
Baranwal A, Huff DF, Bennett CL, Kogler J, Knopf K, Mamgain A, Shimp W, Hrushesky WJM. The tree falling in
the forest: Revised 2012 National Comprehensive Cancer Network guidelines warning against administering
oxaliplatin to older persons with stage II and III colon cancer. Submitted to Journal of Oncology Practice. Jul
2014.
Hrushesky WJM, Fishman M, Huff DF, Davis S, Shimo W, Kogler J, Bobolts L, Armitage M, Baranwal A, Kumar
A, Mamgain A, Bennett A. Overuse and misuse of adjuvant chemotherapy for stages I and II non-small cell
lung cancer chemotherapy: Empirical findings from a privately insured population. Submitted to BMC Cancer.
Jul 2014.
Hrushesky • Curriculum Vitae • Page 38
Appendix IV- Published Scientific Abstracts:
1.
Hrushesky W. Lymphocyturia in human renal allograft rejection. JAMA. Vol. 221, 1972:1424.
2.
Hrushesky W, GP M. A murine renal carcinoma. Proc 6th Ann Mtg, Assoc Acad Surg, 1973.
3.
Hrushesky W. The place of L-asparaginase in cancer therapy. Proc USPHS Prof Assoc. Vol. 11, 1976:56A.
4.
Hrushesky W. Serpentine supravenous fluorouracil hyperpigmentation. JAMA. Vol. 236, 1976:138.
5.
Cohen M, Hrushesky W, Minna J. Chemotherapy response after initial treatment failure in small cell
bronchogenic carcinoma. Proc AACR. Vol. 17, 1976:112.
6.
Hrushesky W, Slavik M, Muggia F. Summary of results with L-asparaginase therapy. Proc ASCO. Vol. 17,
1976:311.
7.
Hrushesky W. What's old and new in advanced renal cell carcinoma. Proc ASCO. Vol. 18, 1977:318.
8.
Hrushesky W, Cornelissen G, Halberg F, Prins JD, Nesbitt M, Kennedy B. Rythm parameters of
experimental data on carcinostatics potentially applicable to clinical chronotherapy. Proc MN Acad Sci. Vol.
46, 1978:26.
9.
Hrushesky W, Sothern R, Halberg F, Haus E, Kennedy B. Toward an experimental circadian chronotherapy
with cisdiamminedichloroplatinum (PI) and adriamycin (Ad) gauged by survial prolongation in
immunocytoma-bearing rats. Clin Res. Vol. 26, 1978:710A.
10.
Hrushesky W, Levi F, Nelson W, Kennedy B. Cisplatin chronotolerance. Proc Conf on Combined
Modalities: Chemotherapy/Radiotherapy. Vol. 3, 1978:58.
11.
Halberg E, Halberg F, Hrushesky W, Cornelissen G, Vener K, Haus E, Scheving L, Kennedy BJ. Circadian
rectal temperature acrophase of rats on daily 8 hour photofraction as reference for
cisdiamminedichloroplatinum chronotolerance. Proc MN Acad Sci. Vol. 46, 1978:22.
12.
Halberg E, Halberg F, Vener K, Scheving L, Cornelissen G, De Prins J, Hrushesky W, Kennedy BJ. Twentyfour hour synchronized chronotolerance of cisdiamminedchloroplatinum (II) by rats on 8h and 12h
photofraction gauged by acrophase and paraphrase of rectal temperature. Chronobiologia. Vol. 5, 1978:213.
13.
Sothern R, Halberg F, Hrushesky W, Doe) ibR. Circadian optimization of cisdiamminedichloroplatinum (PI)
and adriamycin (Ad) combination (PLAd) therapy of an immunocytoma gauged by complete remission or
cure. Clin Res. Vol. 26, 1978:712A.
14.
Sothern R, Hrushesky W, Halberg F, Haus E, Kennedy B. Circadian temperature rhythm in LOU rats with
and without immunocytoma during polychronochemotherapy with Adriamycin and cisdiamminedichloroplaatinum II. Chronobiologia. Vol. 5, 1978:216.
15.
Kennedy B, Levi F, Hrushesky W, Culley D, Cornelissen G, Halberg E, Halberg F. Circadian and circannual
interactions with murine chronotolerance of cisplatin (CP) with and without hydration. Chronobiologia. Vol.
6, 1979:117.
16.
Hrushesky W, Hammerschmidt D. Cefatoxime (HR 756): A platelet-inhibitory cephalosporin antibiotic.
Blood. Vol. 54, 1979:245A.
17.
Hrushesky W, Pleasants M, Levi F, Halberg F, Borch R, Theologides A, Kennedy BJ. Toward clinical
chronotherapy: circadian chronopharmacokinetics of cisdiamminedichloroplatinum (CP) in five patients with
widely metastatic carcinoma. Chronobiologia. Vol. 6, 1979:113.
18.
Hrushesky W. Subcutaneous heparin-induced thrombocytopenia. Toxicol, 1979.
19.
Hrushesky W, Sanchez S, Levi F, Brown H, Halberg F, Haus E, Sothern R, Kennedy BJ. Total RNA content
of cancer patients' mononuclear cells demonstrate marked circadian rhythmicity. Blood. Vol. 54, 1979:221.
Hrushesky • Curriculum Vitae • Page 39
20.
Hrushesky W, Teslow T, Halberg F, Kiang D, Kennedy B. Temporal componets of predictable variability
along the 1-year scale in estrogen receptor concentration of primary human breast cancer. Proc ASCO. Vol.
20, 1979:331.
21.
Hrushesky W, Levi F, Halberg F, Kennedy B. Circadian variation in toxicity and efficacy of adriamycin (Ad)
and platinum (DDP) alone and in combination. Proc MN Soc Intern Med, 1979.
22.
Levi F, Pleasants M, Hrushesky W, Borch R, Halberg F. Rat urinary chronopharmacokinetics of the
antitumor drug cisplatin (CP). Chronobiologia. Vol. 6, 1979:127.
23.
Hrushesky W, Kennedy B. Encouraging results obtained with an adriamycin (Ad), platinum (DDP)
commbination in patients with advanced transitional cell carcinoma of the bladder (TCCB). Proc MN Soc
Intern Med, 1979.
24.
Hrushesky W, Levi F, Fanning R, Halberg F, Kennedy B. Chemotherapy associated changes in circadian
parameters over skin covering histologically validated malignancy. Proc MN Acad Sci, 1979.
25.
Bixby E, Levi F, Haus R, Sackett L, Haus E, Hrushesky W, Halberg F. Circaseptan aspects of cisplatin (CP)
murine nephrotoxicity. Chronobiologia, 1979.
26.
Levi F, Hrushesky W, Halberg F, Kennedy B, Fortuny I. Murine chronotolerance to cisplatin (CP) and its
further optimization by hydration. Proc AACR. Vol. 20, 1979:274.
27.
Hrushesky W, Sanchez S, Levi F, Halberg F, Kennedy B. The RNA content of circulating mononuclear cells
(MC) demonstrates marked circadian rhythmicity (CR). Clin Res. Vol. 28, 1980:349A.
28.
Hrushesky W, Levi F, Sanchez S, Halberg F, Kennedy B. Periodicity of human lymphcyte RNA content.
Proc XIV Ann Cong Amer Assoc Clin Immunol Allergy, 1980:7.
29.
Hrushesky W, Kubicek W, Levi F, Olson M, Beck R, Bliss D, Sanchez S, Halberg F, Kennedy BJ.
Impedance cardiography (IC) detecs adriamycin-induced cardiac dysfunction. Clin Res. Vol. 28, 1980:416A.
30.
Hrushesky W, Levi F, Halberg F, Haus E, Langevin T, Frenning D, Theologides A, Kennedy BJ. Reduced
platinum renal toxicity by treatment based on biologic rhythms. Clin Res. Vol. 28, 1980:708A.
31.
Hrushesky W, Levi F, Kennedy B. Cisdiamminedichloroplatinum (DDP) toxicity to the human kidney
reduced by circadian timing. Proc ASCO. Vol. 21, 1980:330.
32.
Levi F, Halberg F, Sanchez S, Sothern R, Hrushesky W, Langevin T, Haus E, Kennedy BJ. Adriamycin
tolerance improved by timed ACTH pretreatment. Clin Res. Vol. 28, 1980:780A.
33.
Levi F, Halberg F, Hrushesky W, Kennedy B. Chronobiology--an essential perspective for understanding
apparent contradictions in immunotherapy. Proc XIV Ann Cong Am Assoc Clin Immunol Allergy, 1980:4.
34.
Levi F, Lakatua D, Haus E, Hrushesky W, Halberg F, Schwartz S, Kennedy BJ. Circadian urinary N-aacetyl
glucose amidinase (NAG) excretion gauges murine cisdiamminedichloroplatinum (DDP) nephrotoxicity. Proc
AACR. Vol. 21, 1980:307.
35.
Medini E, Levi F, Halberg F, Hrushesky W, Haus E, Lakatua D, Levitt S. Circadian marker rythmometry
before and during chronoradiotherapy of a patient with extranodal lymphoma. Chronobiologia. Vol. 7,
1980:129-130.
36.
Hrushesky W, Halberg F, Heinlen T, Murray C, Kennedy B. Human bone marrow toxicity of adriamycin
(Ad) reduced by optimal circadian timing. Proc AACR. Vol. 21, 1980:307.
37.
Levi F, Hrushesky W, Holtzman J, Halberg F, Sanchez S, Kennedy B. ACTH 1-17(A) raises cardiac-reduced
glutathione(GSH) and protects mice from doxorubicin (D) lethal cardiotoxicity. Notiziario S I Bio C 5, 1981.
38.
Levi F, Hrushesky W, Holtzman J, Halberg F, Sanchez S, Kennedy B. ACTH 1-17 (A) raises cardiac reduced
glutathione (GSH) and protects mice from doxorubicin (D) lethal cardioxictiy. Intl J Chronobiolia. Vol. 7,
1981:277.
Hrushesky • Curriculum Vitae • Page 40
39.
Hrushesky W, Abdel-Monem M. Circadian rhythm in ratio of acetylspermidines in human urine in health.
Clin Res. Vol. 29, 1981:437.
40.
Levi F, Sanchez S, Hrushesky W, Haus E, Lakatua D, Halberg F, Kennedy BJ. Adriamycin (ADR)
cardiotoxicity: early assessment by creatinine phosphokinase (CPK) isoenzymes. Proc AACR. Vol. 22,
1981:259.
41.
Levi F, Hrushesky W, Halberg F, Langevin T, Kennedy B, Murray C. Adriamycin (ADR) cardioxity: tests of
predictable value of circadian cardiovascular rhythm parameters. Proc ASCO. Vol. 22, 1981:364.
42.
Vukelich M, Hrushesky W, Halberg F, Langevin T, Levi F, Kennedy BJ, Gergen J, Goetz F, Theologides A.
Elevated circadian mesor of pulse in recumbency predicts doxorubicin (D)-induced congestive heart failure
(CHF). Notiziario S I Bio C 5, 1981.
43.
Pena SSdl, Sanchez E, Halberg F, Haus E, Hrushesky W. Circadian rhythmic response of murine adrenal
RNA to in vitro stimulation by ACTH 1-17 inhibited by puromycin. Notiziaro S I Bio C 5, 1981.
44.
Vukelich M, Hrushesky W, Halberg F, Langevin T, Levi F, Kennedy BJ, Gergen J, Goetz F, Theologides A.
Elevated circadian mesor of pulse in recumbency predicts doxorubicin (D)-induced congestive heart failure
(CHF). Intl J Chronobiol. Vol. 7, 1981:344.
45.
Hrushesky W, Halberg F, Levi F, Langevin T, Kennedy B. Circadian-circannual aspects of leukocyte count
(WBC) depression and recovery in patients given doxorubicin (D) and cisdiamminedichloroplatinum (C). Intl
J Chronobiol. Vol. 7, 1981:256.
46.
Hrushesky W, Halberg F, Levi F, Langevin T, Kennedy B. Circadian-circannual aspects of leukocyte count
(WBC) depression and recovery in patients given doxorubicin (D) and cisdiamminedichloroplatinum (C).
Notiziario S I Bio C 5, 1981.
47.
Langevin T, Goetz F, Hrushesky W, Halberg F, Steiner B, Gergen J, Levi F, Kennedy BJ. Relative stability
of urinary marker rhythms in cancer patients (CP) receiving intermittent nephrotoxic chemotherapy. Intl J
Chronobiol. Vol. 7, 1981:275.
48.
Hrushesky W, Vukelich M. Increase in 24-hour mean (mesor)recumbent heart rate predicts doxorubicin (D)
induced congestive heart failure (CHF). Clin Res. Vol. 29, 1981:736.
49.
Hrushesky W, Levi F, Kennedy B, Theologies A, Frenning D. Results of circadian time qualified
chemotherapy in patients with advanced ovarian cancer. Proc ASCO. Vol. 22, 1981:472.
50.
Hrushesky W, Borch R, Levi F, Langevin T, Lange P, Kennedy B. Human urinary phaarmacokinetics of
cisplatin: role of circadian drug timing. Proc AACR. Vol. 22, 1981:175.
51.
Langevin T, Goetz F, Hrushesky W, Halberg F, Steiner B, Gergen, J, Levi F, Kennedy BJ. Relative stability
of urinary marker rhythms in cancer patients (CP) receiving intermittent nephrotoxic chemotherapy.
Notiziario S I Bio C 5, 1981.
52.
Hrushesky W, Vukelich M, Halberg F, Levi F, Langevin T, Kennedy BJ, Gergen J, Goetz F, Theologides A.
Optimal circadian treatment time reduces cis-diamminedichloroplatinum (C)- induced vomiting. Intl J
Chronobiol. Vol. 7, 1981:257.
53.
Abdel-Monem M, Hrushesky W, Theologides A. Circadian variation in the urinary excretion of monoacetyl
polyamines. Proc AACR. Vol. 22, 1981:40.
54.
Dell I, Eaton J, Hrushesky W, Halberg F, Sanchez S, Langevin T, Steiner B. Circadian-stage dependent
effect of doxorubicin (D) upon reduced glutathione in the murine heart. Clin Res. Vol. 29, 1981:735A.
55.
Gerritzen F, Langevin T, Halberg F, Levi F, Kennedy B, Hrushesky W. Circadian variation in urinary
chloride excretion stage in nine clinically healthy men on a 300-ml water load. Chronobiologia. Vol. 8,
1981:181.
Hrushesky • Curriculum Vitae • Page 41
56.
Roelofs R, Rogin J, Rosenberg L, Hrushesky W. Cisplatin R-adriamycinR induced polyneuropathy: a near
universal complication of chemotherapy. Neurol. Vol. 4, 1982:A133.
57.
Steiner B, Mukai K, Hrushesky W, Azar S, Dell I, Langevin T, Halberg F. Changes in circadian rythm
characteristics of pulse indicate doxorubicin-induced cardiac damage (DCHF). Proc AACR. Vol. 23,
1982:634.
58.
Steiner B, Azar S, Mukai D, Dell I, Langevin T, Hrushesky W, Halberg F. Circadian pulse amplitude (PA):
an index of cardiac damage? Proc MN Acad Sci. Vol. 23-24, 1982:6-7.
59.
Hrushesky W, Lannin D, Olshefski R, Halberg F. Spatio-temporal interactions with dose of inoculum
characterize transplantable tumor growth. Am Fed Clin Res. Vol. 30, 1982:747A.
60.
Hrushesky W, Dell I, Eaton J, Halberg F. Circadian-stage dependent effect of doxorubicin upon reduced
glutathione in the murine heart. Proc AACR. Vol. 23, 1982:12.
61.
Magnus G, Scheving L, Halberg F, Shankaraiah K, Cornelissen G, Hrushesky W. Autorhythmometry (AR)
validates on small samples sex differences of systolic blood pressure (BP) and pulse (P) in Arkansas high
school populations. Chronobiologia. Vol. 9, 1982:348.
62.
Vogelzang N, Torkelson J, Hrushesky W, Vosika G, Kennedy B. Progress in the chemotherappy of small cell
bronchogenic carcinoma (SCBC). Intl Lung Cancer Mtgs III. Vol. 17-20, 1982:156.
63.
Steiner B, Azar S, Mukai K, Dell I, Langevin T, Hrushesky W, Halberg F. Circadian pulse amplitude (PA):
an index of cardiac damage? Chronobiologia. Vol. 9, 1982:347-348.
64.
Lakatua D, Haus E, Hrushesky W, Langevin T, Halberg F. Persistence of synchronized circadian rhythm in
urinary cortisol excretion in cancer patients. Proc AACR. Vol. 23, 1982:948.
65.
Hrushesky W, Wood P, Eaton J, Meshnick S. Methylene blue prevents anthracycline toxicity. Clin Res. Vol.
31, 1983:778A.
66.
Olshefski R, Rosewall D, Hrushesky W, Hanson R, Langevin T, Wilson D, Halberg F. Chronobiologic
aspects of rat liver cholesterol 7 a-hydroxylase activity (7a). Chronobiologia. Vol. 10, 1983:114.
67.
Rosenberg C, Hrushesky W, Langevin T, Reusch J, Brown J, Lang P, Kennedy BJ. Hormonal and
chemotherapeutic treatment of prostrate cancer. Proc ASCO. Vol. 24, 1983.
68.
Hrushesky W, Fader D. A new method of assessment of cardiovascular age and drug-induced cardiotoxicity.
Clin Res. Vol. 31, 1983:192A.
69.
Jacobson H, Hrushesky W, Janerich D. The cause of seasonal birth patterns is not behavior. Proc XIth World
Cong Fertility and Sterility, 1983.
70.
Jassim A, Brown J, Hrushesky W, Cornelissen G, Halberg F. Reduction by ubiquinone (CoQ10) of
doxorubicin (D) toxicity in LOU rats bearing an immunocytoma. Chronobiologia. Vol. 10, 1983:135.
71.
Brown H, Hrushesky W, Halberg F. Circadian leucoyte rhythms in cancer patients on CIS-platinum,
adriamycin chemotherapy: progress report. Chronobiologia. Vol. 10, 1983:114.
72.
Langevin T, Hrushesky W, Sanchez S, Halberg F. Melatonin (M) modulates survival of CD2F1 mice with
L1210 leukemia. Chronobiologia. Vol. 10, 1983:173-174.
73.
Jacobson H, Janerich D, Nasca P, Langevin T, Steiner B, Hrushesky W. Circannual rhythmicity in the
incidence of endocrine malignancy: evidence for neurohumoral control of cancer (ca) development and
growth. Chronobiologia. Vol. 10, No. 2, 1983:135 (abstract #71).
74.
Hrushesky W, Haus E, Lakatua D, Vogelzang N, Kennedy B. Seasonality in testicular cell proliferation and
seminoma incidence. Proc ASCO. Vol. 24, 1983:18.
Hrushesky • Curriculum Vitae • Page 42
75.
Hrushesky W, Lannin D, Olshefski R. Transplantable growth depends upon: circadian stage, anatomic site,
and size of tumor cell inoculum. Am Assoc Anat. Vol. 205, 1983:85A-86A.
76.
Hrushesky W, Kennedy B. Absence of age-dependent chemotherapy-induced hematologic toxicity. Proc
AACR. Vol. 24, 1983:137.
77.
Hrushesky W. Clinical characterization and attempted control of cisplatin-induced toxicities. 4th Intl Symp
Coordination Complexes in Cancer Chemotherapy, FII, 1983:141.
78.
Wood P, Hrushesky W. Characterization of cisplatin-induced anemia: an erythropoetin deficiency syndrome.
Clin Res. Vol. 31, 1983:743A.
79.
Shimp W, Hrushesky W, Frenning D, Peterson B, Kennedy B, Langevin T. Lack of age-dependent
cisdiamminedichloroplatinum (C-DDP) nephrotoxity. Proc ASCO. Vol. 24, 1983:14.
80.
Hrushesky W, Fader D, Schmitt O. A novel ultradian rhythm analysis: allows rapid noninvasive assessment
of cardiovascular age and function. Chronobiologia. Vol. 10, 1983:134.
81.
Hrushesky W. The Sine-o-graph pulse monitor: an instantaneous, non-invasive quantifier of cardiac wellness
and disease. Proc 2nd U of M/3M Research Poster Session. Vol. #47, 1984.
82.
Hrushesky W, Rushing D. Circadian chronopharmacokinetics and chronotoxicology of doxorubicin and
cisplatin in human beings with cancer. First Intl Montreux Conf Chronopharmacol--Biological Rhythms and
Medications, 1984:p 305.
83.
Chute E, Rohde T, Rupp W, Goldberg F, Hrushesky W, Buchwald H. Diurnal variation in glucose levels can
impede single rate continuous intravenous insulin therapy. First Intl Montreux Conf Chonopharmacol-Biological Rhythms and Medications, 1984:p 410.
84.
Hrushesky W. Non-invasive, quasi-instantaneous, computer-assisted assessment of cardiovascular function
by cosinor analysis of the respiratory sinus arrhythmia (RSA) during voluntary cardiorespiratory
synchronization (VCRS). First Intl Montreux Conf Chronopharmacol--Biological Rhythms and Medications,
1984:p 705.
85.
Hrushesky W, Olshefski R, Wood P, Eaton J, Meshnick S. Doxorubicin toxicity is prevented by methylene
blue. Proc AACR. Vol. 25, 1984:297.
86.
Wood P, Hrushesky W. Cisplatin-induced anemia: an erythropoetin deficiency syndrome? Proc ASCO. Vol.
3, 1984:22.
87.
Hrushesky W, Fader D, Gilbertsen V, Schmitt O, Halberg F. Electrophysiological and mathematical
quantitation of the sinus arrhythmia: an instrumentation and integrated data acquisition transfer and analysis
challenge. Proc 2nd U of M/3M Research Poster Session. Vol. #47, 1984.
88.
Touitou Y, Hrushesky W, Focan C, Auzeby A, Bogdan A. Plasma carcinoembryonic antigen levels in
patients with ovary cancer: lack of rhythmic pattern before and after chemotherapy. First Intl Montreux Conf
Chronopharmacol--Biological Rhythms and Medications, 1984:p 311.
89.
Kennedy B, Hrushesky W. Implantable and extracorporeal programmable drug delivery systems: what to
program. First Intl Montreux Conf Chronopharmacol--Biological Rhythms and Medications, 1984:p 412.
90.
Hrushesky W. Does the circadian timing of anticancer chemotherapy really matter? Clin Res. Vol. 32,
1984:798A.
91.
Shapiro G, Kenyon P, Lang P, Fraley E, Kennedy B, Hrushesky W. Cisplatin (C), doxorubicin (D) therapy: a
highly effective combination for transitional cell carcinoma of the bladder (TCCB). Proc ASCO. Vol. 3,
1984:154.
92.
Hrushesky W, Grage T, Kennedy B. Does the circadian stage at which chemotherapy is given really matter?
Proc ASCO. Vol. 3, 1984:27.
Hrushesky • Curriculum Vitae • Page 43
93.
Hrushesky W, Fader D, Gilbertsen V, Schmitt O, Halberg F. Electrophysiological and mathematical
quantitation of the sinus arrhythmia: an instrumentation and integrated data acquisition transfer and analysis
challenge. Proc 2nd U of M/3M Research Poster Session, 1984.
94.
Roemeling R, Kennedy B, Buchwald H, Hrushesky W. Chemotherapy via implanted infusion pump: a costeffective method for delivery of long-term continuous treatment. Am College Physicians, Ann Mtg, MN
Chapter, 1984.
95.
Hrushesky W, Shimp W, Kennedy BJ. Lack of age-dependent cisplatin nephrotoxicity. Am J Med. 76:579584, 1984.
96.
Roemeling R, Olshefski R, Kennedy B, Buchwald H, Hrushesky W. The case for circadian FUDR
chronotherapy via automatic programmable drug delivery. Proc ASCO. Vol. 4, 1985:87.
97.
Azar S, Hrushesky W. Environmental factor(s) during suckling exert life-long effects upon blood pressure in
genetic hypertension. Clin Res. Vol. 33, 1985:882A.
98.
Berestka J, Roemeling R, Langevin T, Olshefski R, Buchwald H, Grage T, Hrushesky W. FUDR toxicology
in circadian stage dependent. Proc 17th Conf, Intl Soc Chronobiol. Vol. 3-6 Nov., 1985.
99.
Azar S, Hrushesky W. Environmental factor(s) during suckling exert longterm effects upon blood pressure in
genetic hypertension. 39th Ann Fall Conf and Scientific Sessions, Am Heart Assoc. Vol. 18-20 Sept., 1985.
100. Roemeling R, Langevin T, Berestka J, Olshefski R, Buchwald H, Kennedy BJ, Hrushesky W. Automatic
chronotherapy using implanted programmable pumps: an attempt to diminish chemotherapy-related toxicity?
Am College of Physicians, Ann Mtg, MN Chapter. Vol. 22 November, 1985.
101. Roemeling R, Wick M, Berestka J, Lakatua D, Haus E, Hrushesky W. Disulfiram and cisplatin
chronotherapy allows safe and effective megadose therapy. Proc AACR. Vol. 26, 1985:263.
102. Roemeling R, Langevin T, Berestka J, Buchwald H, Grage T, Hrushesky W. Automatic chronotherapy using
an implanted programmable (Medtronic) pump. Proc 17th Conf, Intl Soc Chonobiol. Vol. 3-6 Nov., 1985.
103. Hermida R, Halberg F, Langevin T, Hrushesky W. Circadian stage-dependent response to cisplatin of urinary
potassium acrophase: a cost-effective chronotherapeutic marker. Chronobiologia. Vol. 12, 1985:74.
104. Hrushesky W. Toward the objectification of cardiovascular aging. Am Aging Assoc (AGE). Vol. 9, 1985:45.
105. Hrushesky W, Fader D. Non-invasive, instantaneous quantification of doxorubicin-induced heart damage.
Proc ASCO. Vol. 4, 1985:41.
106. Hrushesky W. Modifying intracellular redox balance: an approach to improving therapeutic index. 4th Intl
Conf Superoxide and Superoxide Dismutase. Vol. 1-6 Sept., 1985.
107. Hrushesky W. Seasonal modulation of breast cancer biology. Breast Can Res Treat. Vol. 6, 1985:179.
108. Hrushesky W. Necessary characteristics for a clinically useful chronobiological monitoring device as
embodied in a quantifier of ultradian heart rate variability. Proc NATO Advanced Workshop for
Chronobiotechnology and Chronobiological Engineering. Vol. 21-25 April, 1985.
109. Halberg F, Hermida R, Langevin T, Hrushesky W. Circadian leucocyte count characteristics as (double)
markers for the timing and myelotoxicity of carcinostatic treatment. Chronobiologia. Vol. 12, 1985:75.
110. Hrushesky W, Roemeling R, Langevin T. Ovarian cancer chronotherapy. Proc 17th Conf, Intl Soc
Chronobiol. Vol. 3-6 Nov., 1985.
111. Roemeling R, Berestka J, Langevin T, Wick M, Lakatua D, Olshefski R, Mormont M-C, Hrushesky W. The
circadian timing of FUDR determines its toxicity. Proc AACR. Vol. 27, 1986:1657.
112. Roemeling R, Hrushesky W. Programmed automatic FUDR chronotherapy improves therapeutic index. Clin
Res. Vol. 34, 1986:569A.
Hrushesky • Curriculum Vitae • Page 44
113. Roemeling R, Langevin T, Ganzer P, Buchwald H, Kennedy B, Hrushesky W. Automatic chronotherapy
using an implanted programmable pump (Medtronic, Inc.). 2nd Intl Montreux Conf Chronopharmacol—
Biological Rhythms and Medications. Vol. 10-13 March, 1986:208.
114. Roemeling R, Rabatin J, Langevin T, Kennedy B, Hrushesky W. High-intensity, time-qualified FUDR
chemotherapy for metastatic hypernephroma. Clin Res. Vol. 34, 1986:968A.
115. Roemeling R, Langevin T, Buchwald H, Grage T, Kennedy B, Hrushesky W. Time of day modified
continuous FUDR infusion, using an implanted programmable pump, improves therapeutic index. Proc
ASCO. Vol. 5, 1986:324.
116. Roemeling R, Hrushesky W. Time-modified continuous FUDR infusion via programmable pump improves
therapeutic index. Clinical Progress in Electrophysiology and Pacing: Proc Cardiostim 86, Monaco. Vol. 4,
1986:353.
117. Roemeling R, Rabatin J, Olshefski R, Berestka J, Mormont C, Kennedy BJ, Fraley E, Hrushesky W.
Automatically delivered, high intensity, time-qualified chemotherapy for kidney cancer. Am College of
Physicians, Reg Mtg, MN Chapter, Mpls, MN. Vol. 21-22 Nov., 1986:#23.
118. Hrushesky W, Fader D, Herzog C. The respiratory sinus arrhythmia: an ultradian rhythm pregnant with
medically relevant information. 2nd Intl Montreux Conf Chronopharmacol—Biological Rhythms and
Medications. Vol. 10-13 March, 1986:V-14.
119. Hrushesky W, Roemeling R, Langevin T. Ovarian cancer chronotherapy: prolonged remission and survival
with lower toxicity. 2nd Intl Montreux Conf Chronopharmacol--Biological Rhythms and Medications. Vol.
10-13 March, 1986:p III-8.
120. Roemeling R, Ganzer P, Berestka J, Langevin T, Wick M, Lakatua D, Mushiya T, Hrushesky W. Circadian
stage dependency of FUDR toxicity. 2nd Intl Montreux Conf Chronophaarmacol--Biological Rhythms and
Medications. Vol. 10-13 March, 1986:p III-8.
121. Roemeling R, Fraley E, Hrushesky W. Urinary bladder cancer responds to chrono-chemotherapy. J Cancer
Res Clin Oncol. Vol. 111, 1986:140.
122. Roemeling R, Langevin T, Berestka J, Rabatin J, Buchwald H, Kennedy BJ, Hrushesky W. Automatic
anticancer chronotherapy using implanted programmable pumps: an attempt to improve therapeutic index. J
Cancer Res Clin Oncol. Vol. 111, 1986:97.
123. Rietveld P, Rietveld W, Boon M, Hrushesky W, Sothern R. Seasonal rhythmicity in incidence of cervical
neoplasia and infections in Dutch women. Intl Symp on Chronobiol and VI Conf, Indian Soc Chronobiol,
Hyderabad, India. Vol. 19-21 Nov., 1986:#31.
124. Hrushesky W. Non-invasive quasi-instantaneous device evaluates cardiac health. Clinical Progress in
Electrophysiology and Pacing: Proc Cardiostim 86, Monaco. Vol. 4, 1986:214.
125. Skubitz K, Olshefski R, Roemeling R, Langevin T, Wick M, Mushiya T, Hrushesky W. Timing of
amphotericin B therapy is a critical determinant of toxicity. 2nd Intl Montreux Conf Chronopharmacol—
Biological Rhythms and Medications. Vol. 10-13 March, 1986:III-6.
126. Hrushesky W. Chronotherapy of ovarian cancer affects tumor response rate and patient survival. 14th Intl
Cancer Cong, Budapest, Hungary 1986; 21-27 Aug.
127. Hrushesky W, Fader D. Instantaneous quantification of office-based anticancer drug-induced heart damage.
World Med Cong Mtg, Mpls, MN. Vol. 7-10 May, 1986:(Suppl.).
128. Hrushesky W, Fader D. Doxorubicin-induced heart damage premonitorily detected at the bedside or in the
office. Proc AACR. Vol. 27, 1986:821.
129. Skubitz K, Wick M, Skubitz A, Olshefski R, Roemeling R, Langevin T, Sothern R, Hrushesky W. Timing of
amphotericin B therapy is a critical determinant of toxicity. Clin Res. Vol. 34, 1986:949A.
Hrushesky • Curriculum Vitae • Page 45
130. Azar S, Hrushesky W, Kabat V, Click R. Environmental factors during development exert a greater
influence upon kidney to body weight ration variability than do genetic factors. Proc 11th Sci Mtg, Intl Soc
Hypertension. Vol. 31 Aug.-7 Sept., 1986.
131. Roemeling R, Buchwald H, Kennedy B, Hrushesky W. Programmed automatic FUDR chronotherapy
improves therapeutic index. Am Coll of Surgeons, Ann Mtg, New Orleans, LA. Vol. Oct., 1986.
132. Hrushesky W, Roemeling R. Drug schedule and circadian timing affect ovarian cancer response and patient
survival. Proc ASCO. Vol. 5, 1986:453.
133. Hrushesky W, Roemeling R. Why automatic drug delivery will change the practice of cancer medicine.
World Med Cong Mtg, Mpls, MN. Vol. 7-10 May, 1986:(Suppl.).
134. Mormont M-C, Berestka J, Langevin T, Roemeling R, Mushiya T, Hrushesky W. Toxicology of a new
anthracycline, epirubicin, is dependent upon when in the day it is given. Proc AACR. Vol. 27, 1986:1658.
135. Hrushesky W. Circadian drug timing affects dosage intensity, ovarian cancer response and patient survival.
Intl Symposium, Ovarian Cancer, Debrecen, Hungary. Vol. 28-29 Aug., 1986.
136. Bowers L, Wick M, Canafax D, Hrushesky W, Benson E. Circadian pharmacodynamics of cyclosporine A in
rats and man. 2nd Intl Montreux Conf Chronopharmacol—Biological Rhythms and Medications. Vol. 10-13
March, 1986:III-16.
137. Berestka J, Roemeling R, Ganzer P, Ratain M, Wick M, Fraley E, Buchwald H, Langevin T, Mushiya T,
Hrushesky W. Circadian dependency of vinblatine toxicity. 2nd Intl Montreux Conf Chronopharmacol—
Biological Rhythms and Medications. Vol. 10-13 March, 1986:III-7.
138. Mulligan J, Roemeling R, Langevin T, van Tornout J, Mormont M, Kennedy BJ, Hrushesky W. The
Intelliject pump: a precision tool for chronobiological drug administration. Chronobiologia. Vol. 14,
1987:214.
139. Mormont M-C, Rabatin J, Lakatua D, Sothern R, Roemeling Rv, Barbason H, Hrushesky W. The tumorpromoting barbiturate phenobarbital selectively alters corticosterone circadian rhythm in rats. Chronobiologia.
Vol. 14, 1987:212-213.
140. Nygaard S, Young J, Langevin T, Hrushesky W. The toxicity of tumor necrosis factor is circadian stage
dependent. Chronobiologia. Vol. 14, 1987:215-216.
141. Peña SSdl, Halberg F, Cornelissen G, Wu J, Wood P, Hrushesky W, Eaton J. Circaseptan aspects of mouse
malaria: agreement of original and new protochronanalyses with metachronanalyses. Chronobiologia. Vol. 14,
1987:222.
142. Lanning R, Roemeling R, Hrushesky W. Circadian based, biochemically optimized infusional chemotherapy
for poorly responsive adenocarcinoma: a phase I study. Central Society for Clinical Research, Midwest
Meeting, Chicago, IL. Vol. 11-13 Nov., 1987.
143. Mormont M-C, Rabatin J, Lakatua D, Sothern R, Roemeling R, Hrushesky W. Is tumor promotion by
phenobarbital related to an altered circadian corticosterone rhythm? Proc AACR. Vol. 28, 1987:675.
144. Brown H, Sothern R, Haus E, Sackett-Lundeen L, Swoyer J, Hrushesky W. Circadian characteristics in
circulating leukocytes in untreated cancer patients and age-matched controls. Chronobiologia. Vol. 14,
1987:155.
145. Langevin T, Mormont M-C, Sothern R, Berestka J, Roemeling R, Hrushesky W. Comparison of murine
circadian susceptibility to two chemically-related anthracyclines, epirubicin and doxorubicin. Chronobiologia.
Vol. 14, 1987:195-196.
146. Roemeling R, Rabatin J, Hrushesky W. Circadian shaping of FUDR infusion reduces toxicity and allows
higher dose intensity. Central Society for Clinical Research, Midwest Meeting, Chicago, IL. Vol. 11-13 Nov.,
1987.
Hrushesky • Curriculum Vitae • Page 46
147. Roemeling R, Rabatin J, Hrushesky W. Long term infusional circadian based chronotherapy controls
progressive metastatic renal cell carcinoma (RCC). Proc ECCO-4, 1987:62 (#233).
148. Scheving L, Tsai T, Sothern R, Hrushesky W. Methylene blue circadian-stage dependently protects mice
from lethal irradiation without interfering with its anti-leukemic effect. Chronobiologia. Vol. 14, 1987:233234.
149. Roemeling R, Rabatin J, Hrushesky W. Hepatic-arterial FUDR infusion is less toxic if flow rate varies over
time. 3rd Intl Conf, Advances in Regional Cancer Therapy, Ulm, West Germany. Vol. 9-12 Sept., 1987.
150. Roemeling R, Mormont M-C, Wick M, Lakatua D, Langevin T, Berestka J, Rabatin J, Hrushesky W. Timeof-day-dependent prevention of cisplatin (CP)-induced kidney damage by disulfiram (DSF). 1st Intl Symp,
Organ Directed Toxicities of Anticancer Drugs, Burlington, VT. Vol. 4-6 June, 1987:#III-11, p. 65.
151. Tornout Jv, Nesbit M, Robison L, Langevin T, Mormont M-C, Sothern R, Hrushesky W. Circannual aspects
of Ewing's sarcoma. Chronobiologia. Vol. 14, 1987:249.
152. Scheving L, Tsai T, Sothern R, Hrushesky W. Methylene blue markedly protects mice from radiationinduced tissue injury and lethality, especially during the activity phase of the circadian cycle. 2nd Intl Conf,
Anticarcinogenesis and Radiation Protection, Gaithersburg, MD. Vol. 8-12 March, 1987.
153. Sothern R, Kanabrocki E, Seidel J, Osis D, Kaplan E, Marks G, Olwin J, Halberg F, Hrushesky W. Circadian
and circannual modulation of aging-related increase in human urinary calcium and zinc excretion.
Chronobiologia. Vol. 14, 1987:242-243.
154. Rabatin J, Bowers L, Canafax D, Cipolle R, Hrushesky W. Circadian characteristics of cyclosporine
pharmacokinetics in pancreas transplant patients. Chronobiologia. Vol. 14, 1987:222.
155. Ratajczak H, Sothern R, Hrushesky W. Estral milieu at the time of resection of primary tumor determines the
metastatic potential of an estrogen receptor-bearing murine cancer. Proc AACR. Vol. 28, 1987:281.
156. Ratajczak H, Sothern R, Hrushesky W. Correlation of metastatic potential with vaginal smear at time of
primary tumor removal. Chronobiologia. Vol. 14, 1987:223.
157. Rabatin J, Roemeling R, Lycka B, Hrushesky W. Toxic epidermal necrolysis following relapse of metastatic
renal cell cancer after successful infusional chemotherapy. American College of Physicians, Minnesota
Regional Meeting, Minneapolis, MN. Vol. 6-7 Nov., 1987.
158. Roemeling R, Rabatin J, Kennedy B, Hrushesky W. Circadian shaping of hepatic-arterial FUDR infusion
(HAI) reduces or prevents severe liver toxicity. Chronobiologia. Vol. 14, 1987:227.
159. Roemeling Rv, Mormont M-C, Walker K, Olshefski R, Langevin T, Rabatin J, Wick M, Hrushesky W.
Cancer control depends upon the circadian shape of continuous FUDR infusion. Proc AACR. Vol. 28, 1987.
160. Ratajczak H, Sothern R, Hrushesky W. Interrelationship of murine mammary adenocarcinoma and cellularity
of vaginal smears. FASEB Proceedings, 1987:#3968.
161. Roemeling R, Hrushesky W. Circadian shaping of FUDR infusion reduces toxicity even at high-dose
intensity. Proc ASCO. Vol. 7, 1987:170.
162. Hrushesky W. Improving the efficacy of ovarian cancer chemotherapy by stipulating drug timing (circadian),
sequence and dose interval. Gordon Research Conference, Boston, MA. Vol. 28 June-5 July, 1987.
163. Hrushesky W. Circadian scheduling of chemotherapy increases ovarian patient survival and cancer responses
significantly. Proc ASCO. Vol. 7, 1987:473.
164. Hrushesky W, Roemeling R, Rabatin J. Circadian shaping of FUDR infusion reduces toxicity even at higher
dose intensity. Proc ECCO-4, 1987:41 (#157).
Hrushesky • Curriculum Vitae • Page 47
165. Hrushesky W, Langevin T, Nygaard S, Young J, Roemeling R. Circadian stipulation required for reduction
of variability in TNF toxicity/efficacy. Intl Conf, Tumor Necrosis Factor and Related Cytotoxins, Heidelberg.
Vol. 14-18 Sept., 1987.
166. Langevin T, Roemeling R, Mulligan J, Mormont M-C, Walker K, Tornout Jv, Hrushesky W. Automatic,
time-qualified infusion of complex, multi-agent therapy with the Intelliject pump. Proc ASCO. Vol. 7,
1987:1070.
167. Hrushesky W, Young J. The toxicity and efficacy of tumor necrosis factor (TNF) are markedly circadian
stage dependent. Gordon Research Conference, Boston, MA. Vol. 28 June-5 July, 1987.
168. Hrushesky W, Roemeling R, Fraley E. Long-term control of locally advanced transitional cell bladder cancer
(TCCB) by high-dose intensity, circadian-based adjuvant chemotherapy. Proc 5th Intl Conf, Adjuvant
Therapy of Cancer, Tucson, AZ. Vol. 11-14 March, 1987:p. 40, #27.
169. Langevin T, Young J, Walker K, Roemeling R, Nygaard S, Hrushesky W. The toxicity of tumor necrosis
factor (TNF) is reproducibly different at specific times of day. Proc AACR. Vol. 28, 1987:281.
170. Hrushesky W, Roemeling R, Rabatin J, Fraley E. Continuous FUDR infusion is effective in progressive renal
cell cancer (RCC). Proc ASCO. Vol. 7, 1987:425.
171. Hrushesky W, Roemeling R, Rabatin J. Circadian shaped continuous FUDR infusion is effective treatment
for progressive renal cell cancer (RCC). Intl Symp, Status of Treatment of Metastatic Renal Cell Carcinoma,
Vienna, Austria. Vol. 13-14 March, 1987:18.
172. Hrushesky W, Roemeling R, Rabatin J, Fraley E. Effective, safe outpatient treatment for progressive
metastatic renal cell cancer (RCC). Proc ASCO. Vol. 7(515), 1988:133.
173. Fischel R, Gruber S, Cahill D, Canafax D, Cipolle R, Erdmann G, Hrushesky W, Najarian J, Ascher N.
Immunologic monitoring of local immunosuppression in a canine renal allograft model. FASEB Journal. Vol.
2:5, 1988:20 March.
174. Roemeling R, Rabatin J, Tuchman M, Buchi K, Moore J, Hrushesky W. Circadian timing and mode of
fluoropyrimidine administration markedly impact organ-specific toxicity and maximal dose intensity. 3rd Intl
Conf of Chronopharmacology, Nice, France. Vol. 14-17 March, 1988.
175. Roemeling R, Hrushesky W. Randomized toxicity and dose intensity (DI) comparison of constant rate
infusion vs. circadian modified continuous FUDR infusion. Proc ASCO. Vol. 7(256), 1988:67.
176. Ratajczak H, Thomas P, Heck D, Vollmuth T, Sothern R, Hrushesky W. Seasonal variation of murine
antibody formation and host resistance. FASEB, 1988.
177. Hrushesky W. Automatic chronotherapy: an integral part of the future of medicine. Cardiostim 6th Intl
Congress, Monaco. Vol. 15-18 June, 1988.
178. Hrushesky W. Drug patterning in toxicity and efficacy. AAPS 4th Japanese-American Conf on
Pharmaceutics, San Francisco, CA. Vol. July, 1988.
179. Roemeling R, Sothern R, Langevin T, Popovich J, Haus R, Hrushesky W. Mitomycin-C toxicity depends
upon the time of day of injection. Proc AACR. Vol. 29(2028), 1988:510.
180. Roemeling R, Rabatin J, Lanning R, Hrushesky W. Circadian timing rather than quasi-intermittency
determines FUDR toxicity at equal dose intensity (DI). Cardiostim 6th Intl Congress, Monaco. Vol. 15-18
June, 1988.
181. Ratajczak H, Thomas P, Vollmuth T, Heck D, Sothern R, Hrushesky W. Seasonal variations of host
resistance and in vitro antibody formation of spleen cells from the B6C3F1 mouse. 3rd Intl Conf of
Chronopharmacology, Nice, France. Vol. 14-17 March, 1988.
Hrushesky • Curriculum Vitae • Page 48
182. Gruber S, Hrushesky W, Canafax D, Simmons R, Matas A. Pharmacokinetic advantage of intra-arterial 6mercaptopurine in a novel canine renal allograft model. American College of Surgeons, Chicago, IL. Vol.
Oct., 1988.
183. Haus E, Nicolau G, Hrushesky W. Chronobiology of cell proliferation and cancer. Gerontology Meeting,
Romania. Vol. June, 1988.
184. Tuchman M, Roemeling R, Lanning R, Sothern R, Hrushesky W. Variability of dehydropyrimidine
dehydrogenase (DPD) activity in human blood mononuclear cells. 3rd Intl Conf of Chronopharmacology,
Nice, France. Vol. 14-17 March, 1988.
185. Gruber S, Hrushesky W, Canafax D, Simmons R, Matas A. Development of a novel canine renal allograft
model to study the pharmacokinetic advantage of local immunosuppression. XII Intl Congress of the
Transplantation Society, Australia. Vol. August, 1988.
186. Wood P, Nygaard S, Hrushesky W. Cisplatin-induced anemia is correctable with erythropoietin. Blood. Vol.
72, 1988:529.
187. Haus E, Hrushesky W, Lakatua D, Nicolau G. Chronopharmacology in oncology. Gerontology Meeting,
Romania. Vol. June, 1988.
188. Hrushesky W, Simmons R. Metastatic potential and splenocyte NK activity are each estral stage dependent.
Natural and Immunity Cell Growth Regulation. Vol. #47 Jan./Feb., 1988:53.
189. Sothern R, Halberg F, Hrushesky W. Persistence of doxorubicin susceptibility rhythm for mice in constant
light: circadian stage vs. time of day. 3rd Intl Conf of Chronopharmacology, Nice, France. Vol. 14-17 March,
1988.
190. Gruber S, Cipolle R, Canafax D, Rabatin J, Erdmann G, Hynes P, Ritz J, Gould F, Hrushesky W. Circadianshaped intrarenal cyclosporine delivery. 3rd Intl Conf of Chronopharmacology, Nice, France. Vol. 14-17
March, 1988.
191. Tornout Jv, Lanning R, Bostrom B, Somani S, Nesbit M, Hrushesky W. Feasibility, safety and accuracy of a
computerized portable automated IV delivery system for antibiotics and chemotherapy. ISCSO, Brussels,
Belgium. Vol. 23-25 Aug., 1988.
192. Tornout Jv, ME Nesbit J, Bostrom B, Ramsay N, Somani S, Roemeling Rv, Langevin T, Hrushesky W.
Feasibility, safety and accuracy of an automated drug delivery system in a pediatric bone marrow transplant
(BMT) setting. Proc ASCO. Vol. 7(1137), 1988:293.
193. Gruber S, Hrushesky W, Canafax D, Simmons R, Matas A. Pharmacokinetic advantage of local 6mercaptopurine (6-MP) in a novel canine renal allograft model. Assoc Acad Surg, 22nd annual meeting. Vol.
27 May, 1988.
194. Langevin T, Sothern R, Hrushesky W. The toxicity of mitomycin-c is circadian stage dependent. 3rd Intl
Conf of Chronopharmacology, Nice, France. Vol. 14-17 March, 1988.
195. Lanning R, Roemeling R, Becicka L, Mulligan J, Echo Dv, Hrushesky W. Circadian based, biochemically
optimized infusional chemotherapy for poorly responsive cancers: a phase I-II study. ISCSO, Brussels,
Belgium. Vol. 23-25 Aug., 1988.
196. Kanabrocki E, Sothern R, Scheving L, Vesely D, Tsai T, Shelstad J, Greco J, Bushnell D, Kaplan E, Rumbyrt
J, Sturtevant R, Sturtevant F, Olwin J, Hrushesky W. Circadian reference data including prohormone atrial
natriuretic peptides for men in fifth decade of life. XIX Intl Conf, Intl Soc Chronobiol, Bethesda, MD. Vol.
20-24 June, 1989:#10-27-P27.
197. Sothern R, Voegele M, Mattson O, Hrushesky W. A chronobiological statistical package for personal
computer. XIX Intl Conf, Intl Soc Chronobiol, Bethesda, MD. Vol. 20-24 June, 1989:#14-2-P2.
198. Hrushesky W, Sothern R, Levi F, Olshefski R, Lanning D, Berestka J, Gruber S. Circadian timing, anatomic
location and dose of tumor cell inoculum each affect tumor biology. Proc AACR. Vol. #323, 1989.
Hrushesky • Curriculum Vitae • Page 49
199. Schraufek S, Sothern R, Voegele M, Ainsworth B, Serfass R, Leon A, Hrushesky W. Enhancement of
respiratory sinus arrhythmia by moderate exercise. XIX Intl Conf, Intl Soc Chronobiol, Bethesda, MD. Vol.
20-24 June, 1989:#F13-5-P5.
200. Swoyer J, Rhame F, Hrushesky W, Sackett-Lundeen L, Sothern R, Haus E. Circadian rhythm alterations in
HIV infected subjects. XIX Intl Conf, Intl Soc Chronobiol, Bethesda, MD. Vol. 20-24 June, 1989:#2-17-P17.
201. Sothern R, Rhame F, Suarez C, Haus E, Hrushesky W. Oral temperature rhythmometry in human
immunodeficiency. XIX Intl Conf, Intl Soc Chronobiol, Bethesda, MD. Vol. 20-24 June, 1989:#2-18-P18.
202. Gonzalez J, Sothern R, Thatcher G, Nguyen N, Hrushesky W. Substantial difference in timing of murine
circadian susceptibility to 5-fluororacil and FUDR. Proc AACR. Vol. #2452, 1989.
203. Teslow T, Hrushesky W, Ashkenazi I. ChronoBioNet: a new facility for society communications. XIX Intl
Conf on Chronobiol, Bethesda, MD. Vol. 20-24 June, 1989:#14-4-P4.
204. Roemeling R, Lanning R, DeConti R, Hrushesky W. Longterm intermittent FUDR delivery by implantable
programmable pump. Proc Second Conf on the Clinical Applications of Concomitant Infusion Chemotherapy
and Radiation, SUNY Health Science Center at Brooklyn, NY. Vol. 6-8 April, 1989:7 [proffered abstract #1].
205. Bellamy N, Sothern R, Campbell J, Hrushesky W. Circadian and circaseptan rhythms in perceived pain
levels in osteoarthritis (OA) of the knee. XIX Intl Conf, Intl Soc Chronobiol, Bethesda, MD. Vol. 20-24 June,
1989:#4-1-P1.
206. Roemeling R, Sothern R, Fudin J, Fukuda E, Hrushesky W. FUDR pharmacokinetics at different circadian
stages. Proc Satellite Symposium on Chronopharmacology, Berlin, GDR. Vol. 30-31 July, 1989:34.
207. Hrushesky W, Sothern R, Boon M, Rietveld P, Rietveld W. Incidence of cervical cancer, premalignant
changes and cytological evidence of papilloma virus infection are each seasonal. Proc AACR. Vol. #1251,
1989.
208. Hrushesky W, Lanning R, Roemeling R, Fraley E, Wesen C, Grage T. Circadian modified FUDR infusion
controls progressive metastatic renal cell cancer (RCC). Proc ASCO. Vol. #520, 1989.
209. Hrushesky W. Temporal control of drug delivery. Proceed Intern Symp Control Rel Bioact Mater, Controlled
Release Society. Vol. 16, 1989:#15.
210. Hrushesky W. Cancer chronotherapy: a drug delivery challenge. Conf in Clinical Chronobiology,
Washington, DC. Vol. 20 June, 1989.
211. Roemeling R, Fukuda E, Fudin J, Mormont M-C, Sothern R, Hrushesky W. Are FUDR pharmacokinetics
circadian stage dependent? Proc AACR. Vol. #2345, 1989.
212. Wesen C, Olson G, Roemeling R, Grage, Hrushesky W. Circadian modified intra-arterial treatment of colorectal carcinoma metastatic to the liver allows higher dose intensity to be safely given. Proc ASCO. Vol. #406,
1989.
213. Lanning R, Roemeling R, Hrushesky W. Cost-effective complex multi-drug infusional home chemotherapy.
World Congress on Home Care, Rome, Italy. Vol. 14-16 March, 1989.
214. Lanning R, Hrushesky W. Outpatient chronotherapy by implantable infusion pump is less costly than flat
delivery by external pump. XIX Intl Conf, Intl Soc Chronobiol, Bethesda, MD. Vol. 20-24 June, 1989:#9-2P2.
215. Pray J, Sothern R, Hrushesky W. Severity of clinical myelotoxicity depends upon the circadian timing and
season of cancer chemotherapy. XIX Intl Conf, Intl Soc Chronobiol, Bethesda, MD. Vol. 20-24 June, 1989.
216. Lanning R, Rabatin J, Roemeling R, Wesen C, Grage T, Hrushesky W. Outpatient chemotherapy pump
implantation is safe and cost effective. Proc ASCO. Vol. #570, 1989.
Hrushesky • Curriculum Vitae • Page 50
217. Bluming A, Gruber S, Hrushesky W. Timing of primary breast cancer surgery relative to menstrual cycle
may affect prognosis. Proc ASCO. Vol. #104, 1989.
218. Rhame F, Sothern R, Haus E, Fletcher C, Sackett-Lundeen L, Hrushesky W. Substantial within-day variation
in zidovudine levels following steady-state dosing in human immunodeficiency virus (HIV) infection. XIX
Intl Conf, Intl Soc Chronobiol, Bethesda, MD. Vol. 20-24 June, 1989:#2-9-P9.
219. Rhame F, Sothern R, Sackett-Lundeen L, Suarez C, Hrushesky W, Haus E. Aberrant circadian physiologic,
immune and endocrine rhythms in HIV-infected individuals. V International Conference on AIDS, Montreal
Canada. Vol. June, 1989:#W.C.P. 81.
220. Tornout Jv, Nesbit M, Bostrom B, Ramsay N, Somani S, Palacio K, Bulger C, Hrushesky W. Computerized
delivery of intravenous chemotherapy to pediatric patients. Proc AACR. Vol. #1104, 1989.
221. Grage T, Wesen C, Hrushesky W. Circadian modification of hepatic intra-arterial FUDR infusion. ICRCT
‘89 Berchtesgaden, June 5-7, 1989.
222. Wesen C, Grage T, Hrushesky W. Reduced hepatic toxicity with circadian modification of intra-arterial
FUDR in patients with colorectal carcinoma metastatic to the liver. Satellite Symp on Clinical Pharmacology
and Therpeutics, Berlin, July 30-31, 1989.
223. Roemeling R, Levi F, Diasio R, Hrushesky W. Circadian time dependencies in toxicity of anticancer drugs. J
Cancer Res Clin Oncol. Vol. 116 (suppl., part II), 1990:1072 (#16.20.03).
224. Roemeling R, Hrushesky W, McDowell R, DeConti R. Maximally tolerated FUDR dose (MTD) and
maximal dose intensity (MDI): a randomized pilot study comparing two opposite circadian schedules.
Cardiostim 90, Nice, France. Vol. 20-24 June, 1990:[abstract #883].
225. Wood P, Peña SSdl, Hrushesky W. Circadian dependency of recombinant human erythropoietin (rhEPO)
response in the mouse. Proc AACR [abstract #471], 1990.
226. Taylor G, Herzog C, Hrushesky W. Indirect non-invasive quasi-instantaneous evaluation of diastolic cardiac
function using quantitative analyses of the respiratory sinus arrhythmia (RSA). Cardiostim 90, Nice, France.
Vol. 20-24 June, 1990:[abstract #60].
227. Hrushesky W, Roemeling R. Circadian floxuridine infusion improves its therapeutic index. Cardiostim 90,
Nice, France. Vol. 20-24 June, 1990:[abstract #882].
228. Roemeling R, Hrushesky W, Remick S, Horton J, Harper G, DeConti R. Continuous intravenous, variable
rate FUDR infusion: A randomized pilot study comparing two circadian schedules for toxicity and maximally
tolerated dose intensity. Proc ASCO [abstract #329] 1990.
229. Hrushesky W, Roemeling R. Circadian floxuridine infusion improves its therapeutic index. J Cancer Res Clin
Oncol. Vol. 116 (suppl., part II), 1990:925 (#10.06.06).
230. Roemeling R, Salzer M, Connerty M, DeMaria L, Wood P, Portuese E, Sanchez S, DeConti R, Chikkappa G,
Pasquale D, Ferro T, Hrushesky W. Circadian stage dependent response to IL-2 bioactivity in mouse spleen
and bone marrow. Proc AACR. Vol. #1571, 1990.
231. Fader D, Taylor G, Hrushesky W. Respiratory sinus arrhythmia amplitude fall adumbrates doxorubicininduced congestive heart failure. Cardiostim 90, Nice, France. Vol. 20-24 June, 1990:[abstract #689].
232. Lanning R, Hrushesky W. Cost comparison of wearable and implantable drug delivery systems. Proc ASCO
[abstract #1244], 1990.
233. DeConti R, France K, Velaardi M, Krause S, Hrushesky W, Roemeling R. Variable rate, circadian infusions
of FUDR by portable programmable Parker micro-pump: Feasibility and safety. Proc ASCO [abstract #1301],
1990.
234. Schraufek S, Taylor G, Ainsworth B, Hrushesky W. Respiratory sinus arrhythmia quantifies aerobic training
capacity. Cardiostim 90, Nice, France. Vol. 20-24 June, 1990:[abstract #868].
Hrushesky • Curriculum Vitae • Page 51
235. Wood P, Martynowicz M, Peña SSdl, Chang C, Hrushesky W. Circadian erythropoietin
pharmacodynamics. Blood. Vol. 70, 1991:16a.
236. Wood P, Peña SSdl, Martynowicz M, Markiewicz M, Hrushesky W. Circadian biodynamics of
erythropoiesis. Amer J Kidney Diseases. Vol. 18:4, 1991:108 [8-9 Feb.].
237. Buchi K, Moore J, Hrushesky W, Sothern R, Rubin N. Circadian rhythm of cellular proliferation in the
human rectal mucosa. Gastroenterology. Vol. 101, 1991:410-415.
238. Markiewicz M, Markiewicz A, Martynowicz M, Hrushesky W. Programmable (micro) infusors and their
clinical applications. First Meeting of the Monitored Therapy Society, Wenecja, Poland. Vol. 31 May-1 June,
1991:[abstract #36].
239. Roemeling R, Fisher H, DeConti R, Horton J, Wilbur H, Hrushesky W, Ruckdeschel J. Continuous FUDR
infusion for hormone refractory prostate cancer: a phase I/II study. Proc Amer Clic Oncol. Vol. 10:171,
1991:abstract #547.
240. Salas A, Rábago M, Sánchez P, García-Saénz M, Hrushesky W, Peña SSdl. Chronoelectrophoretic individual
assessment of human serum proteins. 20th Intl Conf on Chronobiology, Tel Aviv, Israel. Vol. 16-21 June,
1991.
241. Peña SSdl, Wood P, Martyniwicz M, Markiewicz M, Meacham C, Hrushesky W. Reinforcement of the
circadian organization of erythropoiesis by bleeding and/or erythropoietin (EPO) administration. Amer J
Kidney Diseases. Vol. 18:4, 1991:108 [8-9 Feb.].
242. Hrushesky W, Martynowicz M, Peña SSdl, Wood P. Erythropoietin (EPO) modulation of tumor growth.
Blood. Vol. 70, 1991:427a.
243. Hrushesky W, Wood P, Peña SSdl, Martynowicz M, Markiewicz M, Meacham C. Paradoxical hematocrit
(HCT) fall after erythropoietin (EPO). Amer J Kidney Diseases. Vol. 18:4, 1991:108 [8-9 Feb.].
244. Peña SSdl, Wood P, Martynowicz M, Markiewicz M, Hrushesky W. Circadian female mouse hematocrit
changes by serially independent bleeding and erythropoietin administration. 20th Intl Conf on Chronobiology,
Tel Aviv, Israel. Vol. 16-21 June, 1991:[abstract 15.21].
245. Peña SSdl, Hrushesky W. Circadian chronomodulation by interleukin-2 of survival time and tumor growth in
the mouse. 20th Intl Conf on Chronobiology, Tel Aviv, Israel. Vol. 16-21 June, 1991:[abstract 15.25].
246. Martynovicz M, Blumenstock F, Celle PL, Vyzula R, Cope F, Hrushesky W. Stool albumin content
adumbrates fluoropyrimidine induced gut damage. Proc AACR. Vol. 33, 1992.
247. Martynovicz M, Wood P, Peña SSdl, Vyzula R, Wighton T, Hrushesky W. Circadian coordination of
hemopoietic and oncopoietic erythropoietin (EPO) pharmacodynamic. SRBR. Vol. 6-10 May, 1992:140(93).
248. Vyzula R, Wighton T, Traynor K, Martynovicz M, Peña S, Wood P, Hrushesky W. Comparative circadian
organization of the myelopoetic and unexpected oncomodulatory effects of granulocyte colony stimulating
factor (G-CSF). ICCC. Vol. 12-16 July, 1992.
249. Whitaker J, Vyzula R, Clooney M, Abruzzese M, Peña S, Wood P, Hrushesky W. Fertility cycle timing of
cytotoxic therapy affects subsequent fertility. 15th San Antonio Breast Cancer Symposium. Vol. 8-10 Dec.,
1992:23(8):132.
250. Whitaker J, Vyzula R, Clooney M, Abruzzese M, Peña S, Wood P, Hrushesky W. Fertility cycle phase of
cytotoxic therapy affects subsequent fertility. Intl Conf of Chronopharmacology and Chronotherapeutics. Vol.
July, 1992.
251. Wood P, Martynowicz M, Peña SSdl, Hrushesky W. Circadian coordination of hemopoietic and oncopoietic
erythropoietin (EPO) pharmacodynamics. Intl Conf of Chronopharmacology and Chronotherapeutics. Vol. 1216 July, 1992.
Hrushesky • Curriculum Vitae • Page 52
252. Vyzula R, Wighton T, Traynor K, Martynovicz M, Peña S, Wood P, Hrushesky W. Comparative circadian
organization of the myelopoetic and unexpected oncomodulatory effects of granulocyte colony stimulating
factor (G-CSF). SRBR. Vol. 6-10 May, 1992:139(93).
253. Larkin T, Whittaker S, Peña SSdl, Gruen T, Kazlausky T, Hrushesky W. Use of circadian activity pattern to
objectify performance status (quality of life) estimation. ICCC. Vol. 12-16 July, 1992.
254. Peña SSdl, Wood P, Vyzula R, Wighton T, Martynovicz M, Hrushesky W. Ability of ACTH, corticosterone
and melatonin to affect circadian IL-2 anti-cancer pharmacodynamics. SRBR. Vol. 6-10 May, 1992:138(92).
255. Hrushesky W. Applications of chronopharmacology to cancer medicine. AACC, Chicago. Vol. 20 July,
1992:38(6):1130.
256. Hrushesky W. Menstrual cycle biodynamics of breast cancer-host balance. ICCC. Vol. 12-16 July, 1992.
257. Hrushesky W. Menstrual cycle biodynamics of breast cancer-host balance. CTRC. Vol. 8-10 Dec.,
1992:23(3):131.
258. Roemeling R, Martynowicz M, Peña SSdl, Hrushesky W. Diurnal variations of prostatic specific antigen
(PSA) plasma levels in hormone-refractory prostate cancer patients. ICCC. Vol. 12-16 July, 1992.
259. Hrushesky W, Peña SSdl, Wood P, Marynovicz M, Wighton T, Lobo S, Vyzula R. Heterogeneity of
interleukin-2 therapeutic activity. Proc AACR. Vol. 33, 1992:300.
260. Hrushesky W, Martynowicz M, Peña SSdl, Wood P. Erythropoietin (EPO) tumor growth modulation. Proc
AACR. Vol. 33, 1992:269.
261. Peña SSdl, Hrushesky W, Vyzula R, Lobo S, Wood P. Circadian dependent interleukin-2 tumor growth
interaction is favorably modulated by melatonin. Intl Conf of Chronopharmacology and Chronotherapeutics.
Vol. 12-16 July, 1992.
262. Tzannis S, Pryzbycien T, Hrushesky W, Abruzzese M, Wood P. The interaction of formulated interleukin-2
solutions with delivery device surfaces. Proc AACR. Vol. 34, 1993:376.
263. Abruzzese B, D'amico S, Green A, Sothern R, Ataya D, Hrushesky W, Richards E, Cope F. Effect of a low
carbohydrate formula on circadian glycemic control and lipids in elderly patients with non-insulin dependent
diabetes mellitus (NIDDM) receiving total enternal nutrition support. Diabetes. Vol. Proc Federation of
American Societies for Experimental Biology, 28 March-1 April, 1993:(4888-4839):4891.
264. Wood P, Peace D, Hrushesky W. Endogenous erythropoiesis and erythropoietin responsiveness are circadian
time dependent. Blood. Vol. 82(10), 1993:225a.
265. Wood P, Peace D, Hrushesky W. Endogenous erythropoiesis and erythropoietin responsiveness are circadian
time dependent. American Society of Hematology, St. Louis, MI. Vol. 3-7 Dec., 1993.
266. Peña SSdl, Hrushesky W, Wood P, Vyzula R. Host-tumor balance depends upon IL-2 circadian timing. Proc
AACR. Vol. 34, 1993:57.
267. Vyzula R, Hrushesky W, Wood P, Abruzzese M, Borhan-Manesh A, Johnston W, Peña S. Female fertility
cycle phase at cytotoxic treatment determines subsequent sexual dysfunction, infertility, and myelotoxicity.
Proc AACR. Vol. 34, 1993:255.
268. Vyzula R, Hrushesky W, Wood P, Abruzzese M, Borhan-Manesh A, Peña SSdl. Fertility cycle timing of 5FU determines the severity of its hematologic toxicity. Proc Int Soc Chronobiology. Vol. July, 1993.
269. Wood P, Vyzula R, Abruzzese M, Peace D, Peña SSdl, Hrushesky W. Erythropoietin pharmacokinetics and
pharmacodynamics are circadian stage dependent. Proc Int Soc Chronobiology. Vol. July, 1993.
270. Hrushesky W. Enhancing breast cancer cure in young women. Proc Discoveries for America's Veterans,
White River Junction VAM & ROC, VT. Vol. 3 June, 1993.
Hrushesky • Curriculum Vitae • Page 53
271. Hrushesky W, Bjarnason G, Harris J, Marsh R, Diasio R, Huben R, Anderson J, Peterson J, Lokich J,
Hivnor T, Cope F. Fluoropyrimidine circadian continuous infusion shape affects its toxicity profile. La
Société Internationale de Chronobiologie, Proc VII-5, Québec, Canada. Vol. 11-15 July, 1993.
272. Hrushesky W, Wood P, Abruzzese M, Borhan-Manesh A, Peña SSdl. Fertility cycle timing of 5-FU
determines the severity of its hematologic toxicity. La Société Internationale de Chronobiologie, Proc VII-7,
Québec, Canada. Vol. 11-15 July, 1993.
273. Hrushesky W. Does breast cancer resection timing within the menstrual cycle impact curability: a metaanalysis. ASCO, Orlando, FL. Vol. 16-18 May, 1993:201.
274. Hrushesky W. Menstrual cycle biodynamics of breast cancer. La Société Internationale de Chronobiologie,
Proc VII-8, Québec, Canada. Vol. 11-15 July, 1993.
275. Hrushesky W. Fertility cycle modulation of the host-cancer balance. La Société Internationale de
Chronobiologie, Proc XII-9, Québec, Canada. Vol. 11-15 July, 1993.
276. Hrushesky W, Bjarnason G, Harris J, Marsh R, Diasio R, Huben R, Anderson J, Peterson J, Lokich J, Cope
F. Circadian synchrony and stability: is time of day cancer treatment meaningful? La Société Internationale de
Chronobiologie, Proc VII-9, Québec, Canada. Vol. 11-15 July, 1993.
277. Hrushesky W. Fluoropyrimidine circadian chronopharmacodynamics. Fourth Intl Congress on Anti-Cancer
Chemotherapy, Paris. Vol. 2-5 Feb., 1993:29.
278. Hrushesky W, Bjarnason G, Harris J, Marsh R, Diasio R, Huben R, Anderson J, Peterson J, Lokich J, Cope
F. Circadian synchrony and stability: is time of day cancer treatment meaningful? ASCO, Orlando, FL. Vol.
16-18 May, 1993:1600.
279. Hrushesky W. Sex and cancer drug and therapy development. Amer Assoc of Pharmaceutical Scientists,
Lake Buena Vista, FL. Vol. 40, 1993:14-18 Nov.
280. Hrushesky W, Bjarnason G, Harris J, Marsh R, Diasio R, Huben R, Anderson J, Peterson J, Lokich J, Hivnor
T, Cope F. Fluoropyrimidine circadian continuous infusion shape affects its toxicity profile. ASCO, Orlando,
FL. Vol. 16-18 May, 1993:781.
281. Hrushesky W. Predictable within individual temporal variability and clinical trial design. Clinical Trials in
Oncology: Improving Their Design and Analysis, Toronto, Ontario, Oct. 28-30, 1993.
282. Wood P, Peace D, Hrushesky W. Circadian organization and response of the erythron. J Cell Biochem suppl.
Vol. 18A:A313, 1994.
282. Vyzula R, Wood P, Peace D, Troha T, Mann G, Hrushesky W. Pharmacodynamics are affected by both
fertility and circadian time structures. Soc Res Biol Rhythms. Vol. 4-8 May, 1994.
283. Vyzula R, Wood P, Peace D, Troha T, Mann G, Hrushesky W. Cytotoxic impact upon the fertility cycle
stage of 5-fluorouracil (5-FU) exposure. Soc Res Biol Rhythms. Vol. May, 1994.
284. Przybycien T, Tzannis S, Hrushesky W, Wood P. Does formulated interleukin-2 retain full activity during
delivery by continuous infusion? Colorado Protein Stability Conference, 1994.
285. Hrushesky W. Principles of cancer chronotherapy. SRBR, Amelia Island, FL. Vol. 4-8 May, 1994.
286. Hrushesky W. The demands of predictable multi-frequency and chao-periodic biology upon drug delivery
system specifications. SRBR, Amelia Is, FL. Vol. 5-9 July, 1994.
287. Bjarnason G, Hrushesky W, Diasio R, Harris J, Marsh R, Huben R, Lokich J, Anderson J. Flat versus
circadian modified 14 day infusion of FUDR for advanced renal cell cancer (RCC): a phase-III study. ASCO,
Dallas, TX. Vol. 14-17 May, 1994.
288. Hrushesky W. The menstrual cycle and the buidynamics of the balance between host and breast cancer.
SRBR, Amelia Is, FL. Vol. 4-8 May, 1994.
Hrushesky • Curriculum Vitae • Page 54
289. Wood P, Peace D, Troha T, Mann G, Hrushesky W. Efficacy of chronic erythropoietin dependent upon the
time of day of its administration. Exp Hematol. Vol. 22, 1994:704.
290. Tzannis S, Przybycien T, Hrushesky W, Wood P. Protein-surface interactions lead to incomplete delivery of
interleukin-2 with an infusion pump/catheter system. Proceedings Intl Symposia Controlled Release of
Bioactive Materials. Vol. 21, 1994:361-362.
291. Hrushesky W. Applications of chronobiology to cancer medicine. White River Junction VA Meeting, 1994.
292. Hrushesky W. Menstrual cycle-surgery-breast cancer-woman interactions: Is it time for a paradigm shift?
Lancet conference, London, England, 1994.
293. Hrushesky W. Circadian cancer therapy. 1st Annual European-American Conf on Gastrointestinal Oncology,
Bordeaux, France, Sept. 22-24, 1994.
294. Wood P, Peace D, Torosoff M, Vyzula R, Hrushesky W. Can optimal circadian timing of 5-fluorouracil
improve the therapeutic index? Biological Rhythm Research. Vol. 26, 1995:460.
295. Wood P, Peace D, Torosoff M, Vyzula R, Hrushesky W. Can optimal circadian timing of 5-fluorouracil
improve the therapeutic index? World Conference on Chronobiology and Chronotherapeutics, Ferarra, Italy.
Vol. 6-10 Sept., 1995.
296. Wood P, Peace D, Hrushesky W. Circadian dependence of erythropoietin response. Biological Rhythm
Research. Vol. 26, 1995:459.
297. Wood P, Peace D, Hrushesky W. Circadian dependent coordination of normal hematopoiesis varies with
lieage type and level of differentiation. World Conference on Chronobiology and Chronotherapeutics, Ferrara,
Italy. Vol. 6-10 Sept., 1995.
298. Wood P, Peace D, Hrushesky W. Circadian dependence of erythropoietin response. World Conference on
Chronobiology and Chronotherapeutics, Ferarra, Italy. Vol. 6-10 Sept., 1995.
299. Wood P, Peace D, Hrushesky W. Circadian dependent coordination of normal hematopoiesis varies with
lineage type and level of differentiation. Biological Rhythm Research. Vol. 26, 1995:459.
300. Wood P, Peace D, Torrosof M, Hrushesky W. Circadian dependence of 5-fluorouracil (5-FU) anticancer
activity. J Investigative Medicine. Vol. 43, 1995:371A.
301. Wood P, Peace D, Torrosov M, Vyzula R, Hrushesky W. Optimal circadian timing of 5-fluorouracil (5-FU)
improves anti-cancer activity and normal host toxicity and hence therapeutic index. J Investigative Medicine.
Vol. 43, 1995:371A.
302. Wood P, Peace D, Torosoff M, Vyzula R, Hrushesky W. Optimal circadian timing of 5-fluorouracil (5-FU)
improves anticancer activity and normal host toxicity and hence therapeutic index. The Physiologist. Vol.
38(3), 1995:A-31.
303. Hrushesky W, Langevin T, Kim Y, Wood P. Circadian dynamics of tumor necrosis factor (cachetin)
lethality. World Conference on Chronobiology and Chronotherapeutics, Ferrara, Italy. Vol. 6-10 Sept., 1995.
304. Bjarnason G, Marsh R, Chu N, Hrushesky W, Kerr I. Phase-II study of 5-fluorouracil and leukovorin by a
14-day circadian infusion in patients with metastatic colorectal cancer. World Chronobiology Conference,
Ferarra, Italy. Vol. 4-9 Sept., 1995.
305. Hrushesky W, Torosoff M, Peace D, Gupta H, Mann G, Wood P. Fertility cycle modulation of cancer
biology. World Conference on Chronobiology and Chronotherapeutics, Ferrara, Italy. Vol. 6-10 Sept., 1995.
306. Bjarnason G, Hrushesky W, Marsh R, Diasio R, Harris J, Huben R, Lokich J, Dugan W, Anderson J. Flat
versus time modified 14-day infusion of FUDR for advanced renal cell cancer: a phase-III study. World
Conference on Chronobiology and Chronotherapeutics, Ferarra, Italy. Vol. 6-10 Sept., 1995.
Hrushesky • Curriculum Vitae • Page 55
307. Hrushesky W, Torrosov M, Gupta H, Mann G, Vyzula R, Wood P. Fertility cycle modulation of the breast
cancer balance. Proc AACR. Vol. 36, 1995:256.
308. Hrushesky W, Wood P. Breast cancer and the menstrual cycle. World Conference on Chronobiology and
Chronotherapeutics, Ferrara, Italy. Vol. 6-10 Sept., 1995.
309. Hrushesky W, Torosov M, Gupta H, Mann G, Wood P. Modulation of host breast cancer balance by the
fertility cycle. American Physiological Society, 1995.
310. Hrushesky W, Wood P. Breast cancer and the menstrual cycle. Biological Rhythm Research. Vol. 26,
1995:402.
311. Hrushesky W, Langevin T, Kim Y, Wood P. Circadian dynamics of tumor necrosis factor (cachectin)
lethality. Biological Rhythm Research. Vol. 26, 1995:402.
312. Hrushesky W, Torosoff M, Gupta M, Wood P. Modulation of host breast cancer balance by the fertility
cycle. The Physiologist. Vol. 38(3), 1995:A-32.
313. Hrushesky W, Torosoff M, Peace D, Gupta H, Mann G, Wood P. Fertility cycle modulation of cancer
biology. Biological Rhythm Research. Vol. 26, 1995:402.
314. Torossov M, Hrushesky W, Gupta H, Mann G, Vyzula R, Wood P. Fertility cycle dependent tumor growth
non-linearity unmasked. Proc AACR. Vol. 36, 1995:38.
315. Hrushesky W, Torosoff M, Gupta G, Mann G, Vyzula R, Wood P. Fertility cycle modulation of the host
breast cancer balance. Proc AACR. Vol. 36, 1995:256.
316. Hrushesky W, Peace D, Wood P. Circadian timing of tumor necrosis factor alpha determines its therapeutic
index. Proc AACR. Vol. 37, 1996:485.
317. Hrushesky W, Peace D, Wood P. Fertility cycle modulation of breast cancer growth. Breast Cancer Research
and Treatment. Vol. 41(3), 1996:272.
318. Bjarnason G, Marsh R, Chu N, Hrushesky W, Kerr I. Phase-II study of 5-fluorouracil (5-FU) and leucovorin
(LV) by a 14 day circadian infusion in patients with metastatic colorectal cancer. Proc ASCO, 1996.
319. Hrushesky W, Wood P, Bluming A. Optimal timing of breast cancer surgery. Chemotherapy Foundation
Symposium XIV Innovative Cancer Chemotherapy for Tomorrow, November 6-8, 1996:55-56.
320. Hrushesky W. Breast cancer, timing of surgery, and the menstrual cycle: Call for prospective trial. Cell
Proliferation Society conference, March 1997, Baltimore, Maryland.
321. Wood P, Hrushesky W. Circadian rhythms and cancer chemotherapy. Cell Proliferation Society conference,
March 1997, Baltimore, Maryland.
322. Wood P, Hrushesky W. Fertility cycle phase affects 5-fluorouracil (5-FU) antitumor efficacy and toxicity.
Proc AACR, 1997.
323. Wood P, Hrushesky W, Klevecz R. Early and late S phase initiation in marrow is circadian time dependent.
Proc AACR, 1997.
324. Hrushesky W, Wood P. Human circadian rhythms in antifolate and fluoropyrimidine developmental
therapeutics. 11th Inter Symp Chemistry and Biology of Pteridines and Folates, June 1997, Berchtesgaen,
Germany.
325. Wood P, Hrushesky W, Galivan J. Glutamyl hydrolase activity in murine serum and tissues varies with
circadian time. 11th Inter Symp Chemistry and Biology of Pteridines and Folates, June 1997, Berchtesgaen,
Germany.
326. Hrushesky W, Lannin D, Haus E. Clinical evidence for an ontogenetic basis for circadian coordination of
cancer cell proliferation. International Congress on Chronobiology, September 1997, Paris, France.
Hrushesky • Curriculum Vitae • Page 56
327. Wood, P, Hrushesky W. 5-FU antitumor efficacy/toxicity is affected by fertility cycle stage. International
Congress on Chronobiology, September 1997, Paris, France.
328. Wood P, Hrushesky W. Cisplatin-associated anemia: An erythropoietin deficiency syndrome [abstract]. In:
Spivak JL, ed. Yearbook of Hematology. St. Louis: Mosby, 1997:3-4.
329. Wood P, Hrushesky W. Cisplatin-associated anemia: An erythropoietin deficiency syndrome [abstract].
Oncology Digest, 1997;2:(Investigation).
330. Wood P, Hrushesky W, Klevecz R. Complex compartmental circadian coordination of hematopoetic
proliferative dynamics. Proc Cell Prolif Soc. Baltimore, MD, 1998:26.
331. Hrushesky W, Bjarnason G, Fukushima M, Hagimoto H, Wood P. Plasma fluorodeoxyuridine (FUDR)
concentration during therapeutically effective continuous intravenous infusion (CI): possible sex dependence.
Proc AACR. New Orleans, LA, 1998:187.
332. Wood P, Lincoln D, Hrushesky W. Thymidylate synthase activity (TSA) in the marrow and small intestine
are each ryhthmically coordinated within the day. Proc AACR. New Orleans, LA, 1998:469.
333. Wood, PA, Hrushesky, W, Klevecz, RR. Complex compartmental circadian coordination of hematopoietic
proliferation dynamics. Cell Proliferation Society, Baltimore, MD, April 1998.
334. Wood P, Lincoln D, Hrushesky W. Thymidylate synthase (TS), a chemotherapy drug target, varies
rhythmically throughout the day in the host tissues for drug toxicity. 3rd Annual VA Oncology Cancer
Symposium. San Antonio, TX, 1998.
335. Wood P, Hrushesky W, Klevecz R. Lineage specific circadian coordination of hematopoietic proliferative
dynamics and progenitor cell numbers. 3rd Annual VA Oncology Cancer Symposium. San Antonio, TX,
1998.
336. Hrushesky W, Wood P, Bove K. Mammalian fertility cycles modulate cancer growth and spread. 3rd Annual
VA Oncology Cancer Symposium. San Antonio, TX, 1998.
337. Hrushesky W. Circadian cancer therapy. 4th International Symposium on Predictive Oncology and Therapy.
Nice, France, 1998.
338. Bove, K, Wood, PA, Hrushesky W. Vascular endothelial growth factor (VEGF) and basic fibroblast growth
factor (bFGF) expression in breast cancer varies with fertility cycle stage. Proc AACR 40: 1999.
339. Bove, K, Wood, P, Hrushesky, W. Molecular mediators of angiogenesis are modulated by the fertility cycle in
breast cancer (abstract). Joint meeting of the eighth international conference of chronopharmacology and
chronotherapeutics and the american association for medical chronobiology and chronotherapeutics,
Williamsburg, VA, 1999.
340. Lincoln, D, Hrushesky, W,Wood, P. Thymidylate synthase (TS) activity (A) circadian time structure in TS
Inhibitor sensitive tissues (abstract). Joint meeting of the eighth international conference of
chronopharmacology and chronotherapeutics and the american association for medical chronobiology and
chronotherapeutics, Williamsburg, VA, 1999.
341. Hrushesky W, Bove K, Wood P. Breast cancer resection within the menstrual cycle: risks, costs and benefits.
1st Milan Breast Cancer Conference. Milan, Italy, 1999.
342. Hrushesky W, Bove K, Lincoln D, Clark R, Wood P. Consequences of the non-linearity of in vivo critical
drug target expression. Int Conf on Molec Targets & Cancer Therapeutics. Washington, DC, 1999.
343. Thrall M, Wood P, King V, Rivera W, Hrushesky W. Investigation of the comparative toxicity of 5-FU bolus
versus 5-FU continuous infusion chemotherapy with concurrent radiation therapy in locally advanced rectal
cancer. 6th Int Conf on GI cancer. Williamsburg, VA, 1999.
Hrushesky • Curriculum Vitae • Page 57
344. Wood P, Bove K, Clark R, Lincoln D, Maley F, Hrushesky W. Circadian variation of thymidylate synthase
(TS) mRNA and protein levels in normal tissues parallels the rhythm in TS catalytic activity and daily
rhythms in DNA synthesis. Int Conf on Molec Targets & Cancer Therapeutics. Washinton, DC, 1999.
345. Hrushesky W. DVA healthcare network upstate new york at albany a clinical investigations unit: adding
value and quality without adding cost. 4th annual va oncology cancer symposium. Washington, DC, 1999.
346. Bove K, Wood P, Hrushesky W. Molecular mediators of angiogenesis are modulated by the fertility cycle in
breast cancer. 4th annual va oncology cancer symposium. Washington, DC, 1999.
347. Wood, P, Lincoln, D, Bove, K, Clark, R, Hrushesky W. Tumor thymidylate synthase (TS) activity and mRNA
vary rhythmically throughout the day. Proc AACR 2000
348. Bove, K, Lincoln, D, Wood, P, Hrushesky, W. Reproductive cycle coordination of tumor growth and postresection local recurrence of a low metastatic potential, gene marked, breast cell line. Proc AACR 2000
349. Bjarnason, G, Lincoln, D, Hrushesky, W, Li, Q, Ben-Wood, Y, Wood, P. Thymidylate synthase (TS) activity
in human oral mucosa has a circadian variation with peak activity during S-phase. Proc Amer Soc Clin Oncol
2000.
350. Hrusheksy W, Bove K, Chambers A, Wood P. Reproductive cycle and tumor stage affect measures of cell
proliferation and angiogenesis. In: Breast Cancer Research Program, Era of Hope; 2000 June 8-12; Atlanta,
GA; 2000.
351. Robert F, Irwin D, Dallaire B, Shuey S, Alkuzweny B, Nasizadeh H, Hrushesky W, et al. A phase I/II trial of
9-aminocamptothecin (9-AC) utilizing a daily X5 schedule: no response was observed despite achieving
pharmacokinetic targets (abstract). In: Amer Soc of Clin Oncology; 2000; New Orleans, LA; 2000.
352. Hrushesky W, Sothern R, Rietveld W, Boon M. Pap smear detection of uterine cervical epithelial
carcinogenesis and progression is circannually rhythmic and apparently tied to rhythms in human sexuality.
In: Seventh Meeting Society for Research on Biological Rhythms; 2000; Amelia Island Plantation,
Jacksonville, Florida; 2000.
353. Wood P, Bove K, Hrushesky W. Meaningful and reproducible reproductive cycle modulation of cancer
biology. In: Seventh Meeting Society for Research on Biological Rhythms; 2000; Amelia Island Plantation,
Jacksonville, Florida; 2000.
354. HrusheskyW. Tumor Chronobiology. International Symposium on Tumor Targeted Drug Delivery Systems,
NIH, Bethesda, Maryland; Sept 24-27, 2000.
355. Hrushesky W, Sothern R, Rietveld W, Boon, M. Rhythmic Annual Changes in Cancer Biology Affect
Epidemiologic Meaning, the Efficiency of Prevention, Screening and Treatment Strategies; In: 19th Annual
VA Health Services Research and Development Services, Washington, DC; Feb 14-16, 2001.
356. Kobayashi M, Wood P, Hrushesky WJM. Tumor Growth Rate Is Highly and Complexly Organized within
Each Day. Chronobiology in the New Millenium, 25th Conference of the International Society for
Chronobiology, Ankara, Turkey; October 9-13, 2001.
357. Wood P, Bjarnason G, Lincoln D, Hrushesky WJM. Prominent Circadian Organization of Thymidylate
Synthase Activity in Human Oral Mucosa. Chronobiology in the New Millenius, 25th Conference of the
International Society for Chronobiology, Ankara, Turkey; October 9-13, 2001.
358. Kobayashi M, Wood P, Hrushesky W. Tumor Growth Waxes and Wanes Predictably Within Each
Day and This Circadian Pattern Inverts with Cancer Progression. 6th Annual National VA Oncology
Conference, Washington, DC;January 23-25, 2002.
359. Wood P, Bjarnason G, Lincoln D, Hrushesky W. Thymidylate Synthase Activity, An Important Cancer
Chemotherapy Target, Is Organized within Circadian Time in the Human Oral Mucosa. 6th Annual National
VA Oncology Conference, Washington, DC; January 23-25, 2002.
Hrushesky • Curriculum Vitae • Page 58
360. Kobayshi M, You S, Wood P, Rich I, Hrushesky WJM. Prominent Circadian and Estrous Cycle Impact
upon Tumor Biology. Eighth Meeting of the Society for Research on Biological Rhythms. Amelia Island
Plantation and Conference Center, Jacksonville, Florida; May 22-26, 2002.
361. You S, Kobayashi M, Rich I, Musk P, Wood P, Hrushesky WJM. Tissue and cDNA Microarrays for HighThroughout Molecular Profiling of Cancer Chronobiology. Eighth Meeting of the Society for Research on
Biological Rhythms. Amelia Island Plantation and Conference Center, Jacksonville, Florida; May 22-26,
2002.
362. Hrushesky WJM, You S, Kobayashi M., Wood P. Fertility Cycle Coordinates Molecular Pathways
Responsible for Cancer Growth and Spread. Era of Hope 2002 DoD Breast Cancer Research Program
Meeting, Orlando, Florida; September 25-28, 2002.
363. Wood P, You S, Hrushesky WJM. Fertility Cycle Coordinates Molecular Pathways Responsible for Cancer
Growth and Spread. 7th Annual VA National Cancer Symposium, Alexandria, Virginia; October 2-4, 2002.
364. Hrushesky WJM, Wood P, Patterson D, Probst J, Shinogle J, Samuels M. VA Health Care Eliminates Racial
and Rural Health Care Disparities. 7th Annual VA National Cancer Symposium, Alexandria, Virginia;
October 2-4, 2002.
365. You S, Kobayashi M, Wood P, Xu Y, Musk P, Hrushesky W. Mouse Mammary
Circadian Rhythm and mPER1 Gene Expression. 94th Annual AACR Meeting,
Toronto, Canada; April 5-9 2003.
366. You S, Xiong Y, Kobayashi M, Wood P, Bickley S, Simu M, Quiton J, Hrushesky
W. Tumor cell circadian clock genes are rhythmically expressed in coordination
with rhythmic circadian growth and thereby may represent new therapeutic targets.
Molecular Targets and Cancer Therapeutics, Boston, Massachusetts; November 1721, 2003
367. Retsky M, Demicheli R, Hrushesky W. Proposed explanation of mammography paradox for women age 4049. The 7th International Symposium on Predictive Oncology, Nice, France; February 7-10, 2004.
368. Hrushesky W, You S, Xiong Y, Kobayashi M, Bickley S, Quiton J, Wood P. Circadian clocks
meter molecular target availability within cancer cells. 1st ISC International Conference on Cancer
Therapeutics, Florence, Italy; February 19-21, 2004.
369. Demicheli R, Bonadonna G, Hrushesky W, Moliterni A, Retsky M, Valagussa P,
Zambetti M. The timing of breast cancer recurrence after mastectomy and adjuvant
CMF chemotherapy supports a dormancy-based model for metastatic development.
ASCO 2004, New Orleans, Louisiana; June 5-8, 2004.
370. Berk L, Seiferheld W, Rich T, Hrushesky W, Blask D. RTOG BR-0119:
Chronobiological study of the addition of melatonin to radiotherapy for brain
metastases. ASCO 2004, New Orleans, Louisiana; June 5-8, 2004.
371. You S, Li W, Kobayashi M, Xiong Y, Hrushesky W, Wood P. Creation of a stable
breast cancer cell line that maintains fertility cycle cancer biology of the parent
tumor. AACR 2004, Orlando, Florida; March 2004.
372. Hrushesky W, Sothern R, Rietveld W, Quiton J, Boon M. Sun Exposure, Sexual Behavior and Uterine
Cervical Human Papilloma Virus. AACR 2004, Orlando, Florida; March 2004.
373. Hrushesky W. Melatonin: The First Anti-Cancer Chronobiotic. South Carolina Academy of Science 2004,
Charleston, South Carolina; April 2004.
Hrushesky • Curriculum Vitae • Page 59
374. Demicheli R, Bonadonna G, Hrushesky WJM, Moliterni A, Retsky MW, Valagussa P, Zambetti M. The
timing of breast cancer recurrence after mastectomy and adjuvant CMF chemotherapy supports a dormancybased model for metastastic development. ASCO, New Orleans, Louisiana; June 2004.
375. Hrushesky, WJM Observation, Quantitation and Therapeutic Manipulation of Circadian Cancer Biology to
Prevent, Better Diagnose, and More Safely and Effectively Treat Human Cancer. Proceedings of MASCC
International Symposium for Supportive Care in Cancer. Miami, Florida June 24-27, 2004.
376. Hrushesky, WJM . Objectively Measuring Fatigue in Cancer Patients by Measuring Circadian Sleep-Activity
Patterns. Circadian Disruption and Breast Cancer, NIEHS Proceedings, Chapel Hill, NC July 9-11, 2004.
377. Hrushesky, WJM Using Circadian Cancer Biology to Prevent, Better Diagnose, and More Safely and
Effectively Treat Human Cancer. Proceedings of International Chronobiology Society, Graz, Austria,
October 13-15, 2004.
378. Hrushesky, WJM. Chronotherapy of Cancer. Proceedings of the American Association of Pharmaceutical
Scientists. Baltimore, Maryland November 9-11, 2004.
379. Hrushesky WJM Human Cancer Chronobiology. Proceedings of the International Conference on
Chronobiology, January 27-30, 2005, Hamburg, Germany.
380. Lis Chris, Grutch J, Gupta D, Hrushesky WJM. Improved Circadian Function in Patients with Advanced
Non-Small Cell Lung Cancer who Respond to Chemotherapy. AACR, March 2005.
381. Wood P, You S, Xiong Y, Ohmori M, Quiton J, Hrushesky WJM, et al. Continuous Light Increases Cancer
Growth Rate in Clock Gene Replete, but not Per2 Mutant Mice. The First International Congress of Applied
Chronobiology and Chronomedicine. Antalya, Turkey, June 2005.
382. Ohmori M, You S, Quiton J, Berger F, Hrushesky WJM, et al. APCmin/+ Mice have Normal Circadian and
Estrous Time Structures. The First International Congress of Applied Chronobiology and Chronomedicine.
Antalya, Turkey, June 2005.
383. Baum M, Cuzick J, Howell A, Buzdar R, Demicheli R, Greco M, Retsky M, Hrushesky WJM. An
exploration of relapse data by hazard rate as a means of developing biological insights into the natural
history and treatment of breast cancer: Data from “Arimidex’, Tamoxifen, Alone or in Combination(ATAC)
trial and the Milan Institiute Database. Proc ASCO 2005. Orlando, FL. May 13-17, 2005. Abst#612 p31s.
384. Levin RD, Grutsch JM, Hrushesky WJM, Quiton JD, Quinn K, Daehler M. Circadian function of patients
with advanced non-small cell lung cancer. Proc ASCO 2005. Orlando, FL. May 13-17, 2005. Abst#7291
p693s.
385. Du-Quiton J, Levin RD, Grutsch JF, Daehler M, Gupta D, Lis CG, Hrushesky WJM. Quantitative
comparison of three competing actigraphy systems to record and analyze sleep, activity and ambient light.
Proceedings of the AACR-NCI-EORTC International Coference on Lolecular Targets and Cancer
Therapeutics, Philadelphia, Pensylvania, USA. November 14018, 2005.
386. Hrushesky WJM, DeSai B, Du-Quiton J, Wood P, You S, Collier G, Xiong Y, Oh E, Greene E, Ohmori M,
McPartland M . Multi-dimensional depiction of circadian dynamics of tumor cell core clock function,
thymidylate synthase activity, 5-FU antitumor activity and 5-FU therapeutic index and tumor bearing mouse
survival. AACR April 1-5, 2006, Washington, DC.
387. Wood P, You S, Hrushesky WJM. Circadian Clock Coordinates Cancer Cell Cycle Progression, Thymidylate
Synthase (TS), and 5-Fluorouracil (5-FU) Therapeutic Index. AACR April 1-5, 2006, Washington, DC.
388. You S ,Wood P ,Ohmori M ,Xiong Y ,Du-Quiton J , Bickley S ,Hrushesky WJM . Mammary Tumor Growth
Acceleration by Light-at-Night is Associated with Host Circadian Disruption, Altered Tumor Circadian
Clock and Clock-Controlled Protein Expression, and is Behaviorally Avoidable. AACR April 1-5, 2006,
Washington, DC.
Hrushesky • Curriculum Vitae • Page 60
389. Y Xiong, J Quiton, S You, M Ohmori, E Greene, E Oh, V Sue, P Wood, WJM Hrushesky. Host Per2 clock
gene mutation in the cancer host slows transplanted lung and colon Per2-replete tumor growth. AACR April
2006, Washington, DC.
390. E Oh, J Quiton, S You, M Ohmori, Y Xiong, E Greene, V Sue, P Wood, WJM Hrushesky. Season of breast
cancer resection affects surgical cure. AACR April 1-5, 2006, Washington, DC.
391. LE Greene, J Quiton, EYOh, P Wood, SYou, M Ohmari, YXiong, WJM Hrushesky. The Number of Immune
Cells Infiltrating Murine Breast Cancer Predicts Surgical Outcome. AACR April 1-5, 2006, Washington, DC.
392. RD Levin, C Lis, C Peterson, J Grutsch, WJM Hrushesky, J Quiton, K Quiton, M Daehler, D Gupta.
Circadian Function in Patients with Advanced Non-Small cell lung cancer. AACR April 1-5, 2006,
Washington, DC.
393. Grutsch J, Gupta D, Lis C, Levin R, Du-Quiton, Daehler M, Wood P, Hrushesky WJM. Do Self-Reported
Measures of Sleep Quality Correlate with Objective Measures of Circadian Coordination in Patients with
Advanced Lung Cancer? AACR April 14-18, 2007, Los Angeles, CA.
394. Du-Quiton J, Grutsch J, Lis C, Gupta D, Levin R, Tyer K, Daehler M, Wood P, Hrushesky WJM. The
Relationship Between Quality of Life and Circadian Function in Patients with Advanced Lung Cancer.
AACR April 14-18, 2007, Los Angeles, CA.
395. Hrushesky WJM, Sothern RB, Du-Quiton J, Rietveld W, Boon M. Transverse (and Longitudinal) Evidence
for Medically Relevant Circannual and Circahemidecadal and Circadecadal Human Time Structures. Cold
Spring Harbor Laboratory Symposium May 30-June 4, 2007, Cold Spring Harbor, New York (pg 64).
396. Wood PA, Yang X, Hrushesky WJM. Circadian Disruption and Cancer. 72nd Cold Spring
Harbor Laboratory Symposium: Clocks and Rhythms. Cold Spring Harbor Laboratory Symposium May 30June 4, 2007Cold Spring Harbor, NY (pg. 158).
397. Wood PA, Yang X, Taber A, Oh EY, Carnevale K, Berger F, Pena M, Hrushesky WJM. Inactivation of the
Period 2 Circadian Clock Gene Accelerates Intestinal Tumorigenesis in ApcMin/+ Mice. AACR Advances in
Colorectal Cancer, Cambridge, MA; Nov 14-17, 2007.
398. Hyunju L, Arnouk H, Lamoke F, Zhang R, Hunt RC, Hrushesky WJM, Wood PA, Jahng WJ.
Neruroprotective and Pro-Angiogenic Roles of Erythropoietin in Retina Degeneration. 2008 Annual Conf of
Assoc for Research in Vision and Opthamology (ARVO) Ft Lauderdale, FL; April 27 –May1, 2008.
399. Jahng WJ, Arnouk H, Lamoke F, Hunt RC, Hunt DM, Hrushesky WJM, Wood PA, Rando R, Lee H. A New
Retinoid Signaling Molecule in the Retinal Pigment Epithelium:RE45. 2008 Annual Conf of Assoc for
Research in Vision and Opthamology (ARVO) Ft Lauderdale,FL; April 27 –May1, 2008.
400. Zhang R, Chen P, Arnouk H, Yang X, Oh EY, Wood PA, Hrushesky WJM, Davis R, Jahng WJ
Melatonin Protects the Retina from Constant Light Induced Damage via Microtubule Stabilization.
2008 Ann. Conf of Ass for Res in Vision and Opthamology (ARVO) Ft Lauderdale,FL;
Apr 27 –May1, 2008.
401. PA Wood, X Yang, A Taber, EY Oh, K Carnevale, F Berger, M Pena, WJM Hrushesky.
Inactivation of Period2 Clock Gene Accelerates Intestinal Tumorigenesis. 2008 Society for Research on
Biological Rhythms, Sandestin, FL; May 17-21, 2008.
402. JK Singletary, EY Oh, MA Friedman, WJM Hrushesky, PA Wood. Gene Expression Analysis
Grouping with Gener-Rhythm. 2008 Society for Research on Biological Rhythms, Sandestin, FL;
May 17-21, 2008.
Hrushesky • Curriculum Vitae • Page 61
403. EY Oh, A Friedman, J Singletary, X Yang, C Ansell, SLK Kidder, SE Ayers, DF Quiton, C Yang,
PA Wood, WJM Hrushesky. Circadian Breast Cancer Whole Genomic Expression. 2008 Society
for Research on Biological Rhythms, Sandestin, FL; May 17-21, 2008.
404. C Ansell, EY Oh, C Yang, H Nawaz, PA Wood, WJM Hrushesky. Circannual Rhythm of Global
Breast Cancer Incidence. 2008 Society for Research on Biological Rhythms, Sandestin, FL; May
17-21, 2008.
405. SLK Bowers, EY Oh, CM Ansell, C Yang, PA Wood, WJM Hrushesky. Season, Estrous and
Circadian Cycle Timing of Breast Cancer Resection Interact to Determine Post Resection Breast
Cancer Metastatic Recurrence Risk. 2008 Society for Research on Biological Rhythms, Sandestin,
FL; May 17-21, 2008.
406. DF Quiton, J Du-Quiton, PA Wood, JF Grutsch, D Gupta, K Tyer, CG. Lis, RD Levin, JB Burch,
WJM Hrushesky. Sleep-Activity Circadian Rhythm Abnormalities Reflect Self-Assessed
Depression and Anxiety in Patients with Advanced Non-Small Cell Lung Cancer. 2008 Society for
Research on Biological Rhythms, Sandestin, FL; May17-21, 2008.
407. X Yang, PA Wood, EY Oh, J Du-Quiton, C Ansell, WJM Hrushesky. Down regulation of circadian
clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm. 2008
Society for Research on Biological Rhythms, Sandestin, FL; May 17-21, 2008.
408. J Reynolds, J Grutsch, PA Wood, D Gupta, C Lis, R Levin, J Du-Quiton, M Daehler, DF Quiton,
WJM Hrushesky. Sleep Quality and Circadian Function in Patients with Advanced Lung Cancer
2008 Society for Research on Biological Rhythms, Sandestin, FL; May17-21, 2008.
409. PA Wood, Xiaoming Yang, Eun-Yeong Oh, Christine Ansell, Stephanie L.K. Bowers, Chris
Yang, Stacy Ayers, WJM Hrushesky. Light at night-induced breast cancer growth acceleration
depends on melatonin and tumor melatonin MT1 receptor expression. New York Academy of
Sciences, New York, NY. June 20, 2008.
410. J Guess, J Burch, K Ogoussan, HM Zhang, S Wagner, J Hébert, PA Wood, L Hofseth, U Singh, W
Hrushesky. Circadian Disruption and Circulating Inflammatory Cytokines. NYAS Meeting 2009: Circadian
Disruption and Cancer. New York Academy of Sciences, New York, NY. June 19, 2009.
411. WJM Hrushesky. Circadian disruption as preventable cause for and relievable burden of cancer. NYAS
Meeting 2009: Circadian Disruption and Cancer. New York Academy of Sciences, New York, NY. June 19,
2009.
412. X Yang, PA Wood, WJM Hrushesky. Circadian time dependent tumor suppressor function of period genes.
NYAS Meeting 2009: Circadian Disruption and Cancer. New York Academy of Sciences, New York, NY. June
19, 2009.
413. WJM Hrushesky, J Grutsch, PA Wood, C Ferrans, JL Reynolds, DF Quiton, J Du-Quiton, R Levin, C Lis,
D Braun. Defining the burdens of circadian disruption in advanced lung cancer and how they may be
diminished. NYAS Meeting 2009: Circadian Disruption and Cancer. New York Academy of Sciences, New
York, NY. June 19, 2009.
414. Shimp WS, Kumar A, Bobolts L, Krook JE, Fishman V, Davis S, Anthony C, Walton R, Huff D, Fishman ML,
Hrushesky WJM. Improving QOL and safety while reducing costs: Evidence-based adjuvant chemotherapy of
colorectal cancer (CRC). Journal of Clinical Oncology, 2013 ASCO Annual Meeting Proceedings (PostMeeting Edition). 2013 May; 31(15): suppl; e14646.
415. Fishman ML, Kumar A, Shimp WS, Bobolts LR, Krook JE, Fishman V, Davis S, Walton R, Huff DF,
Hrushesky WJM. Effect of pretreatment clinical consultation on oncologist prescribing behavior in the initial
Hrushesky • Curriculum Vitae • Page 62
treatment of NSCLC. Journal of Clinical Oncology, 2013 ASCO Annual Meeting Proceedings (Post-Meeting
Edition). 2013 May; 31(15): suppl; e19130.
416. Huff DF, Hrushesky WJM, Davis S, Bobolts L, Kumar A, Shimp WS, Krook J, Kogler J, Fishman V, Anthony
C, Walton R, Fishman ML. Annual rhythm in filgrastim use in southeast Florida. Journal of Clinical Oncology,
2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2013 May; 31(15): suppl; e20697.
417. Kogler J, Hrushesky WJM, Huff DF, Bobolts L, Kumar A, Shimp WS, Krook JE, Fishman V, Davis S,
Anthony C, Walton R, Fishman ML. Trends in the use of bone agents in metastatic cancer. Journal of Clinical
Oncology, 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2013 May; 31(15): suppl;
e20672.
418. Krook JE, Kumar A, Fishman ML, Shimp WS, Bobolts LR, Fishman V, Davis S, Huff DF, Anthony C, Walton
R, Hrushesky WJM. Community use of anthracyclines in metastatic breast cancer (MBC) (Poster). Journal of
Clinical Oncology, 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2013 May; 31(15): suppl;
e1080.
419. Kumar A, Fishman ML, Shimp WS, Bobolts LR, Krook J, Fishman V, Davis S, Huff DF, Anthony C, Walton
R, Hrushesky WJM. Community use of anthracyclines for adjuvant HER2-positive breast cancer (BC). Journal
of Clinical Oncology, 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2013 May; 31(15):
suppl; e11609.
420. Bobolts LR, Kumar A, Fishman ML, Shimp WS, Krook JE, Fishman V, Davis S, Anthony C, Walton R, Huff
D, Hrushesky WJM. Off-label capecitabine, eribulin, or ixabepilone use in metastatic breast cancer (MBC).
Journal of Clinical Oncology, 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2013 May;
31(15): suppl; e12034.
421. Hrushesky WJM, Huff DF, Davis S, Bobolts LR, Fishman ML, Shimp WS, Kogler J, Fishman V, Walton R.
Ensuring evidence-based cancer medicine by influencing prescribing behavior [poster]. 2013 ASCO Quality
Care Symposium. 2013 Nov 1-2; San Diego, CA.
422. Huff, DFQ, Fishman, ML, Davis S, Shimp WS, Bennett CL, Kogler J, Schorer AE, Laura Rose Bobolts,
Melissa Armitage, William J. Hrushesky; Evidence-based adjuvant chemotherapy for NSCLC in
southeastern United States. 2014 ASCO Annual Meeting (abstract). May 30-June 3, 2014, Chicago, IL. J
Clin Oncol (Meeting Abstracts) May 2014 vol. 32 no. 15_suppl e18504.
423. Hrushesky WJM, Huff DFQ, Anthony C, Bobolts LR, Armitage M, Davis S, Bennett CL, Shimp WS, Schorer
AE, Fishman, ML, Dobies C, Fishman D, Fishman V, Walton R, Kogler J. Use, misuse, and overuse of
white cell growth factors (GF) in community oncology practices in southeastern United States. 2014 ASCO
Annual Meeting (poster). May 30-June 3, 2014, Chicago, IL. J Clin Oncol (Meeting Abstracts) May 2014
vol. 32 no. 15_suppl 9654
424. Hrushesky WJM, Bennett CL, Huff DFQ, Anthony C, Bobolts LR, Kogler J, Armitage M, Fishman ML, Davis
S, Walton R. Effect of Oncology Analytics (OA) cancer care quality initiative on inappropriate use of
erythropoiesis stimulating agents (ESA) among cancer patients receiving chemotherapy with curative intent.
2014 ASCO Annual Meeting (abstract). May 30-June 3, 2014, Chicago, IL. J Clin Oncol (Meeting
Abstracts) May 2014 vol. 32 no. 15_suppl e17552
425. Lis CG, Levin RD, Grutsch JF, Birdsall TC, Wood PA, Huff DFQ, Reynolds JL, Daehler MA, Pearl D, Shen
X, Blask DE, Hrushesky WJM. Evening melatonin (but not morning) prolongs the survival of patients with
advanced non-small cell lung cancer (ANSCLC). 2014 ASCO Annual Meeting (abstract). May 30-June 3,
2014, Chicago, IL. J Clin Oncol (Meeting Abstracts) May 2014 vol. 32 no. 15_suppl e19068
426. Baranwal A, Huff DFQ, Fishman ML, Kogler J, Shimp WS, Bobolts LR, Fishman V, Armitage M, Davis S,
Anthony C, Schorer AE, Bennett CL, Hrushesky WJM. Adjuvant colon cancer care compliance with level I
Hrushesky • Curriculum Vitae • Page 63
data and NCCN guidelines in the elderly. 2014 ASCO Annual Meeting (abstract). May 30-June 3, 2014,
Chicago, IL. J Clin Oncol (Meeting Abstracts) May 2014 vol. 32 no. 15_suppl e14520
427. Bennett CL, Kessler S, Schulz R, Chen B, Magwood J, Yenzen S, Norriz LB, Armitage J, Sartor O, Hrushesky
WJM. Are preclinical research findings replicable: An empirical analysis based on EpoR studies in cancer.
2014 ASCO Annual Meeting (abstract). May 30-June 3, 2014, Chicago, IL. J Clin Oncol (Meeting
Abstracts) May 2014 vol. 32 no. 15_suppl e17697
Submitted Abstracts:
Bennett CLB, Huff DF, Baranwal A, Mamgain A, Hrushesky WJM. Overuse of five expensive oncology
pharmaceuticals in the southeastern United States: A physician-level analysis. Abstract #137637 Submitted for
the 2014 ASCO Quality Care Symposium. Oct17 - 18, 2014. Boston, MA.
Hrushesky WJM, Huff DF, Baranwal A, Mamgain A, Bennett CLB. Cancer care quality and value. Abstract
#137678 Submitted for the 2014 ASCO Quality Care Symposium. Oct17 - 18, 2014. Boston, MA.
Mamgain A, Huff DF, Bennett CL, Shimp WS, Baranwal A, Bobolts LR, Armitage M, Davis S, Schorer AE,
Fishman M, Fishman V, Kogler J, Hrushesky WJM. Adjuvant chemotherapy selection for stage I NSCLC 2011
through 2014 in the southeastern United States. Abstract #137632 Submitted for the 2014 ASCO Quality Care
Symposium. Oct17 - 18, 2014. Boston, MA.
Huff DF, Bennett CL, Shimp WS, Baranwal A Mamgain A, Fishman M, Davis S, Kogler J, Schorer AE, Bobolts
LR, Armitage M, Hrushesky WJM. Quality and value implications of NCCN-compliant use of maintenance
rituximab for patients with low-grade NHL. Abstract #137671 Submitted for the 2014 ASCO Quality Care
Symposium. Oct17 - 18, 2014. Boston, MA.
Baranwal A, Hrushesky WJ, Huff DF, Shimo WS, Mamgain A, Fishman M, Bobolts LR, Schorer AE, Kogler J,
Davis S, Armitage M, Bennett CL. Quality and value-focused albumin-bound Paclitaxel decision support for
pancreatic, lung, and breast cancer in southeastern United States. Abstract #137623 Submitted for the 2014
ASCO Quality Care Symposium. Oct17 - 18, 2014. Boston, MA.
Hrushesky WJM, Baranwal A, Huff DF, Shimp WS, Mamgain A, Fishman M, Schorer AE, Bobolts LR, Davis S,
Kogler J, Armitage M, Bennett CL. Adjuvant colon cancer care quality, risk, value and level one data &
guideline compliance among the elderly privately insured in southeastern USA. Abstract #137633 Submitted
for the 2014 ASCO Quality Care Symposium. Oct17 - 18, 2014. Boston, MA.
Hrushesky • Curriculum Vitae • Page 64
Appendix V-Highly Selected Invited Presentations: (Includes government (e.g. FDA, DOD, NCI) University,
International meetings as well as public communication live, on TV, radio and online conferences abridged list
available on request)
Food and Drug Administration Advisory Board: “A review of the clinical utility and toxicology of Lasparaginase in some 8,000 patients,” December 12, 1975.
Breast Cancer Task Force: “Clinical applications of chronobiology in cancer medicine,” June 29, 1981.
CALGB Chemotherapy Meeting: “Timing: an important variable in toxicity and response,” 1983.
Food and Drug Administration Bureau of Drugs and Biologics: “The need for consideration of the circadian
stage of drug treatment,” June 12, 1985.
National Institutes of Health/National Cancer Institute Scientific Seminar Series: “Chemotherapy timing: a long
ignored, yet relevant variable,” October 15, 1985.
Food and Drug Administration Medical Device Bureau, Office of Science and Technology: “Application of
chronobiologic concepts to diagnostic and drug administration devices,” October 15, 1985.
Gynecologic Oncology Group: “Stipulation of drug timing: automatic chronotherapy,” December, 1985.
Food and Drug Administration General Hospital and Personal Use Devices Panel, 24th Meeting: “Medtronic
DAS,” November 3, 1986.
CALGB Chemotherapy Committee: “Further progress in automatic drug delivery and time-based therapy,”
Boston, 1987.
FDA Bureau of Biologicals: “Log order circadian stage dependence of biological response modifier anticancer
therapeutic index,” October 30, 1987.
Gynecologic Oncology Group: “Ovarian cancer chronotherapy,” February, 1988.
NCI-International Society for Chronobiology, “Circadian timing in cancer chemotherapy,” June 20, 1989.
FDA Oncologic and Pulmonary Drug Products Branch, “Chronobiology and cancer drug development,” May
25, 1990.
National Surgical Adjuvant Breast and Bowel Project, “Menstrual influence on surgical cure of breast cancer,”
February 27, 1991.
NCI Grand Rounds, “Menstrual influence on surgical cure on breast cancer,” August 28, 1991.
NIH Strategic Planning Regional Meeting, Invited Panel Member, University of Connecticut, Farmington, CT,
February 25, 1992.
National Academy of Sciences Institute of Medicine Conference on Drug Development and Women,
Washington D.C., “Drug Development and the Menstrual Cycle,” Invited Speaker, June 22-23, 1992.
President's Cancer Panel Special Commission on Breast Cancer, “Breast Surgery Timing,” Washington D.C.,
Invited Speaker, November 12, 1992.
International Multidisciplinary Conference on Human Behavior and the Meaning of Modern Humanism,
Delphi, Greece, “Multifrequency Chao-Periodic Competitors for Global Impact” and “Chao-Periodic Patterns in
the Achievement of Understanding,” June 14 - 17, 1995.
Hrushesky • Curriculum Vitae • Page 65
“30th International Symposium of the Princess Takamatsu Cancer Research Fund: New Frontiers in Mechanistic
Cancer Research in Animal Models”, Invited Participant, Tokyo, Japan, November 16-18, 1999.
National Public Radio/WYNC Radio NY, NY Talk of the Nation: Science Friday, “Chronobiology: The
Rhythms of Life,” Dec 28, 2001.
National Public Radio/Durham, N.C. The Peoples’ Pharmacy, “Chronobiology Aids the Prevention Diagnosis
and Treatment of Human Disease,” January (several broadcasts) 24, 2002.
National Cancer Institute OCCAM “Melatonin, Chronobiology, and Cancer”, Washington, DC, February 28,
2003.
Gordon Chronobiology Conference “Detection and Improve Treatment”, Barga, Italy, May 11, 2003.
International Conference on Cancer Chronobiology “Chrono-Oncology”, Hamburg, Germany, January 29,
2005.
Morehouse College Neuroscience Institute Seminar Series “Cancer Cell Circadian Clocks Coordinate
Proliferation, Anticancer Drug Sensitivity and Host Toxicity”, Atlanta, GA, October 17, 2007.
Federation of American Societies for Experimental Biology “Circadian Disruption, Light at Night, and Its
Receptors and Breast Cancer Growth”, Snowmass Village, CO, August 10, 2008.
New York Academy of Sciences Conference “Circadian Disruption and Cancer”, New York, NY, June 19,
2009.
“Cancer and Time”, Bob Klevecz Memorial Conference, City of Hope Comprehensive Cancer Center,
Duarte,California, September 24, 2010

Iron Mt MTB Endurance Race Age Group Results Female Open